Systematic identification of genomic markers of drug s

Citation Report

#	ARTICLE	IF	CITATIONS
1	Influence of Zero Locations on the Number of Extrema in the Step Response. , 1991, , .		34
3	Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Frontiers in Oncology, 2012, 2, 109.	1.3	72
4	Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKCÎ± Invasive Signaling Axis. Science Signaling, 2012, 5, ra66.	1.6	69
5	Differential network entropy reveals cancer system hallmarks. Scientific Reports, 2012, 2, 802.	1.6	154
6	Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 2012, 41, D955-D961.	6.5	2,363
7	Expression of MicroRNAs in the NCI-60 Cancer Cell-Lines. PLoS ONE, 2012, 7, e49918.	1.1	19
8	Cells line up to be characterized. Nature Reviews Clinical Oncology, 2012, 9, 249-249.	12.5	1
9	Constructing a 'cancerpaedia'. Nature Reviews Drug Discovery, 2012, 11, 353-353.	21.5	1
11	Biologically Targeted Therapies Plus Chemotherapy Plus Radiotherapy in Stage III Nonâ€"Small-Cell Lung Cancer: A Case of the Icarus Syndrome?. Journal of Clinical Oncology, 2012, 30, 3909-3912.	0.8	7
12	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15030-15035.	3.3	252
13	A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17034-17039.	3.3	167
14	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discovery, 2012, 2, 798-811.	7.7	432
15	Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Research, 2012, 22, 2315-2327.	2.4	177
16	Clinical utility and implementation of gene-expression profiling in myeloma: current status and challenges. International Journal of Hematologic Oncology, 2012, 1, 133-146.	0.7	0
17	DNA repair dysregulation from cancer driver to therapeutic target. Nature Reviews Cancer, 2012, 12, 801-817.	12.8	851
18	New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents. Clinical Cancer Research, 2012, 18, 5837-5844.	3.2	9
19	Identification of DNA Repair Pathways That Affect the Survival of Ovarian Cancer Cells Treated with a Poly(ADP-Ribose) Polymerase Inhibitor in a Novel Drug Combination. Molecular Pharmacology, 2012, 82, 767-776.	1.0	35
20	Integrative Cancer Epidemiologyâ€"The Next Generation. Cancer Discovery, 2012, 2, 1087-1090.	7.7	30

#	Article	IF	Citations
21	Direct and immune mediated antibody targeting of <i>ERBB</i> receptors in a colorectal cancer cell-line panel. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21046-21051.	3.3	41
22	Integrating the <scp>NCI</scp>â€60 Data with â€œOmicsâ€•for Drug Discovery. Drug Development Research, 2012, 73, 420-429.	1.4	3
23	Cancer Vulnerabilities Unveiled by Genomic Loss. Cell, 2012, 150, 842-854.	13.5	209
24	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î² Receptor Signaling. Cell, 2012, 151, 937-950.	13.5	371
25	Twenty-First Century Pathology Sign-Out. Clinics in Laboratory Medicine, 2012, 32, 639-650.	0.7	2
26	Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer, 2012, 12, 767-775.	12.8	599
27	Cancer Epigenetics: From Mechanism to Therapy. Cell, 2012, 150, 12-27.	13.5	2,521
28	Targeting Epigenetic Readers in Cancer. New England Journal of Medicine, 2012, 367, 647-657.	13.9	363
29	Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Medical Genomics, 2012, 5, 66.	0.7	202
30	Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nature Genetics, 2012, 44, 1310-1315.	9.4	365
31	Constructing a 'cancerpaedia'. Nature Reviews Genetics, 2012, 13, 300-300.	7.7	1
32	New readers and interpretations of poly(ADP-ribosyl)ation. Trends in Biochemical Sciences, 2012, 37, 381-390.	3.7	75
33	Molecular simulations of drugâ€"receptor complexes in anticancer research. Future Medicinal Chemistry, 2012, 4, 1961-1970.	1.1	5
34	Molecular analysis of mutants of the Neurospora adenylosuccinate synthetase locus. Journal of Genetics, 2012, 91, 199-204.	0.4	6
35	The SOX family of genes in cancer development: biological relevance and opportunities for therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 903-919.	1.5	87
36	Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes. PLoS ONE, 2012, 7, e42494.	1.1	7
37	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	0.8	279
39	Cancer screen yields drug clues. Nature, 2012, , .	13.7	0

#	ARTICLE	IF	CITATIONS
40	The Investigation of Gene Regulation and Variation in Human Cancers and Other Diseases. , 2012, , .		0
41	Cell lines battle cancer. Nature, 2012, 483, 544-545.	13.7	95
42	Constructing a 'cancerpaedia'. Nature Reviews Cancer, 2012, 12, 315-315.	12.8	0
43	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 2012, 483, 603-607.	13.7	6,473
44	Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 2012, 30, 679-692.	9.4	883
45	Managing drug resistance in cancer: lessons from HIV therapy. Nature Reviews Cancer, 2012, 12, 494-501.	12.8	150
46	Biomedical briefing. Nature Medicine, 2012, 18, 640-641.	15.2	0
47	From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nature Reviews Cancer, 2012, 12, 572-578.	12.8	76
48	Personalized Medicine: Patient-Predictive Panel Power. Cancer Cell, 2012, 21, 455-458.	7.7	16
49	Global Proteome Analysis of the NCI-60 Cell Line Panel. Cell Reports, 2013, 4, 609-620.	2.9	276
50	Management of Soft Tissue Sarcoma. , 2013, , .		38
51	Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics. BMC Cancer, 2013, 13, 93.	1.1	23
52	Optimization of personalized therapies for anticancer treatment. BMC Systems Biology, 2013, 7, 31.	3.0	17
53	Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: Current trends. European Journal of Pharmacology, 2013, 714, 239-248.	1.7	33
54	Personalized therapy for breast cancer: a dream or a reality?. Future Oncology, 2013, 9, 1105-1119.	1.1	27
56	An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules. Cell, 2013, 154, 1151-1161.	13.5	615
57	Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. Cancer Discovery, 2013, 3, 294-307.	7.7	53
58	The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology. Cancer Research, 2013, 73, 4372-4382.	0.4	239

#	ARTICLE	IF	CITATIONS
59	Discovery of Novel Drugs for Promising Targets. Clinical Therapeutics, 2013, 35, 1271-1281.	1.1	15
60	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. Expert Opinion on Drug Discovery, 2013, 8, 1381-1397.	2.5	6
61	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 2013, 31, 1023-1031.	9.4	1,785
62	From Integrative Genomics to Therapeutic Targets. Cancer Research, 2013, 73, 3483-3488.	0.4	19
63	The Clinical Relevance of Cancer Cell Lines. Journal of the National Cancer Institute, 2013, 105, 452-458.	3.0	479
64	High-resolution network biology: connecting sequence with function. Nature Reviews Genetics, 2013, 14, 865-879.	7.7	92
65	Personalized medicine for breast cancer: dream or reality?. Memo - Magazine of European Medical Oncology, 2013, 6, 158-166.	0.3	0
66	Advancing Precision Medicine for Prostate Cancer Through Genomics. Journal of Clinical Oncology, 2013, 31, 1866-1873.	0.8	84
67	PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clinical Cancer Research, 2013, 19, 3533-3544.	3.2	122
68	Automated Tracking of Nanoparticle-labeled Melanoma Cells Improves the Predictive Power of a Brain Metastasis Model. Cancer Research, 2013, 73, 2445-2456.	0.4	49
69	mRMRe: an R package for parallelized mRMR ensemble feature selection. Bioinformatics, 2013, 29, 2365-2368.	1.8	195
70	Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines. Science Signaling, 2013, 6, ra84.	1.6	90
71	Inconsistency in large pharmacogenomic studies. Nature, 2013, 504, 389-393.	13.7	467
72	Drug–Gene Modeling in Pediatric T-Cell Acute Lymphoblastic Leukemia Highlights Importance of 6-Mercaptopurine for Outcome. Cancer Research, 2013, 73, 2749-2759.	0.4	12
73	Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Molecular Aspects of Medicine, 2013, 34, 1066-1087.	2.7	141
74	Discrepancies in drug sensitivity. Nature, 2013, 504, 381-383.	13.7	39
75	Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer. Cell, 2013, 155, 552-566.	13.5	151
76	The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 2013, 45, 1113-1120.	9.4	6,265

#	ARTICLE	IF	CITATIONS
77	Update in Treatment and Targets in Ewing Sarcoma. Hematology/Oncology Clinics of North America, 2013, 27, 1007-1019.	0.9	13
78	Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Systems Biology, 2013, 7, S1.	3.0	83
79	Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treatment Reviews, 2013, 39, 313-320.	3.4	81
80	A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention. Cancer Cell, 2013, 24, 15-29.	7.7	183
81	Proteome-wide Identification of Poly(ADP-Ribosyl)ation Targets in Different Genotoxic Stress Responses. Molecular Cell, 2013, 52, 272-285.	4.5	315
82	Metrics other than potency reveal systematic variation in responses to cancer drugs. Nature Chemical Biology, 2013, 9, 708-714.	3.9	280
83	Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine. American Journal of Pathology, 2013, 183, 1052-1063.	1.9	75
84	Characterization of drugâ€induced transcriptional modules: towards drug repositioning and functional understanding. Molecular Systems Biology, 2013, 9, 662.	3.2	110
85	Scratching the combinatorial drug landscape surface. Pigment Cell and Melanoma Research, 2013, 26, 297-299.	1.5	1
86	Molecular fingerprinting catches responders to therapeutic agents. Genome Biology, 2013, 14, 135.	13.9	0
87	Molecular aspects of cancer cell resistance to chemotherapy. Biochemical Pharmacology, 2013, 85, 1219-1226.	2.0	333
88	Pattern discovery and cancer gene identification in integrated cancer genomic data. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4245-4250.	3.3	361
89	Drugging Topoisomerases: Lessons and Challenges. ACS Chemical Biology, 2013, 8, 82-95.	1.6	698
90	VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer. Molecular Cancer Therapeutics, 2013, 12, 151-161.	1.9	59
91	Omics and Drug Response. Annual Review of Pharmacology and Toxicology, 2013, 53, 475-502.	4.2	130
92	MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Reviews Cancer, 2013, 13, 83-96.	12.8	988
93	Genetics and pharmacogenomics of diffuse gliomas. , 2013, 137, 78-88.		7
94	Prospects and challenges for the development of new therapies for Ewing sarcoma. , 2013, 137, 216-224.		38

#	ARTICLE	IF	CITATIONS
95	Network, nodes and nexus: systems approach to multitarget therapeutics. Current Opinion in Biotechnology, 2013, 24, 1129-1136.	3.3	7
96	Targeting melanoma by small molecules: challenges ahead. Pigment Cell and Melanoma Research, 2013, 26, 464-469.	1.5	10
97	PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy. Molecular Cancer Therapeutics, 2013, 12, 2517-2528.	1.9	60
99	Signaling Network Assessment of Mutations and Copy Number Variations Predict Breast Cancer Subtype-Specific Drug Targets. Cell Reports, 2013, 5, 216-223.	2.9	106
100	What general conclusions can we draw from kinase profiling data sets?. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1425-1433.	1.1	28
102	Cancer genome sequencing: Understanding malignancy as a disease of the genome, its conformation, and its evolution. Cancer Letters, 2013, 340, 152-160.	3.2	21
103	Preventive Evolutionary Medicine of Cancers. Evolutionary Applications, 2013, 6, 134-143.	1.5	25
104	New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncology, The, 2013, 14, e117-e124.	5.1	81
105	Functionalizing Genomic Data for Personalization of Medicine. Clinical Pharmacology and Therapeutics, 2013, 93, 309-311.	2.3	3
106	The Implications of Clonal Genome Evolution for Cancer Medicine. New England Journal of Medicine, 2013, 368, 842-851.	13.9	316
107	The role of tumour–stromal interactions in modifying drug response: challenges and opportunities. Nature Reviews Drug Discovery, 2013, 12, 217-228.	21.5	394
108	Emerging targeted agents in metastatic breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 191-210.	12.5	158
109	Lessons from the Cancer Genome. Cell, 2013, 153, 17-37.	13.5	1,133
110	Evolution and dynamics of pancreatic cancer progression. Oncogene, 2013, 32, 5253-5260.	2.6	167
111	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature Genetics, 2013, 45, 478-486.	9.4	671
112	Journeys into the genome of cancer cells. EMBO Molecular Medicine, 2013, 5, 169-172.	3.3	27
113	Synthetic lethality and cancer: cohesin and PARP at the replication fork. Trends in Genetics, 2013, 29, 290-297.	2.9	31
114	Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models. Cancer Cell, 2013, 23, 121-128.	7.7	343

#	ARTICLE	IF	CITATIONS
115	Accurate Models for P-gp Drug Recognition Induced from a Cancer Cell Line Cytotoxicity Screen. Journal of Medicinal Chemistry, 2013, 56, 5691-5708.	2.9	45
116	Systems biology for molecular life sciences and its impact in biomedicine. Cellular and Molecular Life Sciences, 2013, 70, 1035-1053.	2.4	26
117	Oncogenic ERBB3 Mutations in Human Cancers. Cancer Cell, 2013, 23, 603-617.	7.7	318
118	Dose–finding designs using a novel quasi–continuous endpoint for multiple‰toxicities. Statistics in Medicine, 2013, 32, 2728-2746.	0.8	45
119	EGF-Induced Centrosome Separation Promotes Mitotic Progression and Cell Survival. Developmental Cell, 2013, 25, 229-240.	3.1	65
120	Epigenetic profiling joins personalized cancer medicine. Expert Review of Molecular Diagnostics, 2013, 13, 473-479.	1.5	32
121	Optimal Management of Ewing Sarcoma Family of Tumors: Recent Developments in Systemic Therapy. Paediatric Drugs, 2013, 15, 473-492.	1.3	8
122	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Current Opinion in Pharmacology, 2013, 13, 486-496.	1.7	55
123	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opinion on Therapeutic Targets, 2013, 17, 921-936.	1.5	15
124	Differential Determinants of Cancer Cell Insensitivity to Antimitotic Drugs Discriminated by a One-Step Cell Imaging Assay. Journal of Biomolecular Screening, 2013, 18, 1062-1071.	2.6	7
125	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364.	13.7	993
126	Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment. Journal of Clinical Oncology, 2013, 31, 1858-1865.	0.8	116
127	TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells. Molecular Cancer Research, 2013, 11, 1179-1192.	1.5	31
128	Collections of Simultaneously Altered Genes as Biomarkers of Cancer Cell Drug Response. Cancer Research, 2013, 73, 1699-1708.	0.4	46
129	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. Clinical Cancer Research, 2013, 19, 2381-2392.	3.2	157
130	RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes and Cancer, 2013, 4, 273-284.	0.6	26
131	Oncogene and non-oncogene addiction in inflammation-associated cancers. Future Oncology, 2013, 9, 561-573.	1.1	10
132	Overexpression of the Mitochondrial Folate and Glycine–Serine Pathway: A New Determinant of Methotrexate Selectivity in Tumors. Cancer Research, 2013, 73, 478-482.	0.4	69

#	ARTICLE	IF	CITATIONS
133	Computational Modeling of <i>ERBB2</i> -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors. Science Signaling, 2013, 6, ra68.	1.6	106
134	CancerDR: Cancer Drug Resistance Database. Scientific Reports, 2013, 3, 1445.	1.6	102
135	Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. Annals of Oncology, 2013, 24, 1956-1957.	0.6	21
136	Shape Similarity, Better than Semantic Membership, Accounts for the Structure of Visual Object Representations in a Population of Monkey Inferotemporal Neurons. PLoS Computational Biology, 2013, 9, e1003167.	1.5	80
137	An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development. PLoS Genetics, 2013, 9, e1003254.	1.5	76
138	From Bench to Bedside: Does Preclinical Practice in Translational Oncology Need Some Rebuilding?. Journal of the National Cancer Institute, 2013, 105, 1426-1427.	3.0	13
140	EGFR-Activating Mutations Correlate with a Fanconi Anemiaâ€"like Cellular Phenotype That Includes PARP Inhibitor Sensitivity. Cancer Research, 2013, 73, 6254-6263.	0.4	35
141	Biomarker-driven patient selection for early clinical trials. Current Opinion in Oncology, 2013, 25, 305-312.	1.1	32
142	A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal Cells. Journal of Biomolecular Screening, 2013, 18, 637-646.	2.6	21
143	Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage. Molecular Cancer Therapeutics, 2013, 12, 2591-2600.	1.9	71
144	Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in <i>KRAS</i>-Mutant Lung Cancer. Cancer Discovery, 2013, 3, 548-563.	7.7	153
145	Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma. Cancer Discovery, 2013, 3, 324-337.	7.7	60
146	The UCSC Cancer Genomics Browser: update 2013. Nucleic Acids Research, 2013, 41, D949-D954.	6.5	172
147	<i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors. Molecular Cancer Therapeutics, 2013, 12, 2950-2961.	1.9	18
148	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <i>LKB1</i>-Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879.	7.7	127
149	Metastatic Castration-Resistant Prostate Cancer Hungers for Leucine. Journal of the National Cancer Institute, 2013, 105, 1427-1428.	3.0	1
150	Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Childrenâ€™s Oncology Group. Frontiers in Oncology, 2013, 3, 141.	1.3	36
151	A molecular case report. Cancer Biology and Therapy, 2013, 14, 95-99.	1.5	3

#	ARTICLE	IF	CITATIONS
152	PiHelper: an open source framework for drug-target and antibody-target data. Bioinformatics, 2013, 29, 2071-2072.	1.8	13
153	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 2013, 3, 308-323.	7.7	549
154	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	7.1	33
155	Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications, 2013, 4, 1908.	5.8	310
156	Inhibiting the RASâ€"PI3K Pathway in Cancer Therapy. The Enzymes, 2013, 34 Pt. B, 107-136.	0.7	20
157	Cell Line Identity Finding by Fingerprinting, an Optimized Resource for Short Tandem Repeat Profile Authentication. Genetic Testing and Molecular Biomarkers, 2013, 17, 254-259.	0.3	11
158	the 11q13â€"q14 amplicon: Clinicopathological correlations and potential drivers. Genes Chromosomes and Cancer, 2013, 52, 333-355.	1.5	70
159	DRUG INTERVENTION RESPONSE PREDICTIONS WITH PARADIGM (DIRPP) IDENTIFIES DRUG RESISTANT CANCER CELL LINES AND PATHWAY MECHANISMS OF RESISTANCE. , 2013, , .		9
160	<i>BRAF/NRAS</i> Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research, 2013, 19, 4589-4598.	3.2	115
161	Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2013, 31, 131-161.	0.8	40
162	Bromodomains on the brain. Science-Business EXchange, 2013, 6, 277-277.	0.0	0
163	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. Journal of Clinical Oncology, 2013, 31, 1874-1884.	0.8	101
164	PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21124-21129.	3.3	175
165	Establishing a High-Throughput and Automated Cancer Cell Proliferation Panel for Oncology Lead Optimization. Journal of Biomolecular Screening, 2013, 18, 1043-1053.	2.6	2
166	INK4a/ARF limits the expansion of cells suffering from replication stress. Cell Cycle, 2013, 12, 1948-1954.	1.3	16
167	Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood, 2013, 121, 4166-4174.	0.6	184
168	Comparison and validation of genomic predictors for anticancer drug sensitivity. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 597-602.	2.2	70
169	Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway. Current Pharmaceutical Design, 2013, 19, 883-894.	0.9	47

#	Article	IF	Citations
170	Computation as the Mechanistic Bridge Between Precision Medicine and Systems Therapeutics. Clinical Pharmacology and Therapeutics, 2013, 93, 117-128.	2.3	37
171	Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncology Reports, 2013, 29, 2181-2190.	1.2	55
172	<i>Saccharomyces cerevisiae</i> Genetics Predicts Candidate Therapeutic Genetic Interactions at the Mammalian Replication Fork. G3: Genes, Genomes, Genetics, 2013, 3, 273-282.	0.8	34
173	SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA. , 2013, , .		20
174	Modeling precision treatment of breast cancer. Genome Biology, 2013, 14, R110.	13.9	264
175	Enhancing Cancer Drug Discovery through Novel Cell Signaling Pathway Panel Strategy. Cancer Growth and Metastasis, 2013, 6, CGM.S11134.	3.5	6
176	The Level of Ets-1 Protein Is Regulated by Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Cancer Cells to Prevent DNA Damage. PLoS ONE, 2013, 8, e55883.	1.1	27
177	Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines. PLoS ONE, 2013, 8, e60339.	1.1	6
178	Serine/Threonine Kinase 17A Is a Novel Candidate for Therapeutic Targeting in Glioblastoma. PLoS ONE, 2013, 8, e81803.	1.1	24
179	Epidemiology and therapies for metastatic sarcoma. Clinical Epidemiology, 2013, 5, 147.	1.5	111
180	The Importance of Cancer Cell Lines as in vitro Models in Cancer Methylome Analysis and Anticancer Drugs Testing. , 0, , .		34
182	Emerging Molecular-Targeted Therapies in Early-Phase Clinical Trials and Preclinical Models. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 420-424.	1.8	8
183	Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. PLoS ONE, 2014, 9, e103988.	1.1	319
184	Predicting Response to Preoperative Chemotherapy Agents by Identifying Drug Action on Modeled MicroRNA Regulation Networks. PLoS ONE, 2014, 9, e98140.	1.1	3
185	Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias. PLoS ONE, 2014, 9, e102221.	1.1	18
186	Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer. PLoS ONE, 2014, 9, e106784.	1.1	16
187	pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels. PLoS ONE, 2014, 9, e107468.	1.1	1,363
188	Simulation Studies as Designed Experiments: The Comparison of Penalized Regression Models in the â€œLarge p, Small nâ€•Setting. PLoS ONE, 2014, 9, e107957.	1.1	15

#	ARTICLE	IF	CITATIONS
189	PELP1 Suppression Inhibits Colorectal Cancer through c-Src Downregulation. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-9.	1.9	14
190	Label-free drug discovery. Frontiers in Pharmacology, 2014, 5, 52.	1.6	66
191	Exome sequencing: what clinicians need to know. Advances in Genomics and Genetics, 0, , 15.	0.8	6
192	Cell line modeling for systems medicine in cancers (Review). International Journal of Oncology, 2014, 44, 371-376.	1.4	22
193	Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 23.	5.5	3
194	In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies. Current Medicinal Chemistry, 2014, 21, 1595-1606.	1.2	52
195	Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. Bioinformatics, 2014, 30, 2051-2059.	1.8	30
196	A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nature Communications, 2014, 5, 3608.	5.8	94
197	A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between <i>MSH3</i> and <i>PRKDC</i>. Cancer Discovery, 2014, 4, 592-605.	7.7	60
198	E3 Ubiquitin Ligase HOIP Attenuates Apoptotic Cell Death Induced by Cisplatin. Cancer Research, 2014, 74, 2246-2257.	0.4	61
199	Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma. Journal of Hematology and Oncology, 2014, 7, 76.	6.9	23
200	New Strategies in Ewing Sarcoma: Lost in Translation?. Clinical Cancer Research, 2014, 20, 3050-3056.	3.2	28
201	Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer, 2014, 14, 813.	1.1	132
202	A PTCH1 Homolog Transcriptionally Activated by p53 Suppresses Hedgehog Signaling. Journal of Biological Chemistry, 2014, 289, 33020-33031.	1.6	29
203	Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Research, 2014, 16, 462.	2.2	46
204	The Genome of the Chicken DT40 Bursal Lymphoma Cell Line. G3: Genes, Genomes, Genetics, 2014, 4, 2231-2240.	0.8	25
205	Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer. BMC Pharmacology & Toxicology, 2014, 15, 66.	1.0	23
206	UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Cell Death and Disease, 2014, 5, e1411-e1411.	2.7	33

#	Article	IF	Citations
207	Finding common ground in cancer research. Nature Medicine, 2014, 20, 1-1.	15.2	18
208	IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death and Disease, 2014, 5, e1300-e1300.	2.7	28
209	The AURORA initiative for metastatic breast cancer. British Journal of Cancer, 2014, 111, 1881-1887.	2.9	77
210	Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine. British Journal of Cancer, 2014, 110, 2269-2276.	2.9	22
211	Resolving cancerâ€"stroma interfacial signalling and interventions with micropatterned tumourâ€"stromal assays. Nature Communications, 2014, 5, 5662.	5.8	45
212	An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2014, 11, 995-1008.	1.9	24
213	In vitro clinical trials: the future of cell-based profiling. Frontiers in Pharmacology, 2014, 5, 121.	1.6	16
214	A Diverse Stochastic Search Algorithm for Combination Therapeutics. BioMed Research International, 2014, 2014, 1-9.	0.9	5
215	Engineered reversal of drug resistance in cancer cells--metastases suppressor factors as change agents. Nucleic Acids Research, 2014, 42, 764-773.	6.5	199
216	Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine. PLoS Computational Biology, 2014, 10, e1003554.	1.5	61
217	The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation. PLoS Genetics, 2014, 10, e1004475.	1.5	335
218	Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action. Frontiers in Genetics, 2014, 5, 342.	1.1	61
219	Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning. Bioinformatics, 2014, 30, i556-i563.	1.8	72
220	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Frontiers in Pharmacology, 2014, 5, 252.	1.6	34
221	Cross-species analysis of genetically engineered mouse models of MAPK driven colorectal cancer identifies hallmarks of human disease. DMM Disease Models and Mechanisms, 2014, 7, 613-23.	1.2	5
222	Basal Activity of a PARP1-NuA4 Complex Varies Dramatically across Cancer Cell Lines. Cell Reports, 2014, 8, 1808-1818.	2.9	16
223	Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery. Pharmacogenomics, 2014, 15, 1943-1946.	0.6	5
224	Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity. Cell Reports, 2014, 9, 75-89.	2.9	313

#	Article	IF	Citations
225	Targeting the DNA Repair Pathway in Ewing Sarcoma. Cell Reports, 2014, 9, 829-840.	2.9	141
226	Drug sensitivity prediction for cancer cell lines based on pairwise kernels and miRNA profiles. , 2014, , .		1
227	Multidimensional Profiling in the Investigation of Small-Molecule-Induced Cell Death. Methods in Enzymology, 2014, 545, 265-302.	0.4	9
228	Personalized oncology: genomic screening in phase 1. Apmis, 2014, 122, 723-733.	0.9	18
229	Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers. BMJ Open, 2014, 4, e004188.	0.8	15
230	Induction of p53â€mediated transcription and apoptosis by exportinâ€1 (<scp>XPO</scp>1) inhibition in mantle cell lymphoma. Cancer Science, 2014, 105, 795-801.	1.7	81
231	Cancer Biology, Toxicology and Alternative Methods Development Go Handâ€inâ€Hand. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 50-58.	1.2	22
232	Gene co-expression analysis identifies common modules related to prognosis and drug resistance in cancer cell lines. International Journal of Cancer, 2014, 135, 2795-2803.	2.3	24
233	Phosphatidylinositolâ€3â€kinase pathway aberrations in gastric and colorectal cancer: Metaâ€analysis, coâ€occurrence and ethnic variation. International Journal of Cancer, 2014, 134, 1232-1238.	2.3	50
234	Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas. Journal of the National Cancer Institute, 2014, 106, dju329-dju329.	3.0	26
235	Automated Structureâ€"Activity Relationship Mining: Connecting Chemical Structure to Biological Profiles. Journal of Biomolecular Screening, 2014, 19, 738-748.	2.6	19
236	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cellâ€"like diffuse large B-cell lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2349-2354.	3.3	355
237	Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Frontiers in Oncology, 2014, 4, 42.	1.3	76
238	Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression. BMC Systems Biology, 2014, 8, 74.	3.0	18
239	Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Medicine, 2014, 6, 81.	3.6	31
240	Inference of dynamic biological networks based on responses to drug perturbations. Eurasip Journal on Bioinformatics and Systems Biology, 2014, 2014, 14.	1.4	8
241	The hidden switches underlying RORÎ±-mediated circuits that critically regulate uncontrolled cell proliferation. Journal of Molecular Cell Biology, 2014, 6, 338-348.	1.5	27
242	Innovative Therapies in Ewing Sarcoma. Advances in Anatomic Pathology, 2014, 21, 44-62.	2.4	14

#	Article	IF	Citations
243	Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Current Opinion in Oncology, 2014, 26, 428-433.	1.1	36
244	canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Research, 2014, 42, D1040-D1047.	6.5	69
245	TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas. Journal of Thoracic Oncology, 2014, 9, 872-881.	0.5	22
246	Impact of tumor sequencing on the use of anticancer drugs. Current Opinion in Oncology, 2014, 26, 347-356.	1.1	19
247	Imaging windows for long-term intravital imaging. Intravital, 2014, 3, e29917.	2.0	139
248	LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT. Journal of Thoracic Oncology, 2014, 9, 794-804.	0.5	65
249	Implementing precision medicine initiatives in the clinic. Current Opinion in Oncology, 2014, 26, 340-346.	1.1	17
250	Molecular Pathways: Targeting ETS Gene Fusions in Cancer. Clinical Cancer Research, 2014, 20, 4442-4448.	3.2	54
251	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. Cancer Research, 2014, 74, 2825-2834.	0.4	61
252	Fast randomization of large genomic datasets while preserving alteration counts. Bioinformatics, 2014, 30, i617-i623.	1.8	36
253	Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer. Clinical Cancer Research, 2014, 20, 4274-4288.	3.2	72
255	Deploying Ibrutinib to Lung Cancer: Another Step in the Quest Towards Drug Repurposing. Journal of the National Cancer Institute, 2014, 106, dju250-dju250.	3.0	8
256	Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice. Breast Cancer Research and Treatment, 2014, 148, 19-31.	1.1	2
257	Computational identification of multi-omic correlates of anticancer therapeutic response. BMC Genomics, 2014, 15, S2.	1.2	33
258	Study Design and the Drug Development Process. JAMA - Journal of the American Medical Association, 2014, 311, 2023.	3.8	2
259	A BRCA1deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Research, 2014, 16, R25.	2.2	50
260	VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research, 2014, 16, R53.	2.2	28
261	Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment. Genome Medicine, 2014, 6, 17.	3.6	27

#	ARTICLE	IF	CITATIONS
262	Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling. Cancer Research, 2014, 74, 921-931.	0.4	24
263	Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies?. Clinical Cancer Research, 2014, 20, 1064-1066.	3.2	10
264	KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Nonâ€"Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 1611-1624.	1.9	51
265	FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLCs. Molecular Cancer Research, 2014, 12, 32-37.	1.5	45
266	MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Research, 2014, 42, 10433-10447.	6.5	58
267	Whither Bioinformatics?. Obstetrics and Gynecology, 2014, 123, 1151-1152.	1.2	0
268	Basal Cell Signaling by p63 Controls Luminal Progenitor Function and Lactation via NRG1. Developmental Cell, 2014, 28, 147-160.	3.1	98
269	The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response. Current Opinion in Genetics and Development, 2014, 24, 114-119.	1.5	29
270	Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Research and Treatment, 2014, 143, 301-312.	1.1	52
271	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	13.7	702
272	Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 525-538.	1.1	31
273	Non-synonymous variations in cancer and their effects on the human proteome: workflow for NGS data biocuration and proteome-wide analysis of TCGA data. BMC Bioinformatics, 2014, 15, 28.	1.2	12
274	A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Investigational New Drugs, 2014, 32, 171-177.	1.2	11
275	Targeting tumour-supportive cellular machineries in anticancer drug development. Nature Reviews Drug Discovery, 2014, 13, 179-196.	21.5	202
276	Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors. Journal of Neuro-Oncology, 2014, 118, 83-92.	1.4	13
277	Identification of genomic alterations in oesophageal squamous cell cancer. Nature, 2014, 509, 91-95.	13.7	903
278	Epistatic interactions and drug response. Journal of Pathology, 2014, 232, 255-263.	2.1	24
279	Genomic and molecular characterization of esophageal squamous cell carcinoma. Nature Genetics, 2014, 46, 467-473.	9.4	523

#	ARTICLE	IF	CITATIONS
280	Cancer Cell Lines for Drug Discovery and Development. Cancer Research, 2014, 74, 2377-2384.	0.4	324
281	Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treatment Reviews, 2014, 40, 862-871.	3.4	257
282	Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. Molecular Cancer Therapeutics, 2014, 13, 433-443.	1.9	627
283	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research, 2014, 20, 265-272.	3.2	36
284	The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Advanced Drug Delivery Reviews, 2014, 69-70, 42-51.	6.6	273
285	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications, 2014, 5, 2997.	5.8	741
286	An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. Molecular Oncology, 2014, 8, 378-388.	2.1	10
287	mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1. Cancer Discovery, 2014, 4, 42-52.	7.7	116
288	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	4.0	255
289	Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine. Cancer Letters, 2014, 352, 102-112.	3.2	67
290	Vaccinia Virus Outperforms a Panel of Other Poxviruses as a Potent Oncolytic Agent for the Control of Head and Neck Squamous Cell Carcinoma Cell Lines. Intervirology, 2014, 57, 17-22.	1.2	8
291	Inactivating CUX1 mutations promote tumorigenesis. Nature Genetics, 2014, 46, 33-38.	9.4	111
292	A comparative survey of functional footprints of EGFR pathway mutations in human cancers. Oncogene, 2014, 33, 5078-5089.	2.6	11
293	Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death and Differentiation, 2014, 21, 258-269.	5.0	152
294	Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance. Biochemical Society Transactions, 2014, 42, 758-764.	1.6	5
295	Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Molecular Medicine, 2014, 6, 1279-1293.	3.3	612
296	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Experimental Hematology, 2014, 42, 927-938.	0.2	15
297	Molecular pathology of bone tumours: diagnostic implications. Histopathology, 2014, 64, 461-476.	1.6	21

#	ARTICLE	IF	CITATIONS
298	Prospects and Pitfalls of Personalizing Therapies for Sarcomas: From Children, Adolescents, and Young Adults to the Elderly. Current Oncology Reports, 2014, 16, 401.	1.8	9
299	p53 as a target for the treatment of cancer. Cancer Treatment Reviews, 2014, 40, 1153-1160.	3.4	187
300	The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 2547-2558.	1.9	106
301	The cellular thermal shift assay for evaluating drug target interactions in cells. Nature Protocols, 2014, 9, 2100-2122.	5.5	900
302	Systems biology of cisplatin resistance: past, present and future. Cell Death and Disease, 2014, 5, e1257-e1257.	2.7	625
304	Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science, 2014, 345, 216-220.	6.0	808
305	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nature Communications, 2014, 5, 5006.	5.8	149
306	NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes. ACS Chemical Biology, 2014, 9, 2247-2254.	1.6	60
307	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014, 511, 616-620.	13.7	698
308	Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways. Cancer Research, 2014, 74, 2936-2945.	0.4	82
309	Lean Big Data integration in systems biology and systems pharmacology. Trends in Pharmacological Sciences, 2014, 35, 450-460.	4.0	85
310	Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality. Cell, 2014, 158, 1199-1209.	13.5	249
311	Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends in Genetics, 2014, 30, 326-339.	2.9	230
312	Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization. Journal of Chemical Information and Modeling, 2014, 54, 2347-2359.	2.5	101
313	Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Letters, 2014, 351, 272-280.	3.2	16
314	Three‐dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo. Biotechnology Journal, 2014, 9, 1115-1128.	1.8	316
315	Lentiviral Vector-based Insertional Mutagenesis Identifies Genes Involved in the Resistance to Targeted Anticancer Therapies. Molecular Therapy, 2014, 22, 2056-2068.	3.7	16
316	Novel genetic targets in endometrial cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 725-730.	1.5	16

#	Article	IF	Citations
317	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	13.5	1,184
318	Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiological Genomics, 2014, 46, 699-724.	1.0	26
319	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. Clinical Cancer Research, 2014, 20, 4827-4836.	3.2	186
320	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. Molecular Cancer, 2014, 13, 154.	7.9	2
321	On the use of pharmacogenetics in cancer treatment and clinical trials. European Journal of Cancer, 2014, 50, 2532-2543.	1.3	21
323	Re-evaluation of cytostatic therapies for meningiomas in vitro. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1343-1352.	1.2	14
324	Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biology, 2014, 15, R47.	13.9	645
325	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. Human Molecular Genetics, 2014, 23, 1527-1537.	1.4	19
326	Statistical Analysis of Next Generation Sequencing Data. , 2014, , .		20
327	MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science, 2014, 345, 220-222.	6.0	278
328	CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers. Cancer Research, 2014, 74, 3947-3958.	0.4	107
329	Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?. Cancer Research, 2014, 74, 4016-4023.	0.4	90
330	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery, 2014, 4, 816-827.	7.7	448
331	In silico modeling predicts drug sensitivity of patient-derived cancer cells. Journal of Translational Medicine, 2014, 12, 128.	1.8	26
332	Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biology, 2014, 12, 20.	1.7	34
333	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
334	Drugging MYCN through an Allosteric Transition in Aurora Kinase A. Cancer Cell, 2014, 26, 414-427.	7.7	231
335	Translational research in oncology—10 years of progress and future prospects. Nature Reviews Clinical Oncology, 2014, 11, 649-662.	12.5	65

#	ARTICLE	IF	CITATIONS
336	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection. Molecular Cancer Research, 2014, 12, 571-582.	1.5	94
337	Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opinion on Therapeutic Targets, 2014, 18, 1315-1328.	1.5	53
338	Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth. Clinical Cancer Research, 2014, 20, 1190-1203.	3.2	64
339	A community effort to assess and improve drug sensitivity prediction algorithms. Nature Biotechnology, 2014, 32, 1202-1212.	9.4	653
340	Round cell sarcomas â€" Biologically important refinements in subclassification. International Journal of Biochemistry and Cell Biology, 2014, 53, 493-504.	1.2	62
341	Collection, integration and analysis of cancer genomic profiles: from data to insight. Current Opinion in Genetics and Development, 2014, 24, 92-98.	1.5	22
342	PI3K/AKT signaling pathway and cancer: an updated review. Annals of Medicine, 2014, 46, 372-383.	1.5	887
343	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Research, 2014, 74, 3146-3156.	0.4	69
344	Confocal SERS Mapping of Glycan Expression for the Identification of Cancerous Cells. Analytical Chemistry, 2014, 86, 4775-4782.	3.2	44
345	Advances in Therapy for Pediatric Sarcomas. Current Oncology Reports, 2014, 16, 395.	1.8	25
346	Cell banking for pharmaceutical research. Drug Discovery Today, 2014, 19, 1518-1529.	3.2	13
347	In vitro anticancer drug test: A new method emerges from the model of glioma stem cells. Toxicology Reports, 2014, 1, 188-199.	1.6	21
348	Classification of endometrial carcinoma: more than two types. Lancet Oncology, The, 2014, 15, e268-e278.	5.1	479
349	Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs. FEBS Journal, 2014, 281, 3177-3192.	2.2	22
350	Reading between the lines; understanding drug response in the post genomic era. Molecular Oncology, 2014, 8, 1112-1119.	2.1	12
351	Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93.	2.9	266
352	Oncogenes in melanoma: An update. European Journal of Cell Biology, 2014, 93, 1-10.	1.6	51
353	Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use. PLoS ONE, 2014, 9, e92146.	1.1	86

#	ARTICLE	IF	CITATIONS
354	StickWRLD as an Interactive Visual Pre-Filter for Canceromics-Centric Expression Quantitative Trait Locus Data. Cancer Informatics, 2014, 13s3, CIN.S14024.	0.9	1
355	Evaluation of the Retinoids With Cisplatin and Vincristine in Xenograft Models of Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2014, 36, e23-e27.	0.3	0
356	STEPWISE GROUP SPARSE REGRESSION (SGSR): GENE-SET-BASED PHARMACOGENOMIC PREDICTIVE MODELS WITH STEPWISE SELECTION OF FUNCTIONAL PRIORS. , 2014, , .		3
357	From drug response profiling to target addiction scoring in cancer cell models. DMM Disease Models and Mechanisms, 2015, 8, 1255-1264.	1.2	13
358	A 12â€gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5â€fluorouracil or FOLFIRI. Journal of Pathology: Clinical Research, 2015, 1, 160-172.	1.3	8
359	Mouse models of colorectal cancer as preclinical models. BioEssays, 2015, 37, 909-920.	1.2	59
360	A New Drug Combinatory Effect Prediction Algorithm on the Cancer Cell Based on Gene Expression and Doseâ€"Response Curve. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 80-90.	1.3	31
361	Big Data for Precision Medicine. Engineering, 2015, 1, 277-279.	3.2	31
362	Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Scientific Reports, 2015, 5, 10129.	1.6	45
363	XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Scientific Reports, 2015, 5, 11465.	1.6	20
365	An automated fitting procedure and software for dose-response curves with multiphasic features. Scientific Reports, 2015, 5, 14701.	1.6	132
366	Inhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor Models. Scientific Reports, 2015, 5, 17576.	1.6	33
367	Associations of PI3KR1 and mTOR Polymorphisms with Esophageal Squamous Cell Carcinoma Risk and Gene-Environment Interactions in Eastern Chinese Populations. Scientific Reports, 2015, 5, 8250.	1.6	48
368	A chemicalâ€"genetic interaction map of small molecules using highâ€throughput imaging in cancer cells. Molecular Systems Biology, 2015, 11, 846.	3.2	79
369	Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo. Journal of Visualized Experiments, 2015, , .	0.2	2
370	A genomeâ€scale screen reveals contextâ€dependent ovarian cancer sensitivity to mi <scp>RNA</scp> overexpression. Molecular Systems Biology, 2015, 11, 842.	3.2	10
371	Importance of collection in gene set enrichment analysis of drug response in cancer cell lines. Scientific Reports, 2014, 4, 4092.	1.6	21
372	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics, 2015, 16, S2.	1.2	12

#	Article	IF	Citations
373	Activation of NQO1 in NQO1*2 polymorphic human leukemic HL-60 cells by diet-derived sulforaphane. Experimental Hematology and Oncology, 2015, 5, 27.	2.0	8
374	Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity. Scientific Reports, 2015, 5, 18494.	1.6	40
375	Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of InÂVivo Mouse Models. Cell Reports, 2015, 12, 2060-2071.	2.9	34
376	A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. BMC Genomics, 2015, 16, S6.	1.2	12
377	Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?. Clinical Sarcoma Research, 2015, 5, 20.	2.3	33
378	Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Medical Genomics, 2015, 8, S5.	0.7	56
379	Towards pathwayâ€centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway. Clinical and Translational Medicine, 2015, 4, 66.	1.7	2
380	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: <i>PALB2</i> mutation predicts exceptional <i>in vivo</i> response to BMN 673. Pediatric Blood and Cancer, 2015, 62, 91-98.	0.8	65
381	Network pharmacodynamic models for customized cancer therapy. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 243-251.	6.6	11
382	Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Molecular Cancer Therapeutics, 2015, 14, 2452-2462.	1.9	56
383	Convergent Science Physical Oncology. Convergent Science Physical Oncology, 2015, 1, 010201.	2.6	0
384	miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget, 2015, 6, 6092-6104.	0.8	82
385	Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity. Journal of Proteomics and Bioinformatics, 2015, 08, 204-211.	0.4	12
386	Review Computational characterisation of cancer molecular profiles derived using next generation sequencing. Wspolczesna Onkologia, 2015, 1A, 78-91.	0.7	4
387	Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Medical Journal, 2015, 56, 1186.	0.9	14
388	A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Frontiers in Genetics, 2015, 6, 341.	1.1	9
389	Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Frontiers in Oncology, 2015, 5, 193.	1.3	14
390	A Network Flow-Based Method to Predict Anticancer Drug Sensitivity. PLoS ONE, 2015, 10, e0127380.	1.1	8

#	ARTICLE	IF	CITATIONS
391	Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia. PLoS ONE, 2015, 10, e0127433.	1.1	23
392	Predicting Anticancer Drug Responses Using a Dual-Layer Integrated Cell Line-Drug Network Model. PLoS Computational Biology, 2015, 11, e1004498.	1.5	152
393	Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib. PLoS ONE, 2015, 10, e0130700.	1.1	36
394	Context Sensitive Modeling of Cancer Drug Sensitivity. PLoS ONE, 2015, 10, e0133850.	1.1	13
395	A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions. PLoS ONE, 2015, 10, e0139446.	1.1	39
396	Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. PLoS ONE, 2015, 10, e0140988.	1.1	72
397	Article Commentary: Predictive Modeling of Drug Treatment in the Area of Personalized Medicine. Cancer Informatics, 2015, 14s4, CIN.S19330.	0.9	11
399	Identifying the determinants of response to MDM2 inhibition. Oncotarget, 2015, 6, 7701-7712.	0.8	35
400	The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget, 2015, 6, 18875-18890.	0.8	74
401	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1288-96.	3.3	110
402	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E536-45.	3.3	121
403	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 2015, 6, 6377.	5.8	498
404	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nature Medicine, 2015, 21, 741-750.	15.2	107
405	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer Journal, 2015, 5, e309-e309.	2.8	19
406	HER2-mTOR signaling–driven breast cancer cells require ER-associated degradation to survive. Science Signaling, 2015, 8, ra52.	1.6	27
407	PI3KÎ² Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways. Scientific Reports, 2015, 5, 9465.	1.6	42
408	The Tumor Macroenvironment. Advances in Cancer Research, 2015, 128, 235-262.	1.9	48
409	Raf/MEK/ERK Signaling. , 2015, , 275-305.		0

#	Article	IF	Citations
410	Improving Drug Sensitivity Prediction Using Different Types of Data. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 98-105.	1.3	16
411	Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with doseâ€“response data. Bioinformatics, 2015, 31, 3815-3821.	1.8	31
412	Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition. Pharmacological Research, 2015, 102, 218-234.	3.1	42
413	The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. EBioMedicine, 2015, 2, 1351-1363.	2.7	228
414	The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nature Communications, 2015, 6, 10077.	5.8	46
415	Towards in vitro DT/DNT testing: Assaying chemical susceptibility in early differentiating NT2 cells. Toxicology, 2015, 338, 69-76.	2.0	9
416	Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. International Journal of Oncology, 2015, 47, 446-454.	1.4	34
417	Loss of MLH1 confers resistance to PI3KÎ² inhibitors in renal clear cell carcinoma with SETD2 mutation. Tumor Biology, 2015, 36, 3457-3464.	0.8	19
418	Paired imageâ€•and FACSâ€•based toxicity assays for high content screening of spheroidâ€•type tumor cell cultures. FEBS Open Bio, 2015, 5, 85-90.	1.0	12
419	New therapeutic targets in Ewing sarcoma: from pre-clinical proof-of-concept to clinical trials. , 2015, , 393-405.		0
420	The value of monitoring to control evolving populations. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1007-1012.	3.3	50
421	â€œOmicsâ€•in pharmaceutical research: overview, applications, challenges, and future perspectives. Chinese Journal of Natural Medicines, 2015, 13, 3-21.	0.7	75
422	HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis. FASEB Journal, 2015, 29, 2070-2080.	0.2	39
423	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Reports, 2015, 16, 280-296.	2.0	200
424	Interferon Î±/Î² Enhances the Cytotoxic Response of MEK Inhibition in Melanoma. Molecular Cell, 2015, 57, 784-796.	4.5	29
425	Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures. Medicinal Research Reviews, 2015, 35, 408-36.	5.0	62
426	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research, 2015, 21, 819-832.	3.2	100
427	A Coding Single-Nucleotide Polymorphism in Lysine Demethylase <i>KDM4A</i> Associates with Increased Sensitivity to mTOR Inhibitors. Cancer Discovery, 2015, 5, 245-254.	7.7	25

#	Article	IF	Citations
428	MACE: mutation-oriented profiling of chemical response and gene expression in cancers. Bioinformatics, 2015, 31, 1508-1514.	1.8	5
429	Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes. Molecular Cancer Therapeutics, 2015, 14, 298-306.	1.9	14
430	Understanding and Using Information about Cancer Genomes. , 2015, , 357-368.e3.		0
431	<i>IRS2</i> Copy Number Gain, <i>KRAS</i> and <i>BRAF</i> Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines. Molecular Cancer Therapeutics, 2015, 14, 620-630.	1.9	28
432	Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair, 2015, 28, 107-115.	1.3	55
433	An ecosystem of cancer cell line factories to support a cancer dependency map. Nature Reviews Genetics, 2015, 16, 373-374.	7.7	65
434	Moving ahead on harnessing synthetic lethality to fight cancer. Molecular and Cellular Oncology, 2015, 2, e977150.	0.3	1
435	Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1253-1267.	1.5	2
436	Drugging PI3K in cancer: refining targets and therapeutic strategies. Current Opinion in Pharmacology, 2015, 23, 98-107.	1.7	186
437	MP39-03 LOSS OF MLH1 CONFERS RESISTANCE TO PI3KβÎ² INHIBITORS IN RENAL CLEAR CELL CARCINOMA WITH SETD2 MUTATION. Journal of Urology, 2015, 193, .	0.2	0
438	Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clinical Cancer Research, 2015, 21, 3841-3852.	3.2	80
439	Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics, 2015, 31, 3799-3806.	1.8	17
440	Big Data for Health. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1193-1208.	3.9	571
441	Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. Molecular Cancer Research, 2015, 13, 713-720.	1.5	34
442	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	9.4	451
443	Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors. Cell Death and Disease, 2015, 6, e1757-e1757.	2.7	43
444	Genetic mutations in human rectal cancers detected by targeted sequencing. Journal of Human Genetics, 2015, 60, 589-596.	1.1	25
445	Analysis of impedance-based cellular growth assays. Bioinformatics, 2015, 31, 2705-2712.	1.8	33

#	Article	IF	Citations
446	Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas. BMC Medical Genomics, 2015, 8, 28.	0.7	24
447	MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell, 2015, 28, 129-140.	7.7	110
448	Novel approaches to improving the chemical safety of the meat chain towards toxicants. Meat Science, 2015, 109, 75-85.	2.7	30
449	Precision medicine for metastatic breast cancer—limitations and solutions. Nature Reviews Clinical Oncology, 2015, 12, 693-704.	12.5	272
450	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i>-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	7.7	696
452	Bioreactor-engineered cancer tissue-like structures mimic phenotypes, gene expression profiles and drug resistance patterns observed "inÂvivo". Biomaterials, 2015, 62, 138-146.	5.7	59
453	Publisher's Note: Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction. Computational Biology and Chemistry, 2015, 58, 104-119.	1.1	4
454	Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. Molecular and Cellular Proteomics, 2015, 14, 2479-2492.	2.5	17
455	High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. ACS Medicinal Chemistry Letters, 2015, 6, 948-952.	1.3	30
456	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications, 2015, 6, 7002.	5.8	251
457	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 2015, 17, 35.	2.2	8
458	RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status. European Journal of Cancer, 2015, 51, 841-851.	1.3	15
459	Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Seminars in Cancer Biology, 2015, 35, S25-S54.	4.3	468
460	Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treatment Reviews, 2015, 41, 391-400.	3.4	23
461	Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome. BMC Cancer, 2015, 15, 135.	1.1	19
462	Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer, 2015, 15, 235.	1.1	44
463	Drug sensitivity in cancer cell lines is not tissue-specific. Molecular Cancer, 2015, 14, 40.	7.9	39
464	Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer. Genome Biology, 2015, 16, 61.	3.8	5

#	ARTICLE	IF	CITATIONS
465	Response of Head and Neck Squamous Cell Carcinoma Cells Carrying *PIK3CA* Mutations to Selected Targeted Therapies. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 543.	1.2	25
466	Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. BMC Cancer, 2015, 15, 179.	1.1	15
467	PARP inhibitors: the journey from research hypothesis to clinical approval. Personalized Medicine, 2015, 12, 139-154.	0.8	2
468	Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nature Communications, 2015, 6, 6169.	5.8	247
469	Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology. Annals of Oncology, 2015, 26, 582-588.	0.6	13
470	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	168
471	Exploiting replicative stress to treat cancer. Nature Reviews Drug Discovery, 2015, 14, 405-423.	21.5	243
472	*SLFN11* Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clinical Cancer Research, 2015, 21, 4184-4193.	3.2	89
473	Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, 2015, 161, 933-945.	13.5	1,710
474	RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?. Clinical Cancer Research, 2015, 21, 1802-1809.	3.2	146
475	Combining label-free cell phenotypic profiling with computational approaches for novel drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 331-343.	2.5	19
476	Adolescent and Young Adult (AYA) Oncology in the United States. Journal of Pediatric Hematology/Oncology, 2015, 37, 161-169.	0.3	56
477	*In vitro* human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics, 2015, 16, 273-285.	0.6	127
478	PICan: An integromics framework for dynamic cancer biomarker discovery. Molecular Oncology, 2015, 9, 1234-1240.	2.1	15
479	Organoid development in cancer genome discovery. Current Opinion in Genetics and Development, 2015, 30, 42-48.	1.5	58
480	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511.	9.4	1,372
481	Optimal Drug Prediction From Personal Genomics Profiles. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1264-1270.	3.9	43
482	Robust meta-analysis of gene expression using the elastic net. Nucleic Acids Research, 2015, 43, e79-e79.	6.5	124

#	Article	IF	Citations
483	Lung Cancer Cell Line Screen Links Fanconi Anemia/BRCA Pathway Defects to Increased Relative Biological Effectiveness of Proton Radiation. International Journal of Radiation Oncology Biology Physics, 2015, 91, 1081-1089.	0.4	77
484	Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine, 2015, 21, 440-448.	15.2	408
485	Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. Nature Communications, 2015, 6, 8323.	5.8	74
486	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
487	Large-Scale Drug Screens Support Precision Medicine. Cancer Discovery, 2015, 5, 1130-1132.	7.7	10
488	What role could organoids play in the personalization of cancer treatment?. Pharmacogenomics, 2015, 16, 1523-1526.	0.6	11
489	Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection. BMC Cancer, 2015, 15, 489.	1.1	116
490	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discovery, 2015, 5, 1210-1223.	7.7	575
491	An update on chemotherapy for osteosarcoma. Expert Opinion on Pharmacotherapy, 2015, 16, 2727-2736.	0.9	187
492	Systematic analysis of BRAF^V^{600E} melanomas reveals a role for JNK/c‑Jun pathway in adaptive resistance to drug‑induced apoptosis. Molecular Systems Biology, 2015, 11, 797.	3.2	84
493	BRAF/NRAS wild‑type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell and Melanoma Research, 2015, 28, 117-119.	1.5	49
494	Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4410-7.	3.3	283
495	PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. Molecular Cancer Therapeutics, 2015, 14, 2818-2830.	1.9	52
496	KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. Cancer Research, 2015, 75, 2897-2906.	0.4	37
497	Reprint of "Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction". Computational Biology and Chemistry, 2015, 59, 123-138.	1.1	14
498	Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. Journal of the National Cancer Institute, 2015, 107, djv247.	3.0	18
499	Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). Nature Communications, 2015, 6, 8088.	5.8	463
500	Intelligent Computing Theories and Methodologies. Lecture Notes in Computer Science, 2015, , .	1.0	2

#	ARTICLE	IF	CITATIONS
501	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. Journal of Clinical Oncology, 2015, 33, 3036-3046.	0.8	516
502	Computational Systems Toxicology. Methods in Pharmacology and Toxicology, 2015, , .	0.1	5
503	Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel. Bioinformatics, 2016, 32, 85-95.	1.8	95
504	Improving Prospects for Targeting RAS. Journal of Clinical Oncology, 2015, 33, 3650-3659.	0.8	89
505	Prediction of Clinical Drug Response Based on Differential Gene Expression Levels. Lecture Notes in Computer Science, 2015, , 480-488.	1.0	0
506	Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Acta Biochimica Et Biophysica Sinica, 2016, 48, 11-16.	0.9	17
507	Pharmacogenomic agreement between two cancer cell line data sets. Nature, 2015, 528, 84-87.	13.7	358
508	Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery. Trends in Genetics, 2015, 31, 16-23.	2.9	16
509	Apoptosis and drug resistance in malignant bone tumors. , 2015, , 425-436.		2
510	Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map. Cancer Discovery, 2015, 5, 154-167.	7.7	57
511	Role of phosphoproteomics in the development of personalized cancer therapies. Proteomics - Clinical Applications, 2015, 9, 383-395.	0.8	40
512	A comprehensive transcriptional portrait of human cancer cell lines. Nature Biotechnology, 2015, 33, 306-312.	9.4	556
513	Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors. Annual Review of Medicine, 2015, 66, 455-470.	5.0	399
514	An in silico screen links gene expression signatures to drug response in glioblastoma stem cells. Pharmacogenomics Journal, 2015, 15, 347-353.	0.9	3
515	Designing of promiscuous inhibitors against pancreatic cancer cell lines. Scientific Reports, 2014, 4, 4668.	1.6	19
516	Synthetic Lethal Vulnerabilities of Cancer. Annual Review of Pharmacology and Toxicology, 2015, 55, 513-531.	4.2	38
517	Programmable and Multiparameter DNA-Based Logic Platform For Cancer Recognition and Targeted Therapy. Journal of the American Chemical Society, 2015, 137, 667-674.	6.6	241
518	Quantitative high-throughput screening data analysis: challenges and recent advances. Drug Discovery Today, 2015, 20, 296-300.	3.2	23

#	ARTICLE	IF	CITATIONS
519	The opportunities of mining historical and collective data in drug discovery. Drug Discovery Today, 2015, 20, 422-434.	3.2	27
520	NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene, 2015, 34, 3780-3790.	2.6	40
521	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 2014, 4, 5193.	1.6	243
522	Using drug response data to identify molecular effectors, and molecular â€œomicâ€•data to identify candidate drugs in cancer. Human Genetics, 2015, 134, 3-11.	1.8	27
523	Targeting the histone orthography of cancer: drugs for writers, erasers and readers. British Journal of Pharmacology, 2015, 172, 2716-2732.	2.7	95
524	Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects. MedChemComm, 2015, 6, 24-50.	3.5	109
525	Signaling network analysis of genomic alterations predicts breast cancer drug targets. , 0, , 269-280.		0
526	DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Scientifica, 2016, 2016, 1-11.	0.6	26
527	Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells. ELife, 2016, 5, .	2.8	5
528	Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. Cancers, 2016, 8, 99.	1.7	4
529	Effects of Charged Particles on Human Tumor Cells. Frontiers in Oncology, 2016, 6, 23.	1.3	75
530	Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. Proteomes, 2016, 4, 16.	1.7	5
531	HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Computational Biology, 2016, 12, e1004827.	1.5	27
532	A Novel Drug-Mouse Phenotypic Similarity Method Detects Molecular Determinants of Drug Effects. PLoS Computational Biology, 2016, 12, e1005111.	1.5	9
533	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. PLoS ONE, 2016, 11, e0167397.	1.1	9
534	The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. Oncotarget, 2016, 7, 70803-70821.	0.8	69
535	Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy. Frontiers in Pharmacology, 2016, 7, 312.	1.6	22
536	Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget, 2016, 7, 51619-51625.	0.8	44

#	Article	IF	Citations
537	A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016, 166, 740-754.	13.5	1,518
538	Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3â€"MYC Interactions as a Target in Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 6153-6163.	3.2	56
539	Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. Genome Biology, 2016, 17, 190.	3.8	35
541	Systems Pharmacology and Pharmacodynamics. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , .	0.2	9
542	Consistency in large pharmacogenomic studies. Nature, 2016, 540, E1-E2.	13.7	52
543	Safikhani et al. reply. Nature, 2016, 540, E2-E4.	13.7	22
544	Consistency in drug response profiling. Nature, 2016, 540, E5-E6.	13.7	76
545	Safikhani et al. reply. Nature, 2016, 540, E6-E8.	13.7	10
546	Drug response consistency in CCLE and CGP. Nature, 2016, 540, E9-E10.	13.7	64
547	Safikhani et al. reply. Nature, 2016, 540, E11-E12.	13.7	11
548	A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia. Scientific Reports, 2016, 6, 22811.	1.6	54
549	Modeling Breast Cancer Intertumor and Intratumor Heterogeneity Using Xenografts. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 227-230.	2.0	7
550	Preclinical models of childhood cancer for the development of targeted therapies. Drug Discovery Today: Disease Models, 2016, 21, 3-9.	1.2	0
551	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	1.6	143
552	Driver gene classification reveals a substantial overrepresentation of tumor suppressors among very large chromatin-regulating proteins. Scientific Reports, 2016, 6, 38988.	1.6	22
553	BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action. Scientific Reports, 2016, 6, 25523.	1.6	63
554	OncoScape: Exploring the cancer aberration landscape by genomic data fusion. Scientific Reports, 2016, 6, 28103.	1.6	10
555	Efficient and simple approach to *in vitro* culture of primary epithelial cancer cells. Bioscience Reports, 2016, 36, .	1.1	24

#	ARTICLE	IF	CITATIONS
556	Management of Soft Tissue Sarcoma. , 2016, , .		12
557	Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents. Scientific Reports, 2016, 6, 29741.	1.6	17
558	Using Systems Pharmacology to Advance Oncology Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 421-463.	0.2	1
559	MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated. Nature Communications, 2016, 7, 13701.	5.8	36
560	Chronic oxidative stress promotes H2 AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Molecular Medicine, 2016, 8, 527-549.	3.3	126
561	Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. Scientific Reports, 2016, 6, 20441.	1.6	34
562	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2016, 6, 727-739.	7.7	126
563	Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer, 2016, 16, 34.	1.1	35
564	Novel approaches to map small molecule–target interactions. Bioorganic and Medicinal Chemistry, 2016, 24, 3232-3245.	1.4	20
565	Reproducible pharmacogenomic profiling of cancer cell line panels. Nature, 2016, 533, 333-337.	13.7	258
566	Multilevel models improve precision and speed of IC_{50} estimates. Pharmacogenomics, 2016, 17, 691-700.	0.6	57
567	Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis. American Journal of Human Genetics, 2016, 98, 709-727.	2.6	129
568	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell, 2016, 165, 317-330.	13.5	70
569	Investigational therapies for Ewing sarcoma: a search without a clear finding. Expert Opinion on Investigational Drugs, 2016, 25, 679-686.	1.9	11
570	Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines. BMC Cancer, 2016, 16, 77.	1.1	39
571	DrugMoaMiner: A computational tool for mechanism of action discovery and personalized drug sensitivity prediction. , 2016, , .		4
572	Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biology, 2016, 17, 80.	3.8	170
573	An unbiased metric of antiproliferative drug effect in vitro. Nature Methods, 2016, 13, 497-500.	9.0	92

#	Article	IF	Citations
574	Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nature Methods, 2016, 13, 521-527.	9.0	489
575	Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. Molecular Cancer, 2016, 15, 34.	7.9	57
576	Comparison of two endogenous delivery agents in cancer therapy: Exosomes and ferritin. Pharmacological Research, 2016, 110, 1-9.	3.1	28
577	Screening out irrelevant cell-based models of disease. Nature Reviews Drug Discovery, 2016, 15, 751-769.	21.5	402
578	A Protocol for a High-Throughput Multiplex Cell Viability Assay. Methods in Molecular Biology, 2016, 1470, 75-84.	0.4	13
579	Computational models for predicting drug responses in cancer research. Briefings in Bioinformatics, 2017, 18, bbw065.	3.2	124
580	Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. British Journal of Cancer, 2016, 115, 1058-1068.	2.9	29
581	Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies. Expert Review of Proteomics, 2016, 13, 929-939.	1.3	1
582	Critical parameters in targeted drug development: the pharmacological audit trail. Seminars in Oncology, 2016, 43, 436-445.	0.8	64
583	Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics, 2016, 32, i455-i463.	1.8	87
584	Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation. Trends in Cancer, 2016, 2, 505-518.	3.8	51
585	Cancer network activity associated with therapeutic response and synergism. Genome Medicine, 2016, 8, 88.	3.6	7
586	*RB1*: a prototype tumor suppressor and an enigma. Genes and Development, 2016, 30, 1492-1502.	2.7	360
587	Molecular Pathogenesis of Thyroid Cancer and Oncogenes in Thyroid Cancer. , 2016, , 17-30.		1
588	Patient-derived tumour xenografts for breast cancer drug discovery. Endocrine-Related Cancer, 2016, 23, T259-T270.	1.6	13
589	Prediction of anti-cancer drug response by kernelized multi-task learning. Artificial Intelligence in Medicine, 2016, 73, 70-77.	3.8	39
590	TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types. Bioinformatics, 2016, 32, i413-i420.	1.8	64
591	In vitro models of medulloblastoma: Choosing the right tool for the job. Journal of Biotechnology, 2016, 236, 10-25.	1.9	165

#	ARTICLE	IF	CITATIONS
592	Capture–based next–generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. Molecular Genetics & Genomic Medicine, 2016, 4, 262-272.	0.6	11
593	Cancer drug discovery: recent innovative approaches to tumor modeling. Expert Opinion on Drug Discovery, 2016, 11, 885-894.	2.5	23
594	How Consistent are Publicly Reported Cytotoxicity Data? Large–Scale Statistical Analysis of the Concordance of Public Independent Cytotoxicity Measurements. ChemMedChem, 2016, 11, 57-71.	1.6	23
595	Genomics Study of Gastric Cancer and Its Molecular Subtypes. Advances in Experimental Medicine and Biology, 2016, 908, 419-439.	0.8	10
596	Computational approaches for the study of the role of small molecules in diseases. Perspectives in Science, 2016, 9, 49-52.	0.6	3
597	Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 3097-3109.	1.9	14
598	HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature, 2016, 537, 102-106.	13.7	335
599	Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Journal of Experimental and Clinical Cancer Research, 2016, 35, 179.	3.5	88
600	Compact Integration of Multi-Network Topology for Functional Analysis of Genes. Cell Systems, 2016, 3, 540-548.e5.	2.9	207
601	Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy. Scientific Reports, 2016, 6, 36812.	1.6	43
602	Drug Sensitivity Assays of Human Cancer Organoid Cultures. Methods in Molecular Biology, 2016, 1576, 339-351.	0.4	54
603	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	13.5	376
604	Report on the use of non–clinical studies in the regulatory evaluation of oncology drugs. Cancer Science, 2016, 107, 189-202.	1.7	6
605	Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance. Molecular Cancer Research, 2016, 14, 675-682.	1.5	11
606	A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. Scientific Reports, 2016, 6, 37003.	1.6	9
607	Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nature Communications, 2016, 7, 10539.	5.8	67
608	Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. Nature Communications, 2016, 7, 12619.	5.8	152
609	Adaptive Resistance to an Inhibitor of Chromosomal Instability in Human Cancer Cells. Cell Reports, 2016, 17, 1755-1763.	2.9	45

#	ARTICLE	IF	CITATIONS
610	Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemotherapy and Pharmacology, 2016, 78, 1269-1281.	1.1	7
611	Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for <i>FLT3</i> <i>-</i> ITD acute myeloid leukemia. Science Translational Medicine, 2016, 8, 359ra129.	5.8	53
612	Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer. Breast Cancer Research and Treatment, 2016, 160, 457-474.	1.1	13
613	Multitask learning improves prediction of cancer drug sensitivity. Scientific Reports, 2016, 6, 31619.	1.6	80
614	Big Data Analytics in Genomics. , 2016, , .		7
615	Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue. Nature Communications, 2016, 7, 12917.	5.8	172
616	PARP inhibitor combination therapy. Critical Reviews in Oncology/Hematology, 2016, 108, 73-85.	2.0	175
617	Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic properties. Scientific Reports, 2016, 6, 32679.	1.6	26
618	Mining Massive Genomic Data for Therapeutic Biomarker Discovery in Cancer: Resources, Tools, and Algorithms. , 2016, , 337-355.		0
620	Parallel Algorithms for Multirelational Data Mining: Application to Life Science Problems. Computer Communications and Networks, 2016, , 339-363.	0.8	0
621	An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. Scientific Reports, 2016, 6, 22120.	1.6	11
622	Approaches to modernize the combination drug development paradigm. Genome Medicine, 2016, 8, 115.	3.6	64
623	Systematic Quality Control Analysis of LINCS Data. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 588-598.	1.3	15
624	Expression of immunoproteasome genes is regulated by cell-intrinsic and –extrinsic factors in human cancers. Scientific Reports, 2016, 6, 34019.	1.6	67
625	ApoCanD: Database of human apoptotic proteins in the context of cancer. Scientific Reports, 2016, 6, 20797.	1.6	9
626	Build It, But Will They Come? A Geoscience Cyberinfrastructure Baseline Analysis. Data Science Journal, 2016, 15, 8.	0.6	18
627	Biological Networks for Cancer Candidate Biomarkers Discovery. Cancer Informatics, 2016, 15s3, CIN.S39458.	0.9	13
628	Context-specific functional module based drug efficacy prediction. BMC Bioinformatics, 2016, 17, 275.	1.2	3

#	ARTICLE	IF	CITATIONS
629	Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach. BMC Systems Biology, 2016, 10, 65.	3.0	36
630	The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw100.	1.4	1,085
631	The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs. Drug Discovery Today: Disease Models, 2016, 21, 23-32.	1.2	8
632	Current situation and future usage of anticancer drug databases. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 778-794.	2.2	12
633	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. Journal of the Association for Laboratory Automation, 2016, 21, 27-36.	2.8	22
634	RNA Sequencing and Genetic Disease. Current Genetic Medicine Reports, 2016, 4, 49-56.	1.9	0
635	Use of big data in drug development for precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 245-253.	0.4	28
636	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clinical Cancer Research, 2016, 22, 3961-3970.	3.2	65
637	Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Reports, 2016, 14, 2490-2501.	2.9	97
638	CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery. Trends in Cancer, 2016, 2, 313-324.	3.8	43
639	Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. Journal of Biomolecular Screening, 2016, 21, 931-941.	2.6	112
640	Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip. Molecular Pharmaceutics, 2016, 13, 2214-2223.	2.3	44
641	Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses. BMC Cancer, 2016, 16, 195.	1.1	8
642	Systematic analysis of overall survival and interactions between tumor mutations and drug treatment. Journal of Hematology and Oncology, 2016, 9, 15.	6.9	5
643	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
644	Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics, 2016, 32, 2891-2895.	1.8	113
645	A rescue by chaperones. Nature Chemical Biology, 2016, 12, 58-59.	3.9	11
646	The many genes of drug mechanism. Nature Chemical Biology, 2016, 12, 57-58.	3.9	3

#	ARTICLE	IF	CITATIONS
647	On the pharmacogenetics of non-small cell lung cancer treatment. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 307-317.	1.5	27
648	Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling. Molecular Cancer Therapeutics, 2016, 15, 334-342.	1.9	19
649	Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nature Chemical Biology, 2016, 12, 102-108.	3.9	72
650	Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nature Chemical Biology, 2016, 12, 109-116.	3.9	636
651	Time series modeling of live-cell shape dynamics for image-based phenotypic profiling. Integrative Biology (United Kingdom), 2016, 8, 73-90.	0.6	53
652	Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. Oncogene, 2016, 35, 4741-4751.	2.6	45
653	An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. Molecular Cancer Therapeutics, 2016, 15, 1155-1162.	1.9	220
654	Cancer genomics: opportunities for medicinal chemistry?. Future Medicinal Chemistry, 2016, 8, 357-359.	1.1	4
655	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecologic Oncology, 2016, 141, 49-56.	0.6	33
656	NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. Nucleic Acids Research, 2016, 44, D992-D999.	6.5	95
657	â€œDeath is my Heirâ€â€"Ferroptosis Connects Cancer Pharmacogenomics and Ischemia-Reperfusion Injury. Cell Chemical Biology, 2016, 23, 202-203.	2.5	41
658	Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. Molecular Cancer Therapeutics, 2016, 15, 379-391.	1.9	36
659	The renewed battle against RAS-mutant cancers. Cellular and Molecular Life Sciences, 2016, 73, 1845-1858.	2.4	33
660	Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods, 2016, 13, 310-318.	9.0	209
661	Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. Trends in Cancer, 2016, 2, 49-63.	3.8	222
662	Optimized Ultrasound Conditions for Enhanced Sensitivity of Molecular Beacons in the Detection of MDR1 mRNA in Living Cells. Analytical Chemistry, 2016, 88, 2808-2816.	3.2	12
663	Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity. Cell Chemical Biology, 2016, 23, 225-235.	2.5	217
664	Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3KÎ± and PI3KÎ´, Demonstrates Treatment Strategies for<i>PIK3CA</i>-Dependent Breast Cancers. Molecular Cancer Therapeutics, 2016, 15, 877-889.	1.9	38

#	Article	IF	Citations
665	DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?. Cancer Discovery, 2016, 6, 130-132.	7.7	44
666	Strategies in functional proteomics: Unveiling the pathways to precision oncology. Cancer Letters, 2016, 382, 86-94.	3.2	7
667	Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. European Journal of Cancer, 2016, 53, 171-180.	1.3	38
668	GFI1 as a novel prognostic and therapeutic factor for AML/MDS. Leukemia, 2016, 30, 1237-1245.	3.3	37
669	Integrative analysis for identifying joint modular patterns of gene-expression and drug-response data. Bioinformatics, 2016, 32, 1724-1732.	1.8	75
670	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	0.5	156
671	Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Molecular Cancer Therapeutics, 2016, 15, 783-793.	1.9	79
673	Organoids as Models for Neoplastic Transformation. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 199-220.	9.6	64
674	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell, 2016, 29, 159-172.	7.7	104
675	High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nature Biotechnology, 2016, 34, 419-423.	9.4	245
676	Managing Drug Resistance in Cancer: Role of Cancer Informatics. Methods in Molecular Biology, 2016, 1395, 299-312.	0.4	12
677	Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. European Journal of Cancer, 2016, 56, 69-76.	1.3	13
678	Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets. Modern Pathology, 2016, 29, 616-629.	2.9	36
679	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. Cancer Discovery, 2016, 6, 286-299.	7.7	208
680	PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics, 2016, 32, 1244-1246.	1.8	249
681	An overview on rough neural networks. Neural Computing and Applications, 2016, 27, 1805-1816.	3.2	15
682	Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches. Trends in Genetics, 2016, 32, 127-137.	2.9	69
683	CRISPR-Cas9â€"based target validation for p53-reactivating model compounds. Nature Chemical Biology, 2016, 12, 22-28.	3.9	74

#	ARTICLE	IF	CITATIONS
684	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resistance Updates, 2016, 24, 55-69.	6.5	52
685	Epithelialâ€"Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitorâ€"Mediated Apoptosis in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1674-1686.	3.2	41
686	Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene, 2016, 35, 1483-1492.	2.6	26
687	Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. Oncogene, 2016, 35, 3092-3102.	2.6	20
688	Public data and open source tools for multi-assay genomic investigation of disease. Briefings in Bioinformatics, 2016, 17, 603-615.	3.2	46
689	Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. OncoImmunology, 2016, 5, e1061176.	2.1	30
690	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genetics in Medicine, 2016, 18, 128-136.	1.1	83
691	A survey of current trends in computational drug repositioning. Briefings in Bioinformatics, 2016, 17, 2-12.	3.2	459
692	Role of Merlin/NF2 inactivation in tumor biology. Oncogene, 2016, 35, 537-548.	2.6	307
693	Statistical interactions and Bayes estimation of log odds in case-control studies. Statistical Methods in Medical Research, 2017, 26, 1021-1038.	0.7	3
694	Prediction of cancer drug sensitivity using high-dimensional omic features. Biostatistics, 2017, 18, 1-14.	0.9	10
695	Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene, 2017, 36, 35-46.	2.6	85
696	Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation. Experimental and Molecular Medicine, 2017, 49, e286-e286.	3.2	32
697	Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Systems, 2017, 4, 73-83.e10.	2.9	41
698	Genomic insights in gynecologic cancer. Current Problems in Cancer, 2017, 41, 8-36.	1.0	13
699	Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras. Cell, 2017, 168, 890-903.e15.	13.5	535
700	Inhibition of the Proteasome Î²2 Site Sensitizes Triple-Negative Breast Cancer Cells to Î²5 Inhibitors and Suppresses Nrf1 Activation. Cell Chemical Biology, 2017, 24, 218-230.	2.5	83
701	A Transcriptional Program for Detecting TGFÎ²-Induced EMT in Cancer. Molecular Cancer Research, 2017, 15, 619-631.	1.5	63

#	Article	IF	Citations
702	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers. Cancer Discovery, 2017, 7, 620-629.	7.7	321
703	Rasâ€"MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 694-704.	1.9	19
704	Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. Gut, 2017, 66, 215-225.	6.1	34
705	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	0.6	195
706	AURKA Overexpression Is Driven byÂFOXM1 and MAPK/ERK Activation inÂMelanoma Cells Harboring BRAF orÂNRASÂMutations: Impact on MelanomaÂPrognosis and Therapy. Journal of Investigative Dermatology, 2017, 137, 1297-1310.	0.3	40
707	Integrating functional genomics to accelerate mechanistic personalized medicine. Journal of Physical Education and Sports Management, 2017, 3, a001370.	0.5	7
708	Choosing wisely â€" Preclinical test models in the era of precision medicine. Cancer Treatment Reviews, 2017, 55, 36-45.	3.4	37
709	Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. Cell, 2017, 168, 575-578.	13.5	13
710	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell, 2017, 31, 225-239.	7.7	190
711	IntegratedMRF: random forest-based framework for integrating prediction from different data types. Bioinformatics, 2017, 33, 1407-1410.	1.8	59
713	Hippo pathway mediates resistance to cytotoxic drugs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3729-E3738.	3.3	57
714	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances, 2017, 3, e1600957.	4.7	10
715	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle, 2017, 16, 1790-1799.	1.3	53
716	mTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in cancers. Nucleic Acids Research, 2017, 45, W215-W221.	6.5	12
717	A Concise Integer Linear Programming Formulation for Implicit Search Result Diversification. , 2017, , .		7
718	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nature Communications, 2017, 8, 15165.	5.8	61
719	Using genetics to inform new therapeutics for diabetes. Expert Review of Endocrinology and Metabolism, 2017, 12, 159-169.	1.2	0
720	Stromal <scp>SPOCK</scp>1 supports invasive pancreatic cancer growth. Molecular Oncology, 2017, 11, 1050-1064.	2.1	27

#	Article	IF	Citations
721	Treatment of <i>KRAS-</i>Mutant Non–Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1835.	3.8	12
722	Drug repositioning beyond the low-hanging fruits. Current Opinion in Systems Biology, 2017, 3, 95-102.	1.3	11
723	Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies. Bioinformatics, 2017, 33, 1362-1369.	1.8	10
724	Transfer Learning Approaches to Improve Drug Sensitivity Prediction in Multiple Myeloma Patients. IEEE Access, 2017, 5, 7381-7393.	2.6	46
725	Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science Translational Medicine, 2017, 9, .	5.8	107
726	The ETS family of oncogenic transcription factors in solid tumours. Nature Reviews Cancer, 2017, 17, 337-351.	12.8	234
727	Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status. Journal of Biosciences, 2017, 42, 91-101.	0.5	22
728	Methods, Tools and Current Perspectives in Proteogenomics. Molecular and Cellular Proteomics, 2017, 16, 959-981.	2.5	130
729	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery, 2017, 7, 832-851.	7.7	49
730	Molecular Genetics of Endometrial Carcinoma. Advances in Experimental Medicine and Biology, 2017, , .	0.8	6
731	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	0.8	53
732	Methods to analyze big data in pharmacogenomics research. Pharmacogenomics, 2017, 18, 807-820.	0.6	10
733	Sparse regression Chebyshev polynomial interval method for nonlinear dynamic systems under uncertainty. Applied Mathematical Modelling, 2017, 51, 505-525.	2.2	27
734	Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. Gastroenterology, 2017, 153, 1082-1095.	0.6	55
735	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell, 2017, 31, 820-832.e3.	7.7	433
736	Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells. Current Protocols in Chemical Biology, 2017, 9, 55-74.	1.7	31
737	Predicting the Reliability of Drug-target Interaction Predictions with Maximum Coverage of Target Space. Scientific Reports, 2017, 7, 3820.	1.6	62
738	Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nature Reviews Cancer, 2017, 17, 352-366.	12.8	438

#	ARTICLE	IF	CITATIONS
739	The potential of organoids in urological cancer research. Nature Reviews Urology, 2017, 14, 401-414.	1.9	72
740	PARP inhibitors as precision medicine for cancer treatment. National Science Review, 2017, 4, 576-592.	4.6	12
741	RNAi High-Throughput Screening of Single- and Multi-Cell-Type Tumor Spheroids: A Comprehensive Analysis in Two and Three Dimensions. SLAS Discovery, 2017, 22, 525-536.	1.4	13
742	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Molecular Oncology, 2017, 11, 1156-1171.	2.1	15
744	Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2017, 994, 255-273.	0.8	12
745	<scp>CDK</scp>4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Molecular Medicine, 2017, 9, 1052-1066.	3.3	65
746	Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with I±V-Class integrins to promote EMT. Oncogene, 2017, 36, 5681-5694.	2.6	52
747	Early spatiotemporal-specific changes in intermediate signals are predictive of cytotoxic sensitivity to TNFI± and co-treatments. Scientific Reports, 2017, 7, 43541.	1.6	9
748	Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. Molecular Cancer Therapeutics, 2017, 16, 1054-1067.	1.9	40
749	Systematic identification of key genes and pathways in the development of invasive cervical cancer. Gene, 2017, 618, 28-41.	1.0	32
750	CATTLE (CAncer treatment treasury with linked evidence): An integrated knowledge base for personalized oncology research and practice. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 188-196.	1.3	3
751	Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Typeâ€"Specific Dynamic Logic Models. Cancer Research, 2017, 77, 3364-3375.	0.4	101
752	Drug Resistance in Cancer. , 2017, , 449-473.		2
753	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nature Communications, 2017, 8, 14864.	5.8	112
754	Progress towards precision functional genomics in cancer. Current Opinion in Systems Biology, 2017, 2, 74-83.	1.3	7
755	Translational applications of adult stem cell-derived organoids. Development (Cambridge), 2017, 144, 968-975.	1.2	103
756	Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Molecular Cancer Therapeutics, 2017, 16, 1041-1053.	1.9	12
757	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. , 2017, , .		13

#	Article	IF	Citations
758	From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nature Reviews Clinical Oncology, 2017, 14, 235-246.	12.5	466
759	Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 382-387.	3.3	47
760	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	2.6	34
761	CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1. Oncogene, 2017, 36, 2619-2627.	2.6	28
762	Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy readâ€outs. Biotechnology Journal, 2017, 12, 1600505.	1.8	77
763	Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nature Reviews Cancer, 2017, 17, 751-765.	12.8	222
764	Gene isoforms as expression-based biomarkers predictive of drug response in vitro. Nature Communications, 2017, 8, 1126.	5.8	54
765	Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity. Cell Chemical Biology, 2017, 24, 1356-1367.e8.	2.5	27
766	High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer. Scientific Data, 2017, 4, 170139.	2.4	11
767	Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nature Communications, 2017, 8, 1186.	5.8	78
769	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. Public Health Genomics, 2017, 20, 81-91.	0.6	10
770	Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chemical Biology, 2017, 24, 1075-1091.	2.5	38
771	Resistance to dasatinib is associated with the activation of Akt in oral squamous cell carcinoma. Translational Research in Oral Oncology, 2017, 2, 2057178X1770292.	2.3	1
772	Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. Cell Reports, 2017, 20, 2201-2214.	2.9	95
773	Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Systems, 2017, 5, 105-118.e9.	2.9	40
774	Sensitivity to <i>BUB1B</i> Inhibition Defines an Alternative Classification of Glioblastoma. Cancer Research, 2017, 77, 5518-5529.	0.4	38
775	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports, 2017, 20, 2833-2845.	2.9	40
776	Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities. Nature Biotechnology, 2017, 35, 983-989.	9.4	138

#	Article	IF	Citations
777	Multiplexed imaging for diagnosis and therapy. Nature Biomedical Engineering, 2017, 1, 697-713.	11.6	133
778	Regulation of autophagy, NF-ÎºB signaling, and cell viability by miR-124 in <i>KRAS</i> mutant mesenchymal-like NSCLC cells. Science Signaling, 2017, 10, .	1.6	21
779	Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clinical Cancer Research, 2017, 23, 7301-7311.	3.2	44
780	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 2017, 9, 1011-1029.	3.3	63
781	Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses. Clinical Cancer Research, 2017, 23, 7400-7411.	3.2	44
782	The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations. Molecular and Translational Medicine, 2017, , 133-159.	0.4	2
783	Real-Time Continuous Identification of Greenhouse Plant Pathogens Based on Recyclable Microfluidic Bioassay System. ACS Applied Materials & Interfaces, 2017, 9, 31568-31575.	4.0	28
784	ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer. Scientific Reports, 2017, 7, 10060.	1.6	57
785	Thermoresponsive Elastin-<i>b</i>-Collagen-Like Peptide Bioconjugate Nanovesicles for Targeted Drug Delivery to Collagen-Containing Matrices. Biomacromolecules, 2017, 18, 2539-2551.	2.6	51
786	TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer. Cancer Research, 2017, 77, 5077-5094.	0.4	59
787	The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug Screens. Cell Chemical Biology, 2017, 24, 1066-1074.	2.5	22
788	CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. Cell Systems, 2017, 5, 82-86.e3.	2.9	5
789	Crosstalk and the evolvability of intracellular communication. Nature Communications, 2017, 8, 16009.	5.8	29
790	Integrated Genomic Medicine. Advances in Genetics, 2017, 97, 81-113.	0.8	12
791	Detection of homozygous deletions in tumorâ€suppressor genes ranging from dozen to hundreds nucleotides in cancer models. Human Mutation, 2017, 38, 1449-1453.	1.1	8
792	<i>In Vivo</i> Validation of PAPSS1 (3â€²-phosphoadenosine 5â€²-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target. Clinical Cancer Research, 2017, 23, 6555-6566.	3.2	12
793	TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. Molecular Cancer Therapeutics, 2017, 16, 2543-2551.	1.9	25
794	Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer Cell, 2017, 32, 761-776.e6.	7.7	171

#	ARTICLE	IF	CITATIONS
795	Identification of cancer genes that are independent of dominant proliferation and lineage programs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E11276-E11284.	3.3	20
796	Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open, 2017, 2, e000279.	2.0	109
797	Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Molecular Systems Biology, 2017, 13, 955.	3.2	163
798	High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. Cell Reports, 2017, 21, 1737-1745.	2.9	32
799	New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels. Scientific Reports, 2017, 7, 15126.	1.6	7
800	Pharmacoproteomic characterisation of human colon and rectal cancer. Molecular Systems Biology, 2017, 13, 951.	3.2	44
801	Revealing protein networks and gene-drug connectivity in cancer from direct information. Scientific Reports, 2017, 7, 3739.	1.6	14
802	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	4.0	74
803	Knowledge elicitation via sequential probabilistic inference for high-dimensional prediction. Machine Learning, 2017, 106, 1599-1620.	3.4	19
804	Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nature Communications, 2017, 8, 16022.	5.8	151
805	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. Npj Systems Biology and Applications, 2017, 3, 8.	1.4	55
806	Optimal Therapy of Advanced Stage Mesothelioma. Current Treatment Options in Oncology, 2017, 18, 48.	1.3	4
807	Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Research, 2017, 77, 4626-4638.	0.4	42
808	DeSigN: connecting gene expression with therapeutics for drug repurposing and development. BMC Genomics, 2017, 18, 934.	1.2	62
809	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Molecular Cancer, 2017, 16, 86.	7.9	49
810	Integrative cancer genomics: models, algorithms and analysis. Frontiers of Computer Science, 2017, 11, 392-406.	1.6	3
811	In situ probing of cell–cell communications with surface-enhanced Raman scattering (SERS) nanoprobes and microfluidic networks for screening of immunotherapeutic drugs. Nano Research, 2017, 10, 584-594.	5.8	22
812	Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening. Molecular and Cellular Neurosciences, 2017, 80, 198-207.	1.0	20

#	ARTICLE	IF	CITATIONS
813	New strategies for targeting drug combinations to overcome mutation-driven drug resistance. Seminars in Cancer Biology, 2017, 42, 44-51.	4.3	21
814	Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. International Journal of Cancer, 2017, 140, 662-673.	2.3	67
815	Precision medicine in pediatric oncology: Lessons learned and next steps. Pediatric Blood and Cancer, 2017, 64, e26288.	0.8	71
816	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. Cancer Research, 2017, 77, 153-163.	0.4	26
817	A CDK2 activity signature predicts outcome in CDK2-low cancers. Oncogene, 2017, 36, 2491-2502.	2.6	32
818	Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Leukemia, 2017, 31, 40-50.	3.3	23
819	Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters. Prostate, 2017, 77, 222-233.	1.2	28
820	Synthetic Lethality in Cancer Therapeutics. Annual Review of Cancer Biology, 2017, 1, 141-161.	2.3	36
821	PARP Inhibitor Activity Correlates with <i>SLFN11</i> Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 523-535.	3.2	252
822	Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 566-578.	0.4	38
823	DNA Interstrand Crosslinks by Hâ€pin Polyamide (<i>S</i>)<i>â€seco</i>â€CBI Conjugates. ChemBioChem, 2017, 18, 166-170.	1.3	8
824	False and mycoplasmaâ€contaminated leukemiaâ€"lymphoma cell lines: time for a reappraisal. International Journal of Cancer, 2017, 140, 1209-1214.	2.3	40
825	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	2.9	47
826	Cell Culture System for Analysis of Genetic Heterogeneity WithinÂHepatocellular Carcinomas and Response to Pharmacologic Agents. Gastroenterology, 2017, 152, 232-242.e4.	0.6	107
827	Discordancy Partitioning for Validating Potentially Inconsistent Pharmacogenomic Studies. Scientific Reports, 2017, 7, 15169.	1.6	7
828	Improved detection of synthetic lethal interactions in <i>Drosophila</i> cells using variable dose analysis (VDA). Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10755-E10762.	3.3	8
829	The effect of Nullomer-derived peptides 9R, 9S1R and 124R on the NCI-60 panel and normal cell lines. BMC Cancer, 2017, 17, 533.	1.1	15
830	Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Research, 2017, 27, 1743-1751.	2.4	101

#	Article	IF	Citations
831	Identification of cancer drug sensitivity biomarkers. , 2017, , .		0
832	Remember why we work on cancer. Nature, 2017, 543, 613-615.	13.7	2
833	Five ways consortia can catalyse open science. Nature, 2017, 543, 615-617.	13.7	26
834	Taxol reduces synergistic, mechanobiological invasiveness of metastatic cells. Convergent Science Physical Oncology, 2017, 3, 044002.	2.6	14
835	Dielectrophoresis for Biomedical Sciences Applications: A Review. Sensors, 2017, 17, 449.	2.1	147
836	Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers, 2017, 9, 109.	1.7	36
837	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. International Journal of Molecular Sciences, 2017, 18, 308.	1.8	353
838	Use of Off-Label Targeted Therapies in Refractory Sarcomas: Analysis of Pediatric Data from the French Registry Observatoire de l'Utilisation des ThÃ©rapies CiblÃ©es dans les Sarcomes. Journal of Pediatric Biochemistry, 2017, 06, 136-145.	0.2	0
839	A Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon Cancer. Journal of Cancer, 2017, 8, 1113-1122.	1.2	22
840	Network dynamics-based cancer panel stratification for systemic prediction of anticancer drug response. Nature Communications, 2017, 8, 1940.	5.8	36
841	Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. BMC Cancer, 2017, 17, 513.	1.1	118
842	MD-Miner: a network-based approach for personalized drug repositioning. BMC Systems Biology, 2017, 11, 86.	3.0	14
843	Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies. Journal of Translational Medicine, 2017, 15, 204.	1.8	20
844	Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance. Genome Biology, 2017, 18, 153.	3.8	33
845	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Medicine, 2017, 9, 89.	3.6	39
846	Classifying cancer genome aberrations by their mutually exclusive effects on transcription. BMC Medical Genomics, 2017, 10, 66.	0.7	7
847	Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression. Bioinformatics, 2017, 33, i359-i368.	1.8	58
848	Structure Discovery for Gene Expression Networks with Emerging Stochastic Hardware. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
849	DNA Base Excision Repair: The Achilles' Heel of Tumour Cells and their Microenvironment?. Current Pharmaceutical Design, 2017, 23, 4758-4772.	0.9	10
850	The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology. Oncotarget, 2017, 8, 10883-10890.	0.8	249
851	Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker Based Approaches. Journal of Molecular Biomarkers & Diagnosis, 2017, 08, .	0.4	25
852	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer: Targets and Therapy, 2017, Volume 9, 185-198.	1.0	23
853	Advances in Organoid Culturing of Patient-Derived Tumors. , 2017, , 365-375.		0
854	Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours. Oncotarget, 2017, 8, 97025-97040.	0.8	31
855	TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development. Oncotarget, 2017, 8, 863-882.	0.8	49
856	Advances in the Treatment of Pediatric Bone Sarcomas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 725-735.	1.8	23
857	Toward an integrated map of genetic interactions in cancer cells. Molecular Systems Biology, 2018, 14, e7656.	3.2	64
858	GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. Journal of Dental Research, 2018, 97, 909-916.	2.5	6
859	Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells. Cell Research, 2018, 28, 544-555.	5.7	31
860	Data-DrivenÂMethods for Advancing Precision Oncology. Current Pharmacology Reports, 2018, 4, 145-156.	1.5	6
861	Revisiting the cluster-based paradigm for implicit search result diversification. Information Processing and Management, 2018, 54, 507-528.	5.4	6
862	Tumor xenograft modeling identifies TCF4/ITF2 loss associated with breast cancer chemoresistance. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	15
863	A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Reports, 2018, 23, 918-929.	2.9	39
864	Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell, 2018, 173, 864-878.e29.	13.5	102
865	An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance. Cell, 2018, 173, 649-664.e20.	13.5	238
866	Development of Preclinical Models to Understand and Treat Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2018, 31, 199-204.	0.5	6

#	Article	IF	Citations
867	The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils. Cancer Cell, 2018, 33, 607-619.e15.	7.7	88
868	Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages. Neuro-Oncology, 2018, 20, 1080-1091.	0.6	22
869	Fusion genes: A promising tool combating against cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 149-160.	3.3	36
870	Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. Cell Systems, 2018, 6, 343-354.e5.	2.9	40
871	Differential Effector Engagement by Oncogenic KRAS. Cell Reports, 2018, 22, 1889-1902.	2.9	101
872	Rational cell culture optimization enhances experimental reproducibility in cancer cells. Scientific Reports, 2018, 8, 3029.	1.6	25
873	Making Use of Cancer Genomic Databases. Current Protocols in Molecular Biology, 2018, 121, 19.14.1-19.14.13.	2.9	13
874	Cancer Systems Biology. Methods in Molecular Biology, 2018, , .	0.4	8
875	GDSCTools for mining pharmacogenomic interactions in cancer. Bioinformatics, 2018, 34, 1226-1228.	1.8	45
876	A new approach to assess drug sensitivity in cells for novel drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 339-346.	2.5	6
877	Bioinformatics Approaches to Predict Drug Responses from Genomic Sequencing. Methods in Molecular Biology, 2018, 1711, 277-296.	0.4	12
878	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene, 2018, 37, 1775-1787.	2.6	28
879	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 2018, 33, 202-216.e6.	7.7	116
880	Tissue specificity of in vitro drug sensitivity. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 158-166.	2.2	23
881	ConsensusDriver Improves upon Individual Algorithms for Predicting Driver Alterations in Different Cancer Types and Individual Patients. Cancer Research, 2018, 78, 290-301.	0.4	20
882	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell, 2018, 172, 857-868.e15.	13.5	220
883	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine, 2018, 24, 203-212.	15.2	178
884	Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death and Differentiation, 2018, 25, 616-633.	5.0	137

#	ARTICLE	IF	CITATIONS
885	Perturbation-response genes reveal signaling footprints in cancer gene expression. Nature Communications, 2018, 9, 20.	5.8	436
886	A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nature Communications, 2018, 9, 42.	5.8	194
887	Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment. Human Genomics, 2018, 12, 20.	1.4	11
888	Isolation and characterisation of locally isolated <i>Gluconacetobacter xylinus</i> BCZM sp. with nanocellulose producing potentials. IET Nanobiotechnology, 2018, 12, 52-56.	1.9	15
889	RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines. Bioinformatics, 2018, 34, 3332-3339.	1.8	21
890	Multiparameter Modalities for the Study of Patients in the Setting of Individualized Medicine. , 2018, , 1523-1549.		0
891	Cell Cycle Machinery and Its Alterations in Pancreatic Cancer. , 2018, , 19-49.		2
894	Pancreatic cancer subtypes: a roadmap for precision medicine. Annals of Medicine, 2018, 50, 277-287.	1.5	69
895	Kernelized rank learning for personalized drug recommendation. Bioinformatics, 2018, 34, 2808-2816.	1.8	44
896	Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. Molecular and Cellular Proteomics, 2018, 17, 1245-1258.	2.5	19
897	Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2670-2678.	0.6	5
898	PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies. Nucleic Acids Research, 2018, 46, D994-D1002.	6.5	130
899	Integrity, standards, and QC-related issues with big data in pre-clinical drug discovery. Biochemical Pharmacology, 2018, 152, 84-93.	2.0	3
900	Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models. British Journal of Cancer, 2018, 118, 972-984.	2.9	9
901	Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Developmental Cell, 2018, 44, 555-565.e3.	3.1	154
902	Estimating a sparse reduction for general regression in high dimensions. Statistics and Computing, 2018, 28, 33-46.	0.8	12
903	Predictive approaches for drug combination discovery in cancer. Briefings in Bioinformatics, 2018, 19, 263-276.	3.2	75
904	Mathematical modeling and computational prediction of cancer drug resistance. Briefings in Bioinformatics, 2018, 19, 1382-1399.	3.2	85

#	Article	IF	Citations
905	Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses. Clinical Cancer Research, 2018, 24, 1761-1770.	3.2	12
906	Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. Experimental Neurology, 2018, 299, 281-288.	2.0	15
907	How to secure the meat chain against toxicants?. Innovative Food Science and Emerging Technologies, 2018, 46, 74-82.	2.7	16
908	Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. ACS Chemical Neuroscience, 2018, 9, 118-129.	1.7	17
909	Synthetic Lethal Vulnerabilities in <i>KRAS</i>-Mutant Cancers. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031518.	2.9	63
910	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. Seminars in Radiation Oncology, 2018, 28, 2-11.	1.0	23
911	Biology of Bone Sarcomas and New Therapeutic Developments. Calcified Tissue International, 2018, 102, 174-195.	1.5	106
912	Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer. Cancer Research, 2018, 78, 769-780.	0.4	161
913	Discriminating Live and Dead Cells in Dual-Color Mode with a Two-Photon Fluorescent Probe Based on ESIPT Mechanism. Analytical Chemistry, 2018, 90, 998-1005.	3.2	74
914	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clinical Cancer Research, 2018, 24, 360-369.	3.2	96
915	Accurate prediction and elucidation of drug resistance based on the robust and reproducible chemoresponse communities. International Journal of Cancer, 2018, 142, 1427-1439.	2.3	3
916	Biomarker identification for statin sensitivity of cancer cell lines. Biochemical and Biophysical Research Communications, 2018, 495, 659-665.	1.0	38
917	Identifying DNA mismatches at single-nucleotide resolution by probing individual surface potentials of DNA-capped nanoparticles. Nanoscale, 2018, 10, 538-547.	2.8	11
918	Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics. Molecular Cancer Research, 2018, 16, 269-278.	1.5	127
919	Symbolic Regression Modeling of Drug Responses. , 2018, , .		5
920	Targeting DNA Repair in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1017-1019.	0.8	4
921	Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. Translational Lung Cancer Research, 2018, 7, S265-S269.	1.3	1
922	Accelerating Drug Discovery Using Convolution Neural Network Based Active Learning. , 2018, , .		3

#	ARTICLE	IF	CITATIONS
923	Functional Data Analysis: Omics for Environmental Risk Assessment. Comprehensive Analytical Chemistry, 2018, , 583-611.	0.7	4
924	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports, 2018, 25, 2617-2633.	2.9	74
925	Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model. Cell Systems, 2018, 7, 567-579.e6.	2.9	99
926	Silica Nanoparticles with Up-conversion Fluorescence Based on Tripletâ€"Triplet Annihilation Mechanism for Specific Recognition of Apoptosis Cells. Analytical Chemistry, 2018, 90, 14602-14609.	3.2	10
927	Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association. PLoS ONE, 2018, 13, e0206632.	1.1	2
928	The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines. Oral Oncology, 2018, 87, 144-151.	0.8	27
929	Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics. Cell Systems, 2018, 7, 526-536.e6.	2.9	23
930	Predicting tumor cell line response to drug pairs with deep learning. BMC Bioinformatics, 2018, 19, 486.	1.2	84
931	IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis. Cell Reports, 2018, 25, 3021-3035.e5.	2.9	17
932	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. IScience, 2018, 10, 247-264.	1.9	117
933	Clinical Drug Response Prediction by Using a Lq Penalized Network-Constrained Logistic Regression Method. Cellular Physiology and Biochemistry, 2018, 51, 2073-2084.	1.1	12
934	iTOP: inferring the topology of omics data. Bioinformatics, 2018, 34, i988-i996.	1.8	19
935	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. British Journal of Cancer, 2018, 119, 801-807.	2.9	29
936	A quantile regression forest based method to predict drug response and assess prediction reliability. PLoS ONE, 2018, 13, e0205155.	1.1	21
937	MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG. Nature Chemical Biology, 2018, 14, 1032-1042.	3.9	22
938	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer Discovery, 2018, 8, 1582-1597.	7.7	310
939	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, 2018, 50, 1399-1411.	9.4	145
940	Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma. EBioMedicine, 2018, 36, 196-208.	2.7	17

#	Article	IF	Citations
941	Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies. Scientific Reports, 2018, 8, 13978.	1.6	105
942	Privacy-preserving verifiable elastic net among multiple institutions in the cloud. Journal of Computer Security, 2018, 26, 791-815.	0.5	5
943	Systems biologyâ€"based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. Science Translational Medicine, 2018, 10, .	5.8	54
944	Anti-cancer Drug Response Prediction Using Neighbor-Based Collaborative Filtering with Global Effect Removal. Molecular Therapy - Nucleic Acids, 2018, 13, 303-311.	2.3	56
945	CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nature Communications, 2018, 9, 4275.	5.8	56
946	Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. Oncotarget, 2018, 9, 17589-17596.	0.8	4
947	Network integration of multi-tumour omics data suggests novel targeting strategies. Nature Communications, 2018, 9, 4514.	5.8	33
948	A Hybrid Interpolation Weighted Collaborative Filtering Method for Anti-cancer Drug Response Prediction. Frontiers in Pharmacology, 2018, 9, 1017.	1.6	38
949	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018, 175, 984-997.e24.	13.5	892
950	Mutational processes shape the landscape of TP53 mutations in human cancer. Nature Genetics, 2018, 50, 1381-1387.	9.4	334
951	Recent advances in combinatorial drug screening and synergy scoring. Current Opinion in Pharmacology, 2018, 42, 102-110.	1.7	80
952	Nondestructive Analysis of Tumor-Associated Membrane Protein Integrating Imaging and Amplified Detection in situ Based on Dual-Labeled DNAzyme. Theranostics, 2018, 8, 1075-1083.	4.6	17
953	Improving genomics-based predictions for precision medicine through active elicitation of expert knowledge. Bioinformatics, 2018, 34, i395-i403.	1.8	6
954	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	5.1	61
955	TOMAS: revisiting PARP inhibitor combination therapy. Lancet Oncology, The, 2018, 19, 1269-1270.	5.1	2
956	Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes. Brain Research, 2018, 1700, 199-210.	1.1	25
957	The effect mechanism of <i>Ginnalin A</i> as a homeopathic agent on various cancer cell lines. Open Chemistry, 2018, 16, 790-795.	1.0	0
958	BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS Biology, 2018, 16, e2005756.	2.6	56

#	Article	IF	Citations
959	Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. Journal of Cancer, 2018, 9, 2038-2045.	1.2	40
960	ACSSC 2018 Session TP1a. , 2018, , .		0
961	Robust Unsupervised Two Layered Network with RRAM Synapses for Image Recognition. , 2018, , .		0
962	Head and Neck Tumors. , 2018, , 1-136.		1
963	Network Semantic Segmentation with Application to GitHub. , 2018, , .		0
964	MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Research, 2018, 28, 719-729.	5.7	105
965	NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells. International Journal of Biochemistry and Cell Biology, 2018, 100, 54-60.	1.2	9
966	Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Letters, 2018, 431, 64-72.	3.2	25
967	Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Science Translational Medicine, 2018, 10, .	5.8	70
968	Animal Model: Xenograft Mouse Models in Esophageal Adenocarcinoma. Methods in Molecular Biology, 2018, 1756, 151-164.	0.4	1
969	Current questions in bone sarcomas. Current Opinion in Oncology, 2018, 30, 252-259.	1.1	31
970	Droplet microfluidics for high‐sensitivity and high‐throughput detection and screening of disease biomarkers. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1522.	3.3	60
971	Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines. Cancer Research, 2018, 78, 4396-4410.	0.4	14
972	Boosting the turn-on fluorescent signaling ability of thiazole orange dyes: The effectiveness of structural modification site and its unusual interaction behavior with nucleic acids. Dyes and Pigments, 2018, 159, 449-456.	2.0	17
973	Splicing Nanoparticles-Based â€œClickâ€•SERS Could Aid Multiplex Liquid Biopsy and Accurate Cellular Imaging. Journal of the American Chemical Society, 2018, 140, 10649-10652.	6.6	90
974	Cellular target engagement: a new paradigm in drug discovery. Future Medicinal Chemistry, 2018, 10, 1641-1644.	1.1	7
975	Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells. ELife, 2018, 7, .	2.8	17
976	Genomics and Proteomics in Neuro-Oncology. , 2018, , 75-85.		0

#	ARTICLE	IF	CITATIONS
977	A microfluidics platform for combinatorial drug screening on cancer biopsies. Nature Communications, 2018, 9, 2434.	5.8	177
978	Discovery of two-level modular organization from matched genomic data via joint matrix tri-factorization. Nucleic Acids Research, 2018, 46, 5967-5976.	6.5	27
979	KSRMF: Kernelized similarity based regularized matrix factorization framework for predicting anti-cancer drug responses. Journal of Intelligent and Fuzzy Systems, 2018, 35, 1779-1790.	0.8	13
980	More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens. , 2018, 191, 178-189.		26
981	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular Cancer Therapeutics, 2018, 17, 2060-2071.	1.9	33
982	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene, 2018, 37, 5858-5872.	2.6	20
983	GSEA-InContext: identifying novel and common patterns in expression experiments. Bioinformatics, 2018, 34, i555-i564.	1.8	143
984	Exploration of drug-response mechanism by integrating genetics and epigenetics across cancers. Epigenomics, 2018, 10, 993-1010.	1.0	6
985	Drug Response Prediction by Globally Capturing Drug and Cell Line Information in a Heterogeneous Network. Journal of Molecular Biology, 2018, 430, 2993-3004.	2.0	24
986	Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. ELife, 2018, 7, .	2.8	20
987	Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nature Communications, 2018, 9, 2983.	5.8	206
988	Predicting drug activity by image encoded gene expression profiles. , 2018, , .		0
989	A framework for large-scale metabolome drug profiling links coenzyme A metabolism to the toxicity of anti-cancer drug dichloroacetate. Communications Biology, 2018, 1, 101.	2.0	26
990	Molecular Targeted Therapy of Pediatric Neoplasms. Molecular Pathology Library, 2018, , 67-86.	0.1	0
991	Integrative omics analyses broaden treatment targets in human cancer. Genome Medicine, 2018, 10, 60.	3.6	17
992	BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS ONE, 2018, 13, e0200826.	1.1	50
993	Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. Journal of Clinical Medicine, 2018, 7, 62.	1.0	43
994	Challenging transcription by DNA-binding antitumor drugs. Biochemical Pharmacology, 2018, 155, 336-345.	2.0	15

#	ARTICLE	IF	CITATIONS
995	A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Management and Research, 2018, Volume 10, 1089-1114.	0.9	94
996	PAK2â€"c-Mycâ€"PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect. Cell Death and Disease, 2018, 9, 825.	2.7	63
997	Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?. Frontiers in Oncology, 2017, 7, 330.	1.3	15
998	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific Reports, 2018, 8, 10614.	1.6	13
999	Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses. Scientific Reports, 2018, 8, 9743.	1.6	25
1000	Bosutinib Inhibits EGFR Activation in Head and Neck Cancer. International Journal of Molecular Sciences, 2018, 19, 1824.	1.8	12
1001	A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals, 2018, 11, 22.	1.7	3
1002	PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Medicine, 2018, 10, 41.	3.6	63
1003	An automated microfluidic gene-editing platform for deciphering cancer genes. Lab on A Chip, 2018, 18, 2300-2312.	3.1	31
1004	Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death and Disease, 2018, 9, 792.	2.7	47
1005	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 5094-5106.	0.4	47
1006	Unearthing new genomic markers of drug response by improved measurement of discriminative power. BMC Medical Genomics, 2018, 11, 10.	0.7	9
1007	Efficient differentially private learning improves drug sensitivity prediction. Biology Direct, 2018, 13, 1.	1.9	23
1008	Phenotypic Screening. Methods in Molecular Biology, 2018, , .	0.4	0
1009	High-Dimensional Profiling: The Theta Comparative Cell Scoring Method. Methods in Molecular Biology, 2018, 1787, 171-181.	0.4	3
1010	Multi-Task Regression Learning for Prediction of Response Against a Panel of Anti-Cancer Drugs in Personalized Medicine. , 2018, , .		6
1011	Pathway-based dissection of the genomic heterogeneity of cancer hallmarksâ€™ acquisition with SLAPenrich. Scientific Reports, 2018, 8, 6713.	1.6	24
1012	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. Annual Review of Biomedical Data Science, 2018, 1, 1-27.	2.8	27

#	Article	IF	Citations
1013	A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. Bladder Cancer, 2018, 4, 269-282.	0.2	6
1014	RASâ€"MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. Cancer Research, 2018, 78, 6297-6307.	0.4	43
1015	Label-free real-time ultrasensitive monitoring of non-small cell lung cancer cell interaction with drugs. Biomedical Optics Express, 2018, 9, 4149.	1.5	4
1016	The germline genetic component of drug sensitivity in cancer cell lines. Nature Communications, 2018, 9, 3385.	5.8	38
1017	Personalized treatment based on mini patientâ€derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. Cancer Communications, 2018, 38, 1-7.	3.7	30
1018	FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer. PLoS Computational Biology, 2018, 14, e1006266.	1.5	8
1019	Mouse models in the era of large human tumour sequencing studies. Open Biology, 2018, 8, .	1.5	7
1020	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. Scientific Reports, 2018, 8, 12046.	1.6	22
1021	Genetic and transcriptional evolution alters cancer cell line drug response. Nature, 2018, 560, 325-330.	13.7	662
1022	Subjugation of TGFÎ² Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. Clinical Cancer Research, 2018, 24, 6001-6014.	3.2	71
1023	Application of Systems Biology in the Research of TCM Formulae. , 2018, , 31-67.		5
1024	Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting. BMC Genomics, 2018, 19, 604.	1.2	75
1025	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Oral Oncology, 2018, 82, 144-151.	0.8	13
1026	Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with <i>In Vivo</i> Antitumor Activity. Clinical Cancer Research, 2018, 24, 4256-4270.	3.2	41
1027	Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network. Scientific Reports, 2018, 8, 8440.	1.6	23
1028	Next-Generation Machine Learning for Biological Networks. Cell, 2018, 173, 1581-1592.	13.5	648
1029	Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Cell Death and Disease, 2018, 9, 684.	2.7	34
1030	GDA, a web-based tool for Genomics and Drugs integrated analysis. Nucleic Acids Research, 2018, 46, W148-W156.	6.5	9

#	Article	IF	Citations
1031	Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature. Scientific Reports, 2018, 8, 8857.	1.6	176
1032	CLC-Pred: A freely available web-service for in silico prediction of human cell line cytotoxicity for drug-like compounds. PLoS ONE, 2018, 13, e0191838.	1.1	116
1033	A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens. PLoS Computational Biology, 2018, 14, e1005985.	1.5	45
1034	Toward A variable RBE for proton beam therapy. Radiotherapy and Oncology, 2018, 128, 68-75.	0.3	71
1035	Evaluating the consistency of large-scale pharmacogenomic studies. Briefings in Bioinformatics, 2019, 20, 1734-1753.	3.2	8
1036	HOGMMNC: a higher order graph matching with multiple network constraints model for gene–drug regulatory modules identification. Bioinformatics, 2019, 35, 602-610.	1.8	38
1037	Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Seminars in Cancer Biology, 2019, 55, 37-52.	4.3	125
1038	Dual-layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 17, 1-1.	1.9	2
1039	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene, 2019, 38, 180-193.	2.6	35
1040	Machine learning and feature selection for drug response prediction in precision oncology applications. Biophysical Reviews, 2019, 11, 31-39.	1.5	148
1041	Drug response prediction by ensemble learning and drug-induced gene expression signatures. Genomics, 2019, 111, 1078-1088.	1.3	24
1042	GECO: gene expression correlation analysis after genetic algorithm-driven deconvolution. Bioinformatics, 2019, 35, 156-159.	1.8	5
1043	Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data. Journal of Translational Medicine, 2019, 17, 255.	1.8	11
1044	Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in <i>KRAS</i>-Mutant Cancer Cells. Cancer Research, 2019, 79, 4855-4868.	0.4	15
1045	Synthetic Lethal Interactions for Kinase Deficiencies to DNA Damage Chemotherapeutics. Cancer Research, 2019, 79, 5693-5698.	0.4	1
1046	Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Frontiers in Oncology, 2019, 9, 800.	1.3	123
1047	Spontaneous evolution of human skin fibroblasts into wound-healing keratinocyte-like cells. Theranostics, 2019, 9, 5200-5213.	4.6	16
1048	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 2019, 19, 495-509.	12.8	573

#	ARTICLE	IF	CITATIONS
1049	Applicability of drug response metrics for cancer studies using biomaterials. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180226.	1.8	41
1050	From Gene Expression to Drug Response: A Collaborative Filtering Approach. , 2019, , .		4
1051	A Pharmacogenomic Landscape in Human Liver Cancers. Cancer Cell, 2019, 36, 179-193.e11.	7.7	127
1052	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. , 2019, 203, 107395.		76
1053	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	3.2	42
1054	Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional network. BMC Bioinformatics, 2019, 20, 408.	1.2	101
1055	Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers, 2019, 11, 1098.	1.7	185
1056	Group-sparse SVD Models via L_1- and L_0-norm Penalties and Their Applications in Biological Data. IEEE Transactions on Knowledge and Data Engineering, 2019, , 1-1.	4.0	6
1057	Quality Control of Quantitative High Throughput Screening Data. Frontiers in Genetics, 2019, 10, 387.	1.1	6
1058	Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy. Medicine (United States), 2019, 98, e15582.	0.4	63
1059	A theoretical study of the ESIPT mechanism of 3-hydroxyflavone derivatives: solvation effect and the importance of TICT for its dual fluorescence properties. Organic Chemistry Frontiers, 2019, 6, 3136-3143.	2.3	43
1060	Predicting drug activity against cancer cells by random forest models based on minimal genomic information and chemical properties. PLoS ONE, 2019, 14, e0219774.	1.1	75
1061	Identifying Cancer Driver lncRNAs Bridged by Functional Effectors through Integrating Multi-omics Data in Human Cancers. Molecular Therapy - Nucleic Acids, 2019, 17, 362-373.	2.3	30
1062	A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. Cell Systems, 2019, 9, 35-48.e5.	2.9	95
1063	Weighted elastic net for unsupervised domain adaptation with application to age prediction from DNA methylation data. Bioinformatics, 2019, 35, i154-i163.	1.8	11
1064	Construction of a Multiple-Aptamer-Based DNA Logic Device on Live Cell Membranes via Associative Toehold Activation for Accurate Cancer Cell Identification. Journal of the American Chemical Society, 2019, 141, 12738-12743.	6.6	217
1065	Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors. IScience, 2019, 17, 359-378.	1.9	5
1066	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776.	0.6	141

#	Article	IF	Citations
1067	A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing. International Journal of Molecular Sciences, 2019, 20, 3428.	1.8	14
1068	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	4.6	54
1069	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Medicine, 2019, 11, 42.	3.6	42
1070	The Missing Pieces of Artificial Intelligence in Medicine. Trends in Pharmacological Sciences, 2019, 40, 555-564.	4.0	46
1071	Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization. Molecular Therapy - Nucleic Acids, 2019, 17, 164-174.	2.3	62
1072	Modeling cancer drug response through drug-specific informative genes. Scientific Reports, 2019, 9, 15222.	1.6	42
1073	Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders. Molecular Pharmaceutics, 2019, 16, 4797-4806.	2.3	86
1074	Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Science Translational Medicine, 2019, 11, .	5.8	451
1075	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	7.1	13
1076	Expanding the Connectivity Map Concept as the Functional Look-Up TableÂfor Systems Biology. Advances in Molecular Pathology, 2019, 2, 201-213.	0.2	0
1077	Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines. Scientific Reports, 2019, 9, 14421.	1.6	8
1078	A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin. Cancer & Metabolism, 2019, 7, 9.	2.4	6
1079	Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nature Communications, 2019, 10, 5076.	5.8	30
1080	An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. EBioMedicine, 2019, 49, 106-117.	2.7	20
1081	Elucidating Compound Mechanism of Action and Predicting Cytotoxicity Using Machine Learning Approaches, Taking Prediction Confidence into Account. Current Protocols in Chemical Biology, 2019, 11, e73.	1.7	1
1082	A Toolbox for Functional Analysis and the Systematic Identification of Diagnostic and Prognostic Gene Expression Signatures Combining Meta-Analysis and Machine Learning. Cancers, 2019, 11, 1606.	1.7	12
1083	P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib. PLoS ONE, 2019, 14, e0223084.	1.1	20
1084	Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC. Cancer Research, 2019, 79, 5597-5611.	0.4	28

#	Article	IF	Citations
1085	Network as a Biomarker: A Novel Network-Based Sparse Bayesian Machine for Pathway-Driven Drug Response Prediction. Genes, 2019, 10, 602.	1.0	11
1086	Looking beyond the hype: Applied AI and machine learning in translational medicine. EBioMedicine, 2019, 47, 607-615.	2.7	82
1087	Dissecting phenotypic responses of the druggable targetome in cancers. Scientific Reports, 2019, 9, 12513.	1.6	2
1088	Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. Communications Biology, 2019, 2, 335.	2.0	35
1089	Precision Medicine and its Role in the Treatment of Sepsis: A Personalised View. The Journal of Critical Care Medicine, 2019, 5, 90-96.	0.3	18
1090	Organoids. Methods in Molecular Biology, 2019, , .	0.4	3
1091	Genome-bound enzymes as epigenetic drug targets in cancer. Epigenomics, 2019, 11, 1463-1467.	1.0	0
1092	Signatures of cell death and proliferation in perturbation transcriptomics data—from confounding factor to effective prediction. Nucleic Acids Research, 2019, 47, 10010-10026.	6.5	50
1093	A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity. Genes, 2019, 10, 770.	1.0	3
1094	Defining subpopulations of differential drug response to reveal novel target populations. Npj Systems Biology and Applications, 2019, 5, 36.	1.4	18
1095	Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22020-22029.	3.3	37
1096	Head and Neck Tumors. , 2019, , 627-762.		0
1097	Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model. BMC Bioinformatics, 2019, 20, 44.	1.2	43
1098	USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth. Scientific Reports, 2019, 9, 951.	1.6	28
1099	GLUT1 and GLUT3 involvement in anthocyanin gastric transport- Nanobased targeted approach. Scientific Reports, 2019, 9, 789.	1.6	42
1100	Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. Processes, 2019, 7, 37.	1.3	115
1101	Context-explorer: Analysis of spatially organized protein expression in high-throughput screens. PLoS Computational Biology, 2019, 15, e1006384.	1.5	11
1102	Precision medicine approaches for the management of Ewing sarcoma: current perspectives. Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 9-14.	0.4	9

#	Article	IF	Citations
1103	Regulostat Inferelator: a novel network biology platform to uncover molecular devices that predetermine cellular response phenotypes. Nucleic Acids Research, 2019, 47, e82-e82.	6.5	8
1105	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer, 2019, 19, 593.	1.1	13
1106	Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2019, 20, 3021.	1.8	65
1107	Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Research, 2019, 8, 493.	0.8	57
1108	Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss. Cell Reports, 2019, 27, 3331-3344.e6.	2.9	19
1109	Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features. PLoS Computational Biology, 2019, 15, e1006743.	1.5	4
1110	Pediatric leukemia: Moving toward more accurate models. Experimental Hematology, 2019, 74, 1-12.	0.2	9
1111	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature Cell Biology, 2019, 21, 778-790.	4.6	24
1112	Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction. Cancers, 2019, 11, 795.	1.7	17
1113	RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB. Cancer Research, 2019, 79, 3514-3524.	0.4	58
1114	Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	14
1115	A benchmark-driven approach to reconstruct metabolic networks for studying cancer metabolism. PLoS Computational Biology, 2019, 15, e1006936.	1.5	24
1116	Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nature Communications, 2019, 10, 2198.	5.8	92
1117	Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clinical Cancer Research, 2019, 25, 4723-4734.	3.2	73
1118	Predicting stage-specific cancer related genes and their dynamic modules by integrating multiple datasets. BMC Bioinformatics, 2019, 20, 194.	1.2	4
1119	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189.	5.8	26
1120	Are EWSR1-FLI-positive cell lines from patients with other diagnoses than Ewing sarcoma really Ewing sarcoma cell lines?. Pediatric Blood and Cancer, 2019, 66, e27769.	0.8	0
1121	Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell, 2019, 177, 1903-1914.e14.	13.5	188

#	Article	IF	Citations
1122	The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases. Turkish Journal of Medical Sciences, 2019, 49, 661-674.	0.4	6
1123	A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells. Cancer Research, 2019, 79, 3139-3151.	0.4	88
1124	Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis. Cell, 2019, 176, 1282-1294.e20.	13.5	298
1125	A Comparative Study of Cluster Detection Algorithms in Protein–Protein Interaction for Drug Target Discovery and Drug Repurposing. Frontiers in Pharmacology, 2019, 10, 109.	1.6	26
1126	Encircling the regions of the pharmacogenomic landscape that determine drug response. Genome Medicine, 2019, 11, 17.	3.6	14
1127	On fitness: how do mutations shape the biology of cancer?. Biochemical Society Transactions, 2019, 47, 559-569.	1.6	2
1128	Dr.VAE: improving drug response prediction via modeling of drug perturbation effects. Bioinformatics, 2019, 35, 3743-3751.	1.8	113
1129	FORESEE: a tool for the systematic comparison of translational drug response modeling pipelines. Bioinformatics, 2019, 35, 3846-3848.	1.8	6
1130	Understanding of researcher behavior is required to improve data reliability. GigaScience, 2019, 8, .	3.3	12
1131	Predict drug sensitivity of cancer cells with pathway activity inference. BMC Medical Genomics, 2019, 12, 15.	0.7	36
1132	Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology, 2019, 15, e8323.	3.2	25
1133	Synthetic Lethality in Lung Cancer—From the Perspective of Cancer Genomics. Medicines (Basel,) Tj ETQq1 1 0.784314 rgBT /Overl	0.7	6
1134	Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma. Clinical Cancer Research, 2019, 25, 4063-4078.	3.2	14
1135	Dissecting PARP inhibitor resistance with functional genomics. Current Opinion in Genetics and Development, 2019, 54, 55-63.	1.5	22
1136	Targeting chromatin complexes in fusion protein-driven malignancies. Nature Reviews Cancer, 2019, 19, 255-269.	12.8	55
1137	Socioeconomic Differences in Referral to Phase I Cancer Clinical Trials: A Danish Matched Cancer Case-Control Study. Journal of Clinical Oncology, 2019, 37, 1111-1119.	0.8	8
1138	SET domain containing 1B gene is mutated in primary hepatic neuroendocrine tumors. International Journal of Cancer, 2019, 145, 2986-2995.	2.3	13
1139	Tumor organoids: From inception to future in cancer research. Cancer Letters, 2019, 454, 120-133.	3.2	39

#	Article	IF	Citations
1140	17-Aminogeldanamycin selectively diminishes IRE1Î±-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 596-611.	2.2	14
1141	Autoencoder Based Feature Selection Method for Classification of Anticancer Drug Response. Frontiers in Genetics, 2019, 10, 233.	1.1	54
1142	From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Current Opinion in Genetics and Development, 2019, 54, 33-40.	1.5	20
1143	Lymphoma and Leukemia Cell Vulnerabilities and Resistance Identified by Compound Library Screens. Methods in Molecular Biology, 2019, 1956, 351-362.	0.4	0
1144	Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metabolism, 2019, 29, 1166-1181.e6.	7.2	121
1145	Blockade of PDGFRÎ² circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltrationÂin triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 85.	3.5	13
1146	Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data. Scientific Reports, 2019, 9, 2379.	1.6	11
1147	Network-based approach to identify principal isoforms among four cancer types. Molecular Omics, 2019, 15, 117-129.	1.4	7
1148	Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Molecular Cancer Research, 2019, 17, 1036-1048.	1.5	10
1149	Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. BMC Medical Genomics, 2019, 12, 23.	0.7	33
1150	Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects. Genome Biology, 2019, 20, 27.	3.8	35
1152	Visualized Networking of Co-Regulated Lipids in Human Blood Based on High-Throughput Screening Data: Implications for Exposure Assessment. Environmental Science & Technology, 2019, 53, 2862-2872.	4.6	9
1153	Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets. BMC Bioinformatics, 2019, 20, 83.	1.2	26
1154	A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell, 2019, 35, 457-472.e5.	7.7	169
1155	Deep-Resp-Forest: A deep forest model to predict anti-cancer drug response. Methods, 2019, 166, 91-102.	1.9	182
1156	Multicellular Target QSAR Model for Simultaneous Prediction and Design of Anti-Pancreatic Cancer Agents. ACS Omega, 2019, 4, 3122-3132.	1.6	27
1157	Research Publication Trends in Software Engineering. , 2019, , .		1
1158	Platform Independent Software Analysis for Near Memory Computing. , 2019, , .		5

#	ARTICLE	IF	CITATIONS
1159	Numerical Analysis of Energy Separation in Vortex Tube with Various Nozzles. , 2019, , .		0
1160	New Bounds for GLD Lattices and Codes. , 2019, , .		0
1161	A semidefinite programming approach for stochastic switched optimal control problems. , 2019, , .		0
1162	Competency Test in Cricket Defensive Drive using Double Pendulum Dynamics. , 2019, , .		0
1163	Day-ahead Prediction of Building District Heat Demand for Smart Energy Management and Automation in Decentralized Energy Systems. , 2019, , .		1
1164	Low-Profile Dual-Band Patch Antenna with Improved Bandwidth and Beamwidth By Using Multiresonant Modes. , 2019, , .		1
1165	A Verilog-A based RRAM Switching Model for Simulation and Analysis. , 2019, , .		0
1166	Study on Damping Characteristic Test of Power Transmission Line at Low Temperature. , 2019, , .		0
1167	High Density Arrays of Carbon Nanomembrane Ultrasonic MEMS. , 2019, , .		0
1168	An Investigation of Multiband Triangular Microstrip Patch Antenna using DGS. , 2019, , .		8
1169	Monitoring and Control of the Heat Input in MAG-Laser-Hybrid Welding of High Strength Steel in Telescopic Crane Booms. , 2019, , .		4
1170	Research on Electromagnetic Compatibility Analysis of TETRA Digital Trunk System in Civil Aviation Mobile Communication. , 2019, , .		0
1172	Compaction of a Functional Broadside Test Set through the Compaction of a Functional Test Sequence without Sequential Fault Simulation. , 2019, , .		0
1173	Operational Reliability Analysis of the Cyber-Physical Systems Via Online Indicator Diagrams. , 2019, , .		0
1174	Influence of surface roughness on the adhesion hysteresis of thin film. , 2019, , .		1
1175	A Method of Analyzing the Impact of the Wiring Parameters on the Electromagnetic Coupling to PCB Inside Electronic Equipment. , 2019, , .		2
1176	Limitations in Filtering Structural Vibrations for Unstable Missiles Control. , 2019, , .		0
1177	Semantic Segmentation of Fashion Photos using Light-Weight Asymmetric U-Net. , 2019, , .		1

#	Article	IF	Citations
1178	An Ultral-Wideband Wide-Angle Scan Array Antenna with Big Element Spacing. , 2019, , .		0
1179	Mitigation of thermally induced non-linear effects in silicon ring resonator. , 2019, , .		0
1180	Conditional Generative Adversarial Network on Semi-supervised Learning Task. , 2019, , .		3
1181	Typical Gas Concentration Values and Typical Rate of Gas Increase on DGA Test in PLN UIT-JBT. , 2019, , .		1
1182	Context-Reinforced Semantic Segmentation. , 2019, , .		38
1183	Pest and Disease Identification in the Growth of Sweet Peppers using Faster R-CNN. , 2019, , .		7
1184	Physical Modeling of Bias Temperature Instabilities in SiC MOSFETs. , 2019, , .		17
1185	Identification of Hidden Building Footprints in Interferometric Phase Profile. , 2019, , .		1
1186	Selecting Unrepeatable Random Starting Nodes in Large-Scale Networks for Parallel Computing and Searching. , 2019, , .		0
1187	A Multi-Modular System-Genetics (MMSG) Approach for Deep Representation Learning for Personalized Treatment of Cancer Using Sensitivity Analysis of Precision Drugs and Gene Expression Data. Data-Enabled Discovery and Applications, 2019, 3, 1.	1.2	1
1188	WLS algorithm for a Complex Lattice Linear Predictor for Frequency Estimation and Tracking. , 2019, , .		0
1189	Age Estimation Based on Integrated Convolutional Neural Network. , 2019, , .		2
1190	Disentangling Latent Space for VAE by Label Relevant/Irrelevant Dimensions. , 2019, , .		27
1191	Intelligent Trash Bin (ITB) with Trash Collection Efficiency Optimization using IoT Sensing. , 2019, , .		12
1192	Dielectric Nanofluids for Electrostatic Machines & Actuators. , 2019, , .		2
1193	Multi-Class Classification of Defect Types in Ultrasonic NDT Signals with Convolutional Neural Networks. , 2019, , .		13
1194	Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. IScience, 2019, 21, 664-680.	1.9	52
1195	Network-based Biased Tree Ensembles (NetBiTE) for Drug Sensitivity Prediction and Drug Sensitivity Biomarker Identification in Cancer. Scientific Reports, 2019, 9, 15918.	1.6	20

#	Article	IF	Citations
1196	Reconfigurable Probabilistic AI Architecture for Personalized Cancer Treatment. , 2019, , .		1
1197	Chemogenetic interactions in human cancer cells. Computational and Structural Biotechnology Journal, 2019, 17, 1318-1325.	1.9	8
1198	Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nature Communications, 2019, 10, 5817.	5.8	160
1199	Characterization of cancer omics and drug perturbations in panels of lung cancer cells. Scientific Reports, 2019, 9, 19529.	1.6	13
1200	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. Frontiers in Oncology, 2019, 9, 1327.	1.3	5
1201	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology, 2019, 20, 253.	3.8	16
1202	CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. Journal of Cancer, 2019, 10, 6374-6383.	1.2	25
1203	LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-16.	1.9	78
1204	Disease modelling in human organoids. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	254
1205	Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma. Frontiers in Oncology, 2019, 9, 1416.	1.3	17
1206	Reverse Phase Protein Arrays. Advances in Experimental Medicine and Biology, 2019, , .	0.8	1
1207	A Deep Learning Framework for Predicting Response to Therapy in Cancer. Cell Reports, 2019, 29, 3367-3373.e4.	2.9	137
1208	Genomic characterization of cervical cancer based on human papillomavirus status. Gynecologic Oncology, 2019, 152, 629-637.	0.6	31
1209	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clinical Cancer Research, 2019, 25, 2305-2313.	3.2	43
1210	Genomic evolution of cancer models: perils and opportunities. Nature Reviews Cancer, 2019, 19, 97-109.	12.8	158
1211	Previously Uncharacterized Vacuolar-type ATPase Binding Site Discovered from Structurally Similar Compounds with Distinct Mechanisms of Action. ACS Chemical Biology, 2019, 14, 20-26.	1.6	6
1212	EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs. Journal of Thoracic Oncology, 2019, 14, 513-526.	0.5	17
1213	A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition. Nature Communications, 2019, 10, 96.	5.8	59

#	ARTICLE	IF	CITATIONS
1214	The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity. Clinical Cancer Research, 2019, 25, 1664-1675.	3.2	26
1215	Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the *RB1* Tumor Suppressor Gene. Cancer Discovery, 2019, 9, 248-263.	7.7	152
1216	Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer. Methods in Molecular Biology, 2019, 1888, 205-217.	0.4	7
1217	Exome Sequencing of Drug-Resistant Clones for Target Identification. Methods in Molecular Biology, 2019, 1888, 175-187.	0.4	4
1218	Application of patient€derived liver cancer cells for phenotypic characterization and therapeutic target identification. International Journal of Cancer, 2019, 144, 2782-2794.	2.3	19
1220	Deconvoluting essential gene signatures for cancer growth from genomic expression in compound-treated cells. Bioinformatics, 2019, 35, 1167-1173.	1.8	2
1221	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Clinical Cancer Research, 2019, 25, 312-324.	3.2	11
1222	Cell Model Passports€"a hub for clinical, genetic and functional datasets of preclinical cancer models. Nucleic Acids Research, 2019, 47, D923-D929.	6.5	118
1223	A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF^{high}/AXL^{low} melanoma. Pigment Cell and Melanoma Research, 2019, 32, 280-291.	1.5	31
1224	Web-based drug repurposing tools: a survey. Briefings in Bioinformatics, 2019, 20, 299-316.	3.2	38
1225	Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?. Radiologia Medica, 2019, 124, 282-289.	4.7	14
1226	Artificial intelligence in drug combination therapy. Briefings in Bioinformatics, 2019, 20, 1434-1448.	3.2	60
1227	Molecular subtyping of cancer: current status and moving toward clinical applications. Briefings in Bioinformatics, 2019, 20, 572-584.	3.2	91
1228	Role of Structural Bioinformatics in Drug Discovery by Computational SNP Analysis. Global Heart, 2017, 12, 151.	0.9	38
1229	Comprehensive expression-based isoform biomarkers predictive of drug responses based on isoform co-expression networks and clinical data. Genomics, 2020, 112, 647-658.	1.3	12
1230	Meta-GDBP: a high-level stacked regression model to improve anticancer drug response prediction. Briefings in Bioinformatics, 2020, 21, 996-1005.	3.2	63
1231	Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies. Seminars in Cancer Biology, 2020, 61, 11-22.	4.3	11
1232	Translational genomics and recent advances in oral squamous cell carcinoma. Seminars in Cancer Biology, 2020, 61, 71-83.	4.3	150

#	Article	IF	Citations
1233	Genetic characterization of ABT-199 sensitivity in human AML. Leukemia, 2020, 34, 63-74.	3.3	58
1234	KRCC1: A potential therapeutic target in ovarian cancer. FASEB Journal, 2020, 34, 2287-2300.	0.2	5
1235	Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. British Journal of Cancer, 2020, 122, 735-744.	2.9	134
1236	A sensitive and rapid â€œoffâ€"onâ€•fluorescent probe for the detection of esterase and its application in evaluating cell status and discrimination of living cells and dead cells. Analyst, The, 2020, 145, 1408-1413.	1.7	17
1237	Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response. Molecular Cancer Therapeutics, 2020, 19, 927-936.	1.9	5
1238	eQTL Analysis. Methods in Molecular Biology, 2020, , .	0.4	4
1239	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric Blood and Cancer, 2020, 67, e28073.	0.8	52
1240	Microfluidics as an Enabling Technology for Personalized Cancer Therapy. Small, 2020, 16, e1904321.	5.2	55
1241	Drug sensitivity prediction framework using ensemble and multi-task learning. International Journal of Machine Learning and Cybernetics, 2020, 11, 1231-1240.	2.3	20
1242	CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewingâ€™s sarcoma. Nature Chemical Biology, 2020, 16, 50-59.	3.9	59
1243	Methods and resources to access mutation-dependent effects on cancer drug treatment. Briefings in Bioinformatics, 2020, 21, 1886-1903.	3.2	5
1244	5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2020, 206, 107447.		449
1245	MicroRNA-7 targets T-Box 2 to inhibit epithelial-mesenchymal transition and invasiveness in glioblastoma multiforme. Cancer Letters, 2020, 493, 133-142.	3.2	18
1246	Systematic identification of a nuclear receptor-enriched predictive signature for erastin-induced ferroptosis. Redox Biology, 2020, 37, 101719.	3.9	23
1247	Cell-based multi-target QSAR model for design of virtual versatile inhibitors of liver cancer cell lines. SAR and QSAR in Environmental Research, 2020, 31, 815-836.	1.0	26
1248	STAT3 imparts BRCAnessÂby impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes. PLoS Pathogens, 2020, 16, e1008849.	2.1	12
1249	Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells. Cancer Cell, 2020, 38, 672-684.e6.	7.7	216
1250	Advantages of a 21-loci short tandem repeat method for detection of cross-contamination in human cell lines. Gene, 2020, 763, 145048.	1.0	4

#	ARTICLE	IF	CITATIONS
1251	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell Reports, 2020, 33, 108296.	2.9	86
1252	A guide for bioinformaticians: â€˜omics-based drug discovery for precision oncology. Drug Discovery Today, 2020, 25, 1897-1904.	3.2	10
1253	Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens. Patterns, 2020, 1, 100065.	3.1	6
1254	Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment. Cell Reports, 2020, 32, 107884.	2.9	19
1255	CELLector: Genomics-Guided Selection of Cancer InÂVitro Models. Cell Systems, 2020, 10, 424-432.e6.	2.9	35
1256	Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. PLoS Computational Biology, 2020, 16, e1007909.	1.5	15
1257	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34, 2780-2784.	3.3	6
1258	Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma. Human Cell, 2020, 33, 1302-1310.	1.2	3
1259	A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. Cell Reports, 2020, 32, 107897.	2.9	41
1262	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Translational Lung Cancer Research, 2020, 9, 2214-2232.	1.3	51
1263	Double Empirical Bayes Testing. International Statistical Review, 2020, 88, S91-S113.	1.1	2
1264	A Clinical Genomics-Guided Prioritizing Strategy Enables Selecting Proper Cancer Cell Lines for Biomedical Research. IScience, 2020, 23, 101748.	1.9	0
1265	Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication. BMC Cancer, 2020, 20, 1171.	1.1	7
1266	Quantitative and multiplexed chemical-genetic phenotyping in mammalian cells with QMAP-Seq. Nature Communications, 2020, 11, 5722.	5.8	1
1267	DRIM: A Web-Based System for Investigating Drug Response at the Molecular Level by Condition-Specific Multi-Omics Data Integration. Frontiers in Genetics, 2020, 11, 564792.	1.1	6
1268	An Improved Anticancer Drug-Response Prediction Based on an Ensemble Method Integrating Matrix Completion and Ridge Regression. Molecular Therapy - Nucleic Acids, 2020, 21, 676-686.	2.3	71
1269	Phenotype-related drug sensitivity analysis of single CTCs for medicine evaluation. Chemical Science, 2020, 11, 8895-8900.	3.7	12
1270	Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting. Cancers, 2020, 12, 1939.	1.7	18

#	Article	IF	Citations
1271	SREBP1 regulates mitochondrial metabolism in oncogenic <i>KRAS</i> expressing NSCLC. FASEB Journal, 2020, 34, 10574-10589.	0.2	10
1272	Targeting p53 for the treatment of cancer. Seminars in Cancer Biology, 2022, 79, 58-67.	4.3	177
1273	Amplified AND logic platform for cell identification. Chemical Communications, 2020, 56, 11267-11270.	2.2	12
1274	A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. Journal of Cheminformatics, 2020, 12, 46.	2.8	194
1275	Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1. Human Cell, 2020, 33, 1311-1320.	1.2	8
1276	Prediction of drug response in multilayer networks based on fusion of multiomics data. Methods, 2021, 192, 85-92.	1.9	35
1277	Machine Learning in Oncology: Methods, Applications, and Challenges. JCO Clinical Cancer Informatics, 2020, 4, 885-894.	1.0	42
1278	Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2. Molecular and Cellular Biology, 2020, 40, .	1.1	24
1279	The LL-100 Cell Lines Panel: Tool for Molecular Leukemia–Lymphoma Research. International Journal of Molecular Sciences, 2020, 21, 5800.	1.8	11
1280	Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer. Frontiers in Pharmacology, 2020, 11, 577150.	1.6	4
1281	ADRML: anticancer drug response prediction using manifold learning. Scientific Reports, 2020, 10, 14245.	1.6	3
1282	PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Science Translational Medicine, 2020, 12, .	5.8	23
1283	Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell, 2020, 38, 734-747.e9.	7.7	144
1284	Multifunctional Near-Infrared Fluorescent Probes with Different Ring-Structure Trigger Groups for Cell Health Monitoring and In Vivo Esterase Activity Detection. ACS Sensors, 2020, 5, 3264-3273.	4.0	25
1285	Illuminating the noncoding genome in cancer. Nature Cancer, 2020, 1, 864-872.	5.7	37
1286	Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nature Communications, 2020, 11, 4296.	5.8	98
1287	Generalized finite mixture of multivariate regressions with applications to therapeutic biomarker identification. Statistics in Medicine, 2020, 39, 4301-4324.	0.8	2
1288	Amino Acid Transporters as Targets for Cancer Therapy: Why, Where, When, and How. International Journal of Molecular Sciences, 2020, 21, 6156.	1.8	62

#	Article	IF	Citations
1289	Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells. Cancers, 2020, 12, 2551.	1.7	12
1290	Current Status and Perspectives of Patient-Derived Models for Ewing's Sarcoma. Cancers, 2020, 12, 2520.	1.7	3
1291	GMIEC: a shiny application for the identification of gene-targeted drugs for precision medicine. BMC Genomics, 2020, 21, 619.	1.2	1
1292	Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Human Cell, 2020, 33, 1321-1328.	1.2	8
1293	Applications of organoids for cancer biology and precision medicine. Nature Cancer, 2020, 1, 761-773.	5.7	93
1294	Logic Gates Based on DNA Aptamers. Pharmaceuticals, 2020, 13, 417.	1.7	14
1295	Different Calculation Strategies Are Congruent in Determining Chemotherapy Resistance of Brain Tumors In Vitro. Cells, 2020, 9, 2689.	1.8	4
1296	ncDRMarker: a computational method for identifying non-coding RNA signatures of drug resistance based on heterogeneous network. Annals of Translational Medicine, 2020, 8, 1395-1395.	0.7	5
1297	A metastasis map of human cancer cell lines. Nature, 2020, 588, 331-336.	13.7	214
1298	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	7.7	40
1299	YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting. Cancers, 2020, 12, 1080.	1.7	5
1300	A Multimodal Genotoxic Anticancer Drug Characterized by Pharmacogenetic Analysis in <i>Caenorhabditis elegans</i>. Genetics, 2020, 215, 609-621.	1.2	9
1301	Measurement and models accounting for cell death capture hidden variation in compound response. Cell Death and Disease, 2020, 11, 255.	2.7	10
1302	High polymerase Îµ expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer. PLoS ONE, 2020, 15, e0233066.	1.1	4
1303	Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen. Cancers, 2020, 12, 1123.	1.7	7
1304	The DNA methylation landscape of human cancer organoids available at the American type culture collection. Epigenetics, 2020, 15, 1167-1177.	1.3	20
1305	Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning. Pharmacological Research, 2020, 159, 104932.	3.1	5
1306	Integrating Systems Biology and an ExÂVivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics. IScience, 2020, 23, 101229.	1.9	4

#	Article	IF	Citations
1307	A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. Nature Communications, 2020, 11, 2935.	5.8	57
1308	Machine learning approaches to drug response prediction: challenges and recent progress. Npj Precision Oncology, 2020, 4, 19.	2.3	170
1309	Necessity of guidelines for publication of patient-derived cancer models. Annals of Translational Medicine, 2020, 8, 158-158.	0.7	0
1310	Current status and perspectives of patient-derived rare cancer models. Human Cell, 2020, 33, 919-929.	1.2	15
1311	Computational Methods for the Integrative Analysis of Genomics and Pharmacological Data. Frontiers in Oncology, 2020, 10, 185.	1.3	8
1312	Preliminary Design of DEMO PF Coils Based on EU DEMO 2018 Baseline. IEEE Transactions on Applied Superconductivity, 2020, 30, 1-5.	1.1	7
1313	Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress. Cell Reports, 2020, 30, 4137-4151.e6.	2.9	48
1314	A bioinformatics approach to identify novel long, non-coding RNAs in breast cancer cell lines from an existing RNA-sequencing dataset. Non-coding RNA Research, 2020, 5, 48-59.	2.4	14
1315	Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090604.	1.4	5
1316	Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research. Cancers, 2020, 12, 777.	1.7	37
1317	Investigation and Wideband Modeling of LCC based Â±800 kV UHVDC Converter Station for Electromagnetic Disturbance. , 2020, , .		0
1318	Transient response comparison of virtual oscillator controlled and droop controlled threeâ€phase inverters under load changes. IET Generation, Transmission and Distribution, 2020, 14, 1138-1147.	1.4	3
1319	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 273-287.	1.2	32
1320	Concise Polygenic Models for Cancer-Specific Identification of Drug-Sensitive Tumors from Their Multi-Omics Profiles. Biomolecules, 2020, 10, 963.	1.8	11
1321	The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer. Molecules, 2020, 25, 3045.	1.7	17
1322	Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chemical Biology, 2020, 27, 1359-1370.e8.	2.5	13
1323	QSAR-derived affinity fingerprints (part 2): modeling performance for potency prediction. Journal of Cheminformatics, 2020, 12, 41.	2.8	14
1325	Systematic functional identification of cancer multi-drug resistance genes. Genome Biology, 2020, 21, 27.	3.8	26

#	Article	IF	Citations
1326	Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy. Advanced Therapeutics, 2020, 3, 1900100.	1.6	25
1327	Lucid: A Practical, Lightweight Deep Learning Solution for DDoS Attack Detection. IEEE Transactions on Network and Service Management, 2020, 17, 876-889.	3.2	170
1328	Incidence of Digital Competences in the Completion Rates of MOOCs: Case Study on Energy Sustainability Courses. IEEE Transactions on Education, 2020, 63, 183-189.	2.0	18
1329	Comprehensive pharmacogenomic characterization of gastric cancer. Genome Medicine, 2020, 12, 17.	3.6	20
1330	A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Communications Biology, 2020, 3, 42.	2.0	23
1331	Structured penalized regression for drug sensitivity prediction. Journal of the Royal Statistical Society Series C: Applied Statistics, 2020, 69, 525-545.	0.5	4
1332	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity. European Journal of Medicinal Chemistry, 2020, 193, 112194.	2.6	6
1333	Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma. Cancers, 2020, 12, 232.	1.7	40
1334	Targeting glutamine metabolism slows soft tissue sarcoma growth. Nature Communications, 2020, 11, 498.	5.8	63
1335	Advances in molecular classification and precision oncology in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 215-229.	1.8	311
1336	Cross-Comparison of EMG-to-Force Methods for Multi-DoF Finger Force Prediction Using One-DoF Training. IEEE Access, 2020, 8, 13958-13968.	2.6	22
1337	Old drugs with new tricks. Nature Cancer, 2020, 1, 153-155.	5.7	10
1338	A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer. Journal of Cancer, 2020, 11, 949-961.	1.2	13
1339	Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer, 2020, 1, 235-248.	5.7	430
1340	Ensembled machine learning framework for drug sensitivity prediction. IET Systems Biology, 2020, 14, 39-46.	0.8	25
1341	Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer. IScience, 2020, 23, 100979.	1.9	19
1342	Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations. Biomolecules, 2020, 10, 667.	1.8	9
1343	Novel Target Discovery of Existing Therapies: Path to Personalized Cancer Therapy. INFORMS Journal on Optimization, 2020, 2, 1-13.	0.9	2

#	Article	IF	Citations
1344	CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Molecular Cancer Therapeutics, 2020, 19, 661-672.	1.9	26
1345	Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape. Cells, 2020, 9, 804.	1.8	8
1346	A Network-Centric Analysis for the Internet of Vehicles and Simulation Tools. IEEE Access, 2020, 8, 68342-68364.	2.6	6
1347	Adaptive Resolution Change Using Uncoded Areas and Dictionary Learning-Based Super-Resolution in Versatile Video Coding. , 2020, , .		0
1348	WMMDCA: Prediction of Drug Responses by Weight-Based Modular Mapping in Cancer Cell Lines. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2021, 18, 2733-2740.	1.9	1
1349	Dissecting the Tumorâ€"Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. Clinical Cancer Research, 2020, 26, 3505-3513.	3.2	18
1350	Methodological challenges in translational drug response modeling in cancer: A systematic analysis with FORESEE. PLoS Computational Biology, 2020, 16, e1007803.	1.5	9
1352	Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective. Advances in Experimental Medicine and Biology, 2020, 1243, 163-179.	0.8	18
1353	Pan-cancer analysis and applications. , 2020, , 307-316.		0
1354	Old drugs, new uses: Drug repurposing in hematological malignancies. Seminars in Cancer Biology, 2021, 68, 242-248.	4.3	25
1355	Insights into DNAâ€"drug interactions in the era of omics. Biopolymers, 2021, 112, e23385.	1.2	2
1356	CCLA: an accurate method and web server for cancer cell line authentication using gene expression profiles. Briefings in Bioinformatics, 2021, 22, .	3.2	6
1357	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038240.	2.9	34
1358	Deep learning for drug response prediction in cancer. Briefings in Bioinformatics, 2021, 22, 360-379.	3.2	116
1359	A survey and systematic assessment of computational methods for drug response prediction. Briefings in Bioinformatics, 2021, 22, 232-246.	3.2	42
1360	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology, 2021, 68, 209-229.	4.3	39
1361	Drug sensitivity prediction with normal inverse Gaussian shrinkage informed by external data. Biometrical Journal, 2021, 63, 289-304.	0.6	3
1363	Exploiting Replication Stress as a Novel Therapeutic Intervention. Molecular Cancer Research, 2021, 19, 192-206.	1.5	9

#	Article	IF	Citations
1364	Multiâ€omics integration identifies a selective vulnerability of colorectal cancer subtypes to <scp>YM155</scp>. International Journal of Cancer, 2021, 148, 1948-1963.	2.3	11
1365	CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Research, 2021, 49, D1083-D1093.	6.5	104
1366	Multi-omics analysis of copy number variations of RNA regulatory genes in soft tissue sarcoma. Life Sciences, 2021, 265, 118734.	2.0	17
1367	Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer. Gynecologic Oncology, 2021, 160, 295-301.	0.6	0
1368	SARC025 arms 1 and 2: A phase 1 study of the poly(ADPâ€ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer, 2021, 127, 1301-1310.	2.0	20
1369	Enhanced Antitumoral Activity and Photoacoustic Imaging Properties of AuNPâ€Enriched Endothelial Colony Forming Cells on Melanoma. Advanced Science, 2021, 8, 2001175.	5.6	12
1370	Establishment and characterization of NCC-LMS2-C1â€"a novel patient-derived cancer cell line of leiomyosarcoma. Human Cell, 2021, 34, 279-288.	1.2	1
1371	Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Human Cell, 2021, 34, 246-253.	1.2	8
1372	DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cancer Cell Lines. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2021, 18, 575-582.	1.9	67
1373	Models of Cancer Drug Discovery and Response to Therapy. , 2021, , 269-276.		0
1374	Molecular subtypes of colorectal cancer: AnÂemerging therapeutic opportunity for personalized medicine. Genes and Diseases, 2021, 8, 133-145.	1.5	71
1375	Identification of six hub genes and analysis of their correlation with drug sensitivity in acute myeloid leukemia through bioinformatics. Translational Cancer Research, 2021, 10, 126-140.	0.4	4
1376	BACH2â€mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL. Cancer Science, 2021, 112, 1235-1250.	1.7	7
1377	Machine Learning Applications in Anti-cancer Drug Discovery. EAI/Springer Innovations in Communication and Computing, 2021, , 163-179.	0.9	0
1379	An overview of machine learning methods for monotherapy drug response prediction. Briefings in Bioinformatics, 2022, 23, .	3.2	19
1380	Doseâ€"response modeling in high-throughput cancer drug screenings: an end-to-end approach. Biostatistics, 2022, 23, 643-665.	0.9	8
1381	Predicting Drug Response Based on Multi-Omics Fusion and Graph Convolution. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 1384-1393.	3.9	34
1382	Machine learning in the prediction of cancer therapy. Computational and Structural Biotechnology Journal, 2021, 19, 4003-4017.	1.9	58

#	ARTICLE	IF	CITATIONS
1383	Cancer research needs a better map. Nature, 2021, 589, 514-516.	13.7	57
1384	Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance. Cells, 2021, 10, 260.	1.8	4
1385	Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients' survival. Scientific Reports, 2021, 11, 1321.	1.6	7
1386	Oncogenic potential of ATAD2 in stomach cancer and insights into the protein-protein interactions at its AAA‰+‰ATPase domain and bromodomain. Journal of Biomolecular Structure and Dynamics, 2022, 40, 5606-5622.	2.0	5
1387	Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature, 2021, 590, 486-491.	13.7	135
1388	Data types and resources. , 2021, , 27-60.		3
1389	Machine Learning for Pharmacogenomics and Personalized Medicine: A Ranking Model for Drug Sensitivity Prediction. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 2324-2333.	1.9	6
1390	Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro. MBio, 2021, 12, .	1.8	16
1391	Generation of Patient-Derived Colorectal Cancer Organoids for RAS Studies. Methods in Molecular Biology, 2021, 2262, 349-360.	0.4	2
1392	Systems biology and molecular characterization of subtypes to guide targeted therapies in gastric cancer. , 2021, , 259-288.		0
1393	Multivariate variable selection by means of null-beamforming. Electronic Journal of Statistics, 2021, 15, .	0.4	1
1394	Transcriptionally active enhancers in human cancer cells. Molecular Systems Biology, 2021, 17, e9873.	3.2	28
1395	Machine Learning Perspective in Cancer Research. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 142-163.	0.1	2
1396	Graph Convolutional Networks for Drug Response Prediction. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 146-154.	1.9	55
1397	Predicting chemosensitivity using drug perturbed gene dynamics. BMC Bioinformatics, 2021, 22, 15.	1.2	1
1398	Accucopy: accurate and fast inference of allele-specific copy number alterations from low-coverage low-purity tumor sequencing data. BMC Bioinformatics, 2021, 22, 23.	1.2	3
1399	Promising Investigational New Drugs for Mesothelioma: What Is the Next Stage of the Treatment for Advanced Mesothelioma?. Respiratory Disease Series, 2021, , 279-289.	0.1	0
1400	The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance. , 2021, 4, 365-381.		4

#	Article	IF	Citations
1401	Developing Novel Anticancer Drugs for Targeted Populations: An Update. Current Pharmaceutical Design, 2021, 27, 250-262.	0.9	3
1404	Impact of between-tissue differences on pan-cancer predictions of drug sensitivity. PLoS Computational Biology, 2021, 17, e1008720.	1.5	5
1407	The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia. Npj Precision Oncology, 2021, 5, 13.	2.3	16
1408	Current status and future outlook for patient‐derived cancer models from a rare cancer research perspective. Cancer Science, 2021, 112, 953-961.	1.7	20
1410	An Extracellular Matrix-Based Signature Associated With Immune Microenvironment Predicts the Prognosis and Therapeutic Responses of Patients With Oesophageal Squamous Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 598427.	1.6	8
1411	Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy. Scientific Reports, 2021, 11, 7259.	1.6	20
1412	A survey of cancer genome signatures identifies genes connected to distinct chromosomal instability phenotypes. Pharmacogenomics Journal, 2021, 21, 390-401.	0.9	3
1413	Multi‐modal meta‐analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. Molecular Systems Biology, 2021, 17, e9526.	3.2	8
1414	HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line. Pathology and Oncology Research, 2021, 27, 636088.	0.9	5
1415	Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types. Journal of Translational Medicine, 2021, 19, 124.	1.8	7
1416	Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines. Clinical Epigenetics, 2021, 13, 49.	1.8	14
1417	High KDM1A Expression Associated with Decreased CD8+T Cells Reduces the Breast Cancer Survival Rate in Patients with Breast Cancer. Journal of Clinical Medicine, 2021, 10, 1112.	1.0	3
1418	In search for biomarkers and potential drug targets for uterine serous endometrial cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1647-1658.	1.2	5
1419	Current Status of Management and Outcome for Patients with Ewing Sarcoma. Cancers, 2021, 13, 1202.	1.7	29
1421	Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i> -amplified neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	10
1423	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology, 2021, 11, 638360.	1.3	42
1424	High SLC2A1 expression associated with suppressing CD8 T cells and B cells promoted cancer survival in gastric cancer. PLoS ONE, 2021, 16, e0245075.	1.1	21
1426	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resistance Updates, 2021, 55, 100744.	6.5	43

#	ARTICLE	IF	CITATIONS
1427	Targeted therapy in metastatic, recurrent and refractory Ewing sarcoma and osteogenic sarcoma. Review of literature. Russian Journal of Pediatric Hematology and Oncology, 2021, 8, 57-63.	0.1	1
1428	Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. PLoS ONE, 2021, 16, e0248380.	1.1	7
1429	X-ray on chip: Quantifying therapeutic synergies between radiotherapy and anticancer drugs using soft tissue sarcoma tumor spheroids. Radiotherapy and Oncology, 2021, 157, 175-181.	0.3	8
1430	A computational method for drug sensitivity prediction of cancer cell lines based on various molecular information. PLoS ONE, 2021, 16, e0250620.	1.1	11
1431	MP3RNA‐seq: Massively parallel 3′ end RNA sequencing for high‐throughput gene expression profiling and genotyping. Journal of Integrative Plant Biology, 2021, 63, 1227-1239.	4.1	4
1432	Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulates the Cellular Phenotypes of Fanconi Anemia. Genes, 2021, 12, 548.	1.0	2
1434	The landscape of metabolic pathway dependencies in cancer cell lines. PLoS Computational Biology, 2021, 17, e1008942.	1.5	9
1435	CASB: a concanavalin A‐based sample barcoding strategy for single‐cell sequencing. Molecular Systems Biology, 2021, 17, e10060.	3.2	14
1436	Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines. BMC Genomics, 2021, 22, 272.	1.2	25
1437	Graph Convolutional Network for Drug Response Prediction Using Gene Expression Data. Mathematics, 2021, 9, 772.	1.1	18
1438	Swarm ascending: Swarm intelligence-based exemplar group detection for robust clustering. Applied Soft Computing Journal, 2021, 102, 107062.	4.1	1
1439	Predicting Anticancer Drug Response With Deep Learning Constrained by Signaling Pathways. Frontiers in Bioinformatics, 2021, 1, .	1.0	19
1440	DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration. Briefings in Bioinformatics, 2021, 22, .	3.2	25
1441	Identification of novel prognostic biomarkers by integrating multi-omics data in gastric cancer. BMC Cancer, 2021, 21, 460.	1.1	13
1442	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair‐Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer Discovery, 2021, 11, 1923-1937.	7.7	48
1445	Therapeutic applications of three-dimensional organoid models in lung cancer. Organoid, 0, 1, e6.	0.0	0
1446	Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. Scientific Reports, 2021, 11, 11234.	1.6	27
1447	Aberrant methylation modifications reflect specific drug responses in small cell lung cancer. Genomics, 2021, 113, 1114-1126.	1.3	4

#	ARTICLE	IF	CITATIONS
1449	Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. Cell Reports Medicine, 2021, 2, 100267.	3.3	4
1450	Predicting breast cancer drug response using a multiple-layer cell line drug response network model. BMC Cancer, 2021, 21, 648.	1.1	8
1451	High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer. PLoS ONE, 2021, 16, e0252052.	1.1	13
1452	Pan-cancer characterization of metabolism-related biomarkers identifies potential therapeutic targets. Journal of Translational Medicine, 2021, 19, 219.	1.8	8
1453	Predicting Cancer Drug Response Using an Adapted Deep Neural Network Model. , 2021, , .		0
1454	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. Nature Communications, 2021, 12, 2498.	5.8	20
1455	Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell Systems, 2021, 12, 401-418.e12.	2.9	22
1456	Thunor: visualization and analysis of high-throughput dose–response datasets. Nucleic Acids Research, 2021, 49, W633-W640.	6.5	4
1458	A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles. Cell Reports Methods, 2021, 1, 100039.	1.4	8
1459	Predicting anti-cancer drug response by finding optimal subset of drugs. Bioinformatics, 2021, 37, 4509-4516.	1.8	3
1460	A Novel Classification of Glioma Subgroup, Which Is Highly Correlated With the Clinical Characteristics and Tumor Tissue Characteristics, Based on the Expression Levels of GÎ² and GÎ³ Genes. Frontiers in Oncology, 2021, 11, 685823.	1.3	5
1461	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 4883-4897.	3.2	11
1462	A Comprehensive Review on Deep Synergistic Drug Prediction Techniques for Cancer. Archives of Computational Methods in Engineering, 2022, 29, 1443-1461.	6.0	14
1463	Preclinical Models for Bladder Cancer Research. Hematology/Oncology Clinics of North America, 2021, 35, 613-632.	0.9	7
1465	Ewing sarcoma: investigational mono- and combination therapies in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 653-663.	1.9	6
1466	N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production. Molecular Metabolism, 2021, 48, 101217.	3.0	10
1467	A Methodological Framework to Discover Pharmacogenomic Interactions Based on Random Forests. Genes, 2021, 12, 933.	1.0	1
1468	Recent scientific/intellectual movements in biomedicine. Social Science and Medicine, 2021, 278, 113950.	1.8	7

#	Article	IF	Citations
1470	Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes, 2021, 12, 899.	1.0	44
1472	An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach. Cancers, 2021, 13, 2893.	1.7	6
1474	Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. Journal of Experimental and Clinical Cancer Research, 2021, 40, 185.	3.5	20
1475	Conditional Cell Reprogramming in Modeling Digestive System Diseases. Frontiers in Cell and Developmental Biology, 2021, 9, 669756.	1.8	3
1476	The TP53-Related Signature Predicts Immune Cell Infiltration, Therapeutic Response, and Prognosis in Patients With Esophageal Carcinoma. Frontiers in Genetics, 2021, 12, 607238.	1.1	9
1477	High BMI1 Expression with Low CD8+ and CD4+ T Cell Activity Could Promote Breast Cancer Cell Survival: A Machine Learning Approach. Journal of Personalized Medicine, 2021, 11, 739.	1.1	1
1478	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 71.	2.3	12
1479	Consistency of in vitro drug sensitivities within pharmacological classes. University of Toronto Journal of Undergraduate Life Sciences, 2021, 15, 12.	0.2	0
1480	ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Cancers, 2021, 13, 3321.	1.7	11
1481	Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Human Cell, 2021, 34, 1899-1910.	1.2	9
1482	Quantitative *In Vivo* Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma. Cancer Research, 2021, 81, 4570-4580.	0.4	13
1483	DNA and RNA Sequencing Recapitulated Aberrant Tumor Metabolism in Liver Cancer Cell Lines. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 823-836.	1.8	0
1484	The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chemical Biology, 2022, 29, 202-214.e7.	2.5	19
1485	High WHSC1L1 Expression Reduces Survival Rates in Operated Breast Cancer Patients with Decreased CD8+ T Cells: Machine Learning Approach. Journal of Personalized Medicine, 2021, 11, 636.	1.1	6
1487	Investigation of REFINED CNN ensemble learning for anti-cancer drug sensitivity prediction. Bioinformatics, 2021, 37, i42-i50.	1.8	12
1488	Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery. EMBO Molecular Medicine, 2021, 13, e13189.	3.3	5
1489	Genetic Susceptibility to Acute Kidney Injury. Journal of Clinical Medicine, 2021, 10, 3039.	1.0	13
1490	Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma. BMC Cancer, 2021, 21, 849.	1.1	13

#	Article	IF	Citations
1491	Screening and Validation of Molecular Targeted Radiosensitizers. International Journal of Radiation Oncology Biology Physics, 2021, 111, e63-e74.	0.4	10
1492	Non-coding RNAs as Novel Biomarkers in Cancer Drug Resistance. Current Medicinal Chemistry, 2021, 28, .	1.2	10
1495	Combined evaluation of proliferation and apoptosis to calculate IC50 of VPA-induced PANC-1 cells and assessing its effect on the Wnt signaling pathway. Medical Oncology, 2021, 38, 109.	1.2	2
1497	SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents. Molecular Cancer Therapeutics, 2021, 20, 2151-2165.	1.9	6
1498	Multiple strategies with the synergistic approach for addressing colorectal cancer. Biomedicine and Pharmacotherapy, 2021, 140, 111704.	2.5	25
1499	A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Molecular Cell, 2021, 81, 4076-4090.e8.	4.5	31
1500	Drug sensitivity prediction from cell line-based pharmacogenomics data: guidelines for developing machine learning models. Briefings in Bioinformatics, 2021, 22, .	3.2	26
1501	Cell-cell adhesion regulates Merlin/NF2 interaction with the PAF complex. PLoS ONE, 2021, 16, e0254697.	1.1	2
1502	Logic devices based on nucleic acid selfâ€assembly. InformaÄnÃ-MateriÃ¡ly, 2021, 3, 1070-1082.	8.5	8
1503	Pharmaco-omics data sheds light on therapy-oriented prospects of precision medicine. EBioMedicine, 2021, 70, 103493.	2.7	0
1504	Data-driven approaches to advance research and clinical care for pediatric cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188571.	3.3	5
1506	Monitoring of circulating epithelial tumor cells using the MaintracÂ® method and its potential benefit for the treatment of patients with colorectal cancer. Molecular and Clinical Oncology, 2021, 15, 201.	0.4	2
1507	A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling. Briefings in Bioinformatics, 2021, 22, .	3.2	7
1508	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. Cancers, 2021, 13, 4601.	1.7	19
1509	Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles. Biomedicines, 2021, 9, 1319.	1.4	13
1510	Representation of molecules for drug response prediction. Briefings in Bioinformatics, 2022, 23, .	3.2	14
1513	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. Npj Genomic Medicine, 2021, 6, 76.	1.7	10
1514	How much can deep learning improve prediction of the responses to drugs in cancer cell lines?. Briefings in Bioinformatics, 2022, 23, .	3.2	12

#	ARTICLE	IF	CITATIONS
1515	Identification of Prognostic Biomarker Candidates Associated With Melanoma Using High-Dimensional Genomic Data. Frontiers in Genetics, 2021, 12, 707105.	1.1	0
1516	Multiplex gene quantification as digital markers for extremely rapid evaluation of chemo-drug sensitivity. Patterns, 2021, 2, 100360.	3.1	4
1517	Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 5911-5925.	0.8	9
1518	Schlafen 11 Expression in Human Acute Leukemia Cells with Gain-of-Function Mutations in the Interferon-JAK Signaling Pathway. IScience, 2021, 24, 103173.	1.9	6
1519	Establishment and characterization of NCC-LGFMS1-C1: a novel patient-derived cell line of low-grade fibromyxoid sarcoma. Human Cell, 2021, 34, 1919-1928.	1.2	1
1520	A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma. BMC Cancer, 2021, 21, 1035.	1.1	12
1521	Assessment of Metastatic Colorectal Cancer (CRC) Tissues for Interpreting Genetic Data in Forensic Science by Applying 16 STR Loci among Saudi Patients. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2797-2806.	0.5	2
1523	Stromal fibroblasts shape the myeloid phenotype in normal colon and colorectal cancer and induce CD163 and CCL2 expression in macrophages. Cancer Letters, 2021, 520, 184-200.	3.2	40
1524	Regulated cell death and drug resistance in malignant bone tumors. , 2022, , 703-716.		0
1525	Liquid biopsy in bone sarcomas and identification of new biomarkers. , 2022, , 487-500.		0
1526	Recent Advances of Deep Learning in Biology. Studies in Computational Intelligence, 2021, , 709-732.	0.7	3
1527	Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy. Computational and Structural Biotechnology Journal, 2021, 19, 4059-4066.	1.9	4
1528	A Novel Sparse Graph-Regularized Singular Value Decomposition Model and Its Application to Genomic Data Analysis. IEEE Transactions on Neural Networks and Learning Systems, 2022, 33, 3842-3856.	7.2	4
1529	Computational cancer genomics. , 2021, , 329-359.		0
1530	Minimal genome-wide human CRISPR-Cas9 library. Genome Biology, 2021, 22, 40.	3.8	40
1531	A Systematic Review of Applications of Machine Learning in Cancer Prediction and Diagnosis. Archives of Computational Methods in Engineering, 2021, 28, 4875-4896.	6.0	24
1532	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. Genome Medicine, 2021, 13, 11.	3.6	17
1533	High-Content Analysis-Based Sensitivity Prediction and Novel Therapeutics Screening for c-Met-Addicted Glioblastoma. Cancers, 2021, 13, 372.	1.7	6

#	Article	IF	Citations
1534	Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome. Computational and Structural Biotechnology Journal, 2021, 19, 4435-4446.	1.9	4
1535	Patient-derived organoid (PDO) platforms to facilitate clinical decision making. Journal of Translational Medicine, 2021, 19, 40.	1.8	62
1536	Genetic alteration in notch pathway is associated with better prognosis in renal cell carcinoma. BioFactors, 2016, 42, 41-48.	2.6	16
1537	Systems Biology Analysis for Ewing Sarcoma. Methods in Molecular Biology, 2021, 2226, 303-333.	0.4	2
1538	Label-Free Cell Phenotypic Profiling and Screening: Techniques, Experimental Design, and Data Assessment. Methods in Pharmacology and Toxicology, 2015, , 17-33.	0.1	2
1539	Computational Analyses Connect Small-Molecule Sensitivity to Cellular Features Using Large Panels of Cancer Cell Lines. Methods in Molecular Biology, 2019, 1888, 233-254.	0.4	1
1540	Bioinformatics Tools and Resources for Cancer Immunotherapy Study. Methods in Molecular Biology, 2020, 2055, 649-678.	0.4	7
1541	Privacy-Preserving Elastic Net for Data Encrypted by Different Keys - With an Application on Biomarker Discovery. Lecture Notes in Computer Science, 2017, , 185-204.	1.0	5
1542	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
1543	Towards the routine use of *in silico* screenings for drug discovery using metabolic modelling. Biochemical Society Transactions, 2020, 48, 955-969.	1.6	13
1544	Homologous recombination repair deficiency as a therapeutic target in sarcoma. Seminars in Oncology, 2020, 47, 380-389.	0.8	26
1587	Abstract LB-174: Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy.. Cancer Research, 2013, 73, LB-174-LB-174.	0.4	7
1588	Ewingâ€™s sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. Journal of Clinical Investigation, 2014, 124, 3061-3074.	3.9	70
1589	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. Journal of Clinical Investigation, 2017, 127, 2392-2406.	3.9	64
1590	Drug-perturbation-based stratification of blood cancer. Journal of Clinical Investigation, 2017, 128, 427-445.	3.9	124
1591	Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. Journal of Clinical Investigation, 2018, 128, 2951-2965.	3.9	36
1592	Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data. F1000Research, 2016, 5, 2927.	0.8	21
1593	Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data. F1000Research, 2016, 5, 2927.	0.8	23

#	ARTICLE	IF	CITATIONS
1594	Hub genes in a pan-cancer co-expression network show potential for predicting drug responses. F1000Research, 2018, 7, 1906.	0.8	4
1595	Recent advances in targeted therapy for Ewing sarcoma. F1000Research, 2016, 5, 2077.	0.8	45
1596	Assessment of pharmacogenomic agreement. F1000Research, 2016, 5, 825.	0.8	34
1597	Revisiting inconsistency in large pharmacogenomic studies. F1000Research, 2016, 5, 2333.	0.8	79
1598	Revisiting inconsistency in large pharmacogenomic studies. F1000Research, 0, 5, 2333.	0.8	8
1599	Revisiting inconsistency in large pharmacogenomic studies. F1000Research, 2016, 5, 2333.	0.8	51
1600	Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action. PLoS Computational Biology, 2015, 11, e1004202.	1.5	17
1601	Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression. PLoS Computational Biology, 2017, 13, e1005347.	1.5	14
1602	Epigenetics in Cancer: A Hematological Perspective. PLoS Genetics, 2016, 12, e1006193.	1.5	77
1603	Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection. PLoS ONE, 2012, 7, e46518.	1.1	42
1604	A Head and Neck Cancer Tumor Response-Specific Gene Signature for Cisplatin, 5-Fluorouracil Induction Chemotherapy Fails with Added Taxanes. PLoS ONE, 2012, 7, e47170.	1.1	11
1605	High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models. PLoS ONE, 2013, 8, e56185.	1.1	25
1606	Functional Profiling of Precursor MicroRNAs Identifies MicroRNAs Essential for Glioma Proliferation. PLoS ONE, 2013, 8, e60930.	1.1	43
1607	Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties. PLoS ONE, 2013, 8, e61318.	1.1	406
1608	Comprehensive Genomic Characterization of Cutaneous Malignant Melanoma Cell Lines Derived from Metastatic Lesions by Whole-Exome Sequencing and SNP Array Profiling. PLoS ONE, 2013, 8, e63597.	1.1	32
1609	Widespread Molecular Patterns Associated with Drug Sensitivity in Breast Cancer Cell Lines, with Implications for Human Tumors. PLoS ONE, 2013, 8, e71158.	1.1	6
1610	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388.	1.1	50
1611	Detection of Viral Proteins in Human Cells Lines by Xeno-Proteomics: Elimination of the Last Valid Excuse for Not Testing Every Cellular Proteome Dataset for Viral Proteins. PLoS ONE, 2014, 9, e91433.	1.1	3

#	ARTICLE	IF	CITATIONS
1612	High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner. PLoS ONE, 2014, 9, e92047.	1.1	36
1613	NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses. PLoS ONE, 2014, 9, e101670.	1.1	38
1614	A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. PLoS ONE, 2014, 9, e103050.	1.1	7
1615	Robust Prediction of Anti-Cancer Drug Sensitivity and Sensitivity-Specific Biomarker. PLoS ONE, 2014, 9, e108990.	1.1	9
1616	Molecular Integrative Clustering of Asian Gastric Cell Lines Revealed Two Distinct Chemosensitivity Clusters. PLoS ONE, 2014, 9, e111146.	1.1	2
1617	DISIS: Prediction of Drug Response through an Iterative Sure Independence Screening. PLoS ONE, 2015, 10, e0120408.	1.1	18
1618	Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS ONE, 2015, 10, e0125021.	1.1	16
1619	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS ONE, 2015, 10, e0140310.	1.1	39
1620	Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS ONE, 2016, 11, e0149833.	1.1	21
1621	Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer. PLoS ONE, 2016, 11, e0158667.	1.1	15
1622	Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment. PLoS ONE, 2017, 12, e0169797.	1.1	25
1623	A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib. PLoS ONE, 2017, 12, e0181991.	1.1	2
1624	Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide. PLoS ONE, 2020, 15, e0242497.	1.1	18
1625	Advances in the Treatment of Pediatric Bone Sarcomas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 725-735.	1.8	18
1626	PI3 Kinase in Cancer: From Biology to Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e93-e98.	1.8	4
1627	Drug mechanismâ€ofâ€action discovery through the integration of pharmacological and <scp>CRISPR</scp> screens. Molecular Systems Biology, 2020, 16, e9405.	3.2	63
1628	The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment.. Acta Biochimica Polonica, 2012, 59, .	0.3	101
1629	An Improved Parallelized mRMR for Gene Subset Selection in Cancer Classification. International Journal on Advanced Science, Engineering and Information Technology, 2017, 7, 1595.	0.2	3

#	ARTICLE	IF	CITATIONS
1630	Tumor suppression by miR-31 in esophageal carcinoma is p21-dependent. Genes and Cancer, 2014, 5, 436-444.	0.6	19
1631	Functional proteomic characterization of cancer cell lines. Oncoscience, 2017, 4, 41-42.	0.9	2
1632	*TP53* mutant *MDM2*-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. Oncotarget, 2016, 7, 46203-46218.	0.8	22
1633	Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget, 2016, 7, 57651-57670.	0.8	29
1634	Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget, 2016, 7, 58759-58767.	0.8	59
1635	Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget, 2016, 7, 76534-76550.	0.8	219
1636	Potential approaches to the treatment of Ewing's sarcoma. Oncotarget, 2017, 8, 5523-5539.	0.8	39
1637	Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia. Oncotarget, 2017, 8, 1529-1540.	0.8	11
1638	KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. Oncotarget, 2017, 8, 3206-3225.	0.8	9
1639	EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. Oncotarget, 2017, 8, 24679-24693.	0.8	20
1640	Robust *in-silico* identification of cancer cell lines based on next generation sequencing. Oncotarget, 2017, 8, 34310-34320.	0.8	12
1641	Synthetic lethal interaction between the tumour suppressor *STAG2* and its paralog *STAG1*. Oncotarget, 2017, 8, 37619-37632.	0.8	61
1642	Insights from animal models of bladder cancer: recent advances, challenges, and opportunities. Oncotarget, 2017, 8, 57766-57781.	0.8	45
1643	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget, 2017, 8, 85120-85135.	0.8	15
1644	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. Oncotarget, 2017, 8, 59008-59022.	0.8	11
1645	Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget, 2014, 5, 3697-3710.	0.8	96
1646	Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. Oncotarget, 2017, 8, 77292-77308.	0.8	21
1647	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget, 2017, 8, 81776-81793.	0.8	34

#	ARTICLE	IF	CITATIONS
1648	Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget, 2017, 8, 113418-113430.	0.8	20
1649	Organotypic three-dimensional cancer cell cultures mirror drug responses *in vivo*: lessons learned from the inhibition of EGFR signaling. Oncotarget, 2017, 8, 107423-107440.	0.8	36
1650	Molecular-genetic profiling and high-throughput *in vitro* drug screening in NUT midline carcinomaâ€"an aggressive and fatal disease. Oncotarget, 2017, 8, 112313-112329.	0.8	29
1651	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. Oncotarget, 2017, 8, 115114-115127.	0.8	1
1652	Persistent DNA strand breaks induce a CAF-like phenotype in normal fibroblasts. Oncotarget, 2018, 9, 13666-13681.	0.8	20
1653	High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. Oncotarget, 2018, 9, 26064-26071.	0.8	13
1654	Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity. Oncotarget, 2018, 9, 30115-30127.	0.8	25
1655	PARP1 is required for preserving telomeric integrity but is dispensable for A-NHEJ. Oncotarget, 2018, 9, 34821-34837.	0.8	14
1656	BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner. Oncotarget, 2015, 6, 7608-7618.	0.8	38
1657	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget, 2015, 6, 9627-9642.	0.8	103
1658	Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget, 2012, 3, 596-600.	0.8	30
1659	Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget, 2015, 6, 44675-44687.	0.8	27
1660	LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. Oncotarget, 2015, 6, 38469-38486.	0.8	34
1661	Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating *BRAF* mutations. Oncotarget, 2016, 7, 565-579.	0.8	31
1662	Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations. Oncotarget, 2016, 7, 9404-9419.	0.8	12
1663	An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget, 2016, 7, 8743-8755.	0.8	36
1664	Systematic drug perturbations on cancer cells reveal diverse exit paths from proliferative state. Oncotarget, 2016, 7, 7415-7425.	0.8	13
1665	A BRCA1 deficient, NFÎºB driven immune signal predicts good outcome in triple negative breast cancer. Oncotarget, 2016, 7, 19884-19896.	0.8	30

#	ARTICLE	IF	CITATIONS
1666	Advances in Targeting Signal Transduction Pathways. Oncotarget, 2012, 3, 1505-1521.	0.8	41
1667	Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer. Oncotarget, 2016, 7, 23335-23345.	0.8	45
1668	Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget, 2016, 7, 22128-22139.	0.8	21
1669	The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. Oncotarget, 2016, 7, 35932-35945.	0.8	31
1670	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget, 2016, 7, 27599-27612.	0.8	21
1671	Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. Oncotarget, 2016, 7, 27802-27818.	0.8	46
1672	Evolution and Restoration of Structures and Functions of the Human Central Nervous System—A Review. Translational Neuroscience and Clinics, 2015, 1, 60-70.	0.1	1
1673	Targeting the LKB1 Tumor Suppressor. Current Drug Targets, 2014, 15, 32-52.	1.0	43
1674	Drugs and their Interactions. Current Drug Discovery Technologies, 2013, 10, 106-113.	0.6	14
1675	The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs. Life Science Alliance, 2019, 2, e201900445.	1.3	9
1676	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biology and Medicine, 2016, 13, 87-100.	1.4	21
1677	Integrated Computational Approaches and Tools for Allosteric Drug Discovery. International Journal of Molecular Sciences, 2020, 21, 847.	1.8	73
1679	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S579-92.	0.6	37
1680	Predictive Modeling of Drug Treatment in the Area of Personalized Medicine. Cancer Informatics, 2015, 14, 95-103.	0.9	17
1681	Use of a Combined Gene Expression Profile in Implementing a Drug Sensitivity Predictive Model for Breast Cancer. Cancer Research and Treatment, 2017, 49, 116-128.	1.3	9
1682	Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Neoplasma, 2020, 67, 430-437.	0.7	34
1683	Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma. Turkish Journal of Haematology, 2016, 33, 286-292.	0.2	2
1684	Perspectives of Integrative Cancer Genomics in Next Generation Sequencing Era. Genomics and Informatics, 2012, 10, 69.	0.4	16

#	ARTICLE	IF	CITATIONS
1685	Translational genomics in cancer research: converting profiles into personalized cancer medicine. Cancer Biology and Medicine, 2013, 10, 214-20.	1.4	10
1686	Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. ELife, 2014, 3, e02200.	2.8	205
1687	Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. ELife, 2014, 3, .	2.8	116
1688	Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. ELife, 2015, 4, .	2.8	67
1689	A signature for success. ELife, 2015, 4, .	2.8	3
1690	Challenges in validating candidate therapeutic targets in cancer. ELife, 2018, 7, .	2.8	25
1691	A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates. ELife, 2020, 9, .	2.8	16
1692	Identification of significant genes signatures and prognostic biomarkers in cervical squamous carcinoma via bioinformatic data. PeerJ, 2020, 8, e10386.	0.9	10
1693	Prediction of cancer cell sensitivity to natural products based on genomic and chemical properties. PeerJ, 2015, 3, e1425.	0.9	11
1694	The role of TRIM51 as a multipurpose biomarker in melanoma. Translational Cancer Research, 2021, 10, 4327-4337.	0.4	1
1695	PharmacoDB 2.0: improving scalability and transparency of *in vitro* pharmacogenomics analysis. Nucleic Acids Research, 2022, 50, D1348-D1357.	6.5	15
1697	Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers. Frontiers in Oncology, 2021, 11, 719564.	1.3	47
1699	Differentiable biology: using deep learning for biophysics-based and data-driven modeling of molecular mechanisms. Nature Methods, 2021, 18, 1169-1180.	9.0	44
1702	Glioblastoma cytotoxicity conferred through dual disruption of endolysosomal homeostasis by Vacquinol-1. Neuro-Oncology Advances, 2021, 3, vdab152.	0.4	1
1703	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers, 2021, 13, 5014.	1.7	9
1705	Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses. Biomedicine and Pharmacotherapy, 2021, 144, 112278.	2.5	5
1706	Sarcomas More Common in Children. , 2013, , 221-250.		1
1707	CellLineMiner: a knowledge portal for human cell lines. Bioinformation, 2012, 8, 1119-1122.	0.2	0

#	Article	IF	Citations
1708	A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal Cells. Blood, 2012, 120, 1373-1373.	0.6	0
1709	Personalized cancer treatments suffer setback. Nature, 0, , .	13.7	1
1710	Sarcoma genomics. Bone and Joint 360, 2013, 2, 2-8.	0.1	0
1711	Hepatic Tumors in Childhood. , 2014, , 547-614.		3
1714	Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology. World Journal of Clinical Oncology, 2015, 6, 184.	0.9	0
1715	Evolution and restoration of structures and functions of the human central nervous system&mdash;A review. Translational Neuroscience and Clinics, 2015, 1, 60-70.	0.1	0
1716	Recurrent Bone Tumors. Pediatric Oncology, 2015, , 221-263.	0.5	0
1717	Biomarkers for PARP Inhibitors. Cancer Drug Discovery and Development, 2015, , 553-579.	0.2	0
1718	Novel Therapies on the Horizon. Pediatric Oncology, 2015, , 265-291.	0.5	0
1719	Computational Data Integration in Toxicogenomics. Methods in Pharmacology and Toxicology, 2015, , 371-392.	0.1	0
1721	Sarcomas More Common in Children. , 2016, , 243-274.		0
1722	Chemotherapy and Novel Cancer Targeted Therapies. , 2016, , 135-152.		0
1728	Bone Sarcomas in the Adolescent and Young Adult Population. Pediatric Oncology, 2017, , 417-427.	0.5	1
1733	Heterogeneous Cancer Cell Line Data Fusion forÂIdentifying Novel Response Determinants inÂPrecision Medicine. Lecture Notes in Computer Science, 2017, , 414-419.	1.0	0
1734	Multiparameter Modalities for the Study of Patients in the Setting of Individualized Medicine. , 2017, , 1-27.		0
1735	Cell Cycle Machinery and Its Alterations in Pancreatic Cancer. , 2017, , 1-31.		0
1736	The Molecular Pathology of Serous Endometrial Cancer. Molecular Pathology Library, 2017, , 87-122.	0.1	0
1737	â€œBig Data and Dynamicsâ€â€"The Mathematical Toolkit Towards Personalized Medicine. Springer Proceedings in Mathematics and Statistics, 2017, , 338-369.	0.1	0

#	ARTICLE	IF	CITATIONS
1756	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
1757	HighhThroughput Drug Screening Identifies Pazopanib and Clofilium Tosylate As Promising Treatments for Malignant Rhabdoid Tumors. SSRN Electronic Journal, 0, , .	0.4	0
1758	Prediction of Drug Response with a Topology Based Dual-Layer Network Model. Lecture Notes in Computer Science, 2018, , 3-12.	1.0	0
1759	Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 147-180.	0.1	0
1760	CellMinerCDB for Integrative Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. SSRN Electronic Journal, 0, , .	0.4	0
1764	Statistical Methods for Evaluation of Bioactivity of Chemicals Using Quantitative High Throughput Screening. Japanese Journal of Biometrics, 2018, 38, 93-105.	0.0	0
1775	AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets. , 2018, , .		3
1778	Drug Screening Platforms and RPPA. Advances in Experimental Medicine and Biology, 2019, 1188, 203-226.	0.8	4
1779	Unmet Needs and Future Outlook of Mesothelioma Management. , 2019, , 331-340.		0
1780	Applications of Microarray in Cancer Cell Signaling Pathways. , 2019, , 369-387.		0
1781	Applications of Dielectrophoresis in the Field of Medical Sciences. International Journal of Scientific Research in Science and Technology, 2019, , 328-341.	0.1	2
1783	Insights into breast cancer phenotying through molecular omics approaches and therapy response. , 2019, 2, 527-538.		2
1785	Hub genes in a pan-cancer co-expression network show potential for predicting drug responses. F1000Research, 2018, 7, 1906.	0.8	3
1798	Sparse Partial Least Squares Methods for Joint Modular Pattern Discovery. Methods in Molecular Biology, 2020, 2082, 173-186.	0.4	0
1807	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	21.5	41
1808	Studies of Glyoxalase 1-Linked Multidrug Resistance Reveal Glycolysis-Derived Reactive Metabolite, Methylglyoxal, Is a Common Contributor in Cancer Chemotherapy Targeting the Spliceosome. Frontiers in Oncology, 2021, 11, 748698.	1.3	10
1810	Introduction to Molecular Targeted Radiosensitizers: Opportunities and Challenges. Cancer Drug Discovery and Development, 2020, , 1-16.	0.2	2
1812	Learning Cancer Drug Sensitivities in Large-Scale Screens from Multi-omics Data with Local Low-Rank Structure. Lecture Notes in Computer Science, 2020, , 67-79.	1.0	0

#	Article	IF	Citations
1816	Defect of SLC38A3 promotes epithelial mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 547-563.	0.7	7
1818	Artificial Intelligence, Machine Learning, and Deep Learning in Real-Life Drug Design Cases. Methods in Molecular Biology, 2022, 2390, 383-407.	0.4	12
1819	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	5.8	35
1820	Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Human Cell, 2022, 35, 392-399.	1.2	6
1824	Contemporary Approach to Therapy for Ewing Sarcoma. Pediatric Oncology, 2021, , 111-128.	0.5	1
1833	CTDPathSim. , 2020, , .		1
1834	Two-step multi-omics modelling of drug sensitivity in cancer cell lines to identify driving mechanisms. PLoS ONE, 2020, 15, e0238961.	1.1	5
1835	Ewing's sarcoma: overcoming the therapeutic plateau. Discovery Medicine, 2012, 13, 405-15.	0.5	22
1837	The Stream algorithm: computationally efficient ridge-regression via Bayesian model averaging, and applications to pharmacogenomic prediction of cancer cell line sensitivity. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2014, , 27-38.	0.7	13
1838	Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2014, , 63-74.	0.7	76
1839	Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2014, , 125-35.	0.7	10
1840	Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2015, , 32-43.	0.7	4
1841	Apoptotic agents. Translational Lung Cancer Research, 2013, 2, 238-43.	1.3	3
1842	Advanced colorectal adenoma related gene expression signature may predict prognostic for colorectal cancer patients with adenoma-carcinoma sequence. International Journal of Clinical and Experimental Medicine, 2015, 8, 4883-98.	1.3	4
1843	CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation. International Journal of Clinical and Experimental Medicine, 2015, 8, 11692-700.	1.3	10
1844	Comprehensive pharmacological profiling of neurofibromatosis cell lines. American Journal of Cancer Research, 2017, 7, 923-934.	1.4	14
1845	Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment. Asian Pacific Journal of Cancer Prevention, 2017, 18, 293-294.	0.5	15
1847	Multifaceted regulation and functions of replication factor C family in human cancers. American Journal of Cancer Research, 2018, 8, 1343-1355.	1.4	17

#	ARTICLE	IF	CITATIONS
1848	AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2019, 24, 248-259.	0.7	1
1849	Targeting mitotic exit in solid tumors. American Journal of Cancer Research, 2021, 11, 3698-3710.	1.4	0
1850	Looking back at the first twenty years of genomics. Quantitative Biology, 2022, 10, 6-16.	0.3	0
1851	Systems biology and big data analytics. , 2022, , 425-442.		0
1852	Q-omics: Smart Software for Assisting Oncology and Cancer Research. Molecules and Cells, 2021, 44, 843-850.	1.0	18
1853	Out-of-distribution generalization from labelled and unlabelled gene expression data for drug response prediction. Nature Machine Intelligence, 2021, 3, 962-972.	8.3	7
1854	Animal Models in Bladder Cancer. Biomedicines, 2021, 9, 1762.	1.4	4
1855	Therapeutic Response-Based Reclassification of Multiple Tumor Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers. Frontiers in Cell and Developmental Biology, 2021, 9, 773101.	1.8	0
1856	Understanding the Role of the Antioxidant Drug Erdosteine and Its Active Metabolite on Staphylococcus aureus Methicillin Resistant Biofilm Formation. Antioxidants, 2021, 10, 1922.	2.2	1
1857	Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. Molecular Oncology, 2022, 16, 2451-2469.	2.1	8
1858	Winsorization for Robust Bayesian Neural Networks. Entropy, 2021, 23, 1546.	1.1	9
1859	One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma. Journal of Bone Oncology, 2021, 31, 100404.	1.0	12
1860	Mutational landscape of primary and recurrent Ewing sarcoma. Wspolczesna Onkologia, 2021, 25, 241-248.	0.7	4
1861	Functionalizing Fibrin Hydrogels with Thermally Responsive Oligonucleotide Tethers for On-Demand Delivery. Bioengineering, 2022, 9, 25.	1.6	4
1862	Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of *KRAS* Mutations in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 1640-1650.	3.2	19
1863	Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review. Cellular and Molecular Biology Letters, 2022, 27, 9.	2.7	13
1864	Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Drug Resistance Updates, 2022, 60, 100806.	6.5	41
1865	Matching anticancer compounds and tumor cell lines by neural networks with ranking loss. NAR Genomics and Bioinformatics, 2022, 4, lqab128.	1.5	2

#	ARTICLE	IF	CITATIONS
1867	Pan-Cancer Prediction of Cell-Line Drug Sensitivity Using Network-Based Methods. International Journal of Molecular Sciences, 2022, 23, 1074.	1.8	7
1868	Predicting Anticancer Drug Resistance Mediated by Mutations. Pharmaceuticals, 2022, 15, 136.	1.7	4
1869	Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives. Forum of Clinical Oncology, 2022, .	0.1	0
1870	Cell cycle-related genes associate with sensitivity to hydrogen peroxide-induced toxicity. Redox Biology, 2022, 50, 102234.	3.9	9
1871	Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia. Blood Science, 2022, 4, 16-28.	0.4	8
1873	SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types. Cell Genomics, 2022, 2, 100099.	3.0	2
1874	Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth. Nature Metabolism, 2022, 4, 239-253.	5.1	13
1875	Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Liâ€"Fraumeni syndrome. Human Cell, 2022, 35, 756-766.	1.2	2
1876	Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis. Scientific Reports, 2021, 11, 23933.	1.6	5
1877	Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. Genome Medicine, 2021, 13, 187.	3.6	25
1878	Challenges for assessing replicability in preclinical cancer biology. ELife, 2021, 10, .	2.8	136
1879	Patient-Derived In Vitro and In Vivo Models of Cancer. Advances in Experimental Medicine and Biology, 2022, 1361, 215-233.	0.8	2
1881	A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. Scientific Reports, 2022, 12, 2478.	1.6	2
1882	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. Cancer Research, 2022, 82, 1174-1192.	0.4	21
1883	Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human Cell, 2022, 35, 936.	1.2	1
1884	Inhibitors of PARP: Number crunching and structure gazing. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2121979119.	3.3	52
1886	EviCor: Interactive Web Platform for Exploration of Molecular Features and Response to Anti-cancer Drugs. Journal of Molecular Biology, 2022, 434, 167528.	2.0	4
1887	Reassessing pharmacogenomic cell sensitivity with multilevel statistical models. Biostatistics, 2022, , .	0.9	0

#	Article	IF	Citations
1888	A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response. Nature Communications, 2022, 13, 1714.	5.8	65
1890	Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. Frontiers in Oncology, 2022, 12, 837233.	1.3	2
1891	secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer Journal, 2022, 12, 39.	2.8	5
1893	Multivariate response regression with low-rank and generalized sparsity. Journal of the Korean Statistical Society, 2022, 51, 847-867.	0.3	1
1894	Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. Nature Chemical Biology, 2022, 18, 605-614.	3.9	24
1895	The IC-50-time evolution is a new model to improve drug responses consistency of large scale studies. F1000Research, 0, 11, 284.	0.8	0
1896	Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma. Communications Biology, 2022, 5, 213.	2.0	10
1897	Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	2
1898	BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma. Cancer Research Communications, 2022, 2, 220-232.	0.7	6
1899	KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response. Cell Death and Disease, 2022, 13, 303.	2.7	15
1900	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligenceâ€"Enabled Studies of Acute Phosphoproteomic Changes. Molecular Cancer Therapeutics, 2022, 21, 1020-1029.	1.9	3
1901	Identifying Biomarkers of Cisplatin Sensitivity in Non-Small Cell Lung Cancer <i>via</i> Comprehensive Integrative Analysis. Current Bioinformatics, 2022, 17, 498-509.	0.7	1
1902	A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens. Scientific Reports, 2022, 12, 5571.	1.6	11
1903	Preclinical Drug Response Metric Based on Cellular Response Phenotype Provides Better Pharmacogenomic Variables with Phenotype Relevance. Pharmaceuticals, 2021, 14, 1324.	1.7	0
1904	Organoids in Lung Cancer Management. Frontiers in Surgery, 2021, 8, 753801.	0.6	5
1905	Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 13297.	1.8	8
1907	Tissue and Drug Specificity of Drug Sensitivities in Different Cancer Cell Lines. , 2021, , .		0
1908	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer, 2022, 22, 394.	1.1	7

#	Article	IF	Citations
1909	Establishment and characterization of a novel patient-derived Ewing sarcoma cell line, NCC-ES2-C1. Human Cell, 2022, , .	1.2	1
1910	Novel Targeted Therapeutic Strategies for Ewing Sarcoma. Cancers, 2022, 14, 1988.	1.7	4
1911	Real-time luminescence enables continuous drugâ€"response analysis in adherent and suspension cell lines. Cancer Biology and Therapy, 2022, 23, 358-368.	1.5	0
1912	The Polypharmacology Gap Between Chemical Biology and Drug Discovery. Chemical Biology, 2017, , 349-370.	0.1	0
1921	Establishment of four Head and Neck Squamous Cell Carcinoma Cell Lines: Importance of Reference DNA is Essential for accurate genomic characterization.. Journal of Laryngology and Otology, 2022, , 1-21.	0.4	0
1925	Dissecting the Genome for Drug Response Prediction. Methods in Molecular Biology, 2022, 2449, 187-196.	0.4	1
1926	Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). Journal of Gynecologic Oncology, 2022, 33, .	1.0	4
1927	Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells. Methods in Molecular Biology, 2022, 2449, 327-348.	0.4	4
1928	Stepwise-edited, human melanoma models reveal mutationsâ€™ effect on tumor and microenvironment. Science, 2022, 376, eabi8175.	6.0	24
1929	Application of computational screening tools and nanotechnology for enhanced drug synergism in cancer therapy. Current Drug Delivery, 2022, 19, .	0.8	0
1930	EBSRMF: Ensemble based similarity-regularized matrix factorization to predict anticancer drug responses. Journal of Intelligent and Fuzzy Systems, 2022, , 1-10.	0.8	1
1931	Integrated computational analysis reveals HOX genes cluster as oncogenic drivers in head and neck squamous cell carcinoma. Scientific Reports, 2022, 12, 7952.	1.6	1
1932	Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity. Cancer Research, 2022, 82, 2378-2387.	0.4	4
1933	MALAT1 as master regulator of biomarkers predictive of pan-cancer multi-drug resistance in the context of recalcitrant NRAS signaling pathway identified using systems-oriented approach. Scientific Reports, 2022, 12, 7540.	1.6	2
1934	DWUT-MLP: Classification of anticancer drug response using various feature selection and classification techniques. Chemometrics and Intelligent Laboratory Systems, 2022, 225, 104562.	1.8	5
1936	Evaluation of statistical approaches for association testing in noisy drug screening data. BMC Bioinformatics, 2022, 23, 188.	1.2	5
1937	Development of a Chemoresistant Risk Scoring Model for Prechemotherapy Osteosarcoma Using Single-Cell Sequencing. Frontiers in Oncology, 2022, 12, .	1.3	12
1938	Establishment and characterization of a novel patient-derived cell line of dedifferentiated liposarcoma, NCC-DDLPS6-C1. Human Cell, 0, , .	1.2	0

#	Article	IF	Citations
1939	CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling. Oncotarget, 2022, 13, 695-706.	0.8	12
1940	Functional characterization and clinical significance of super‑enhancers in lung adenocarcinoma. Molecular Carcinogenesis, 2022, 61, 776-786.	1.3	2
1941	A Novel Classification Model for Lower-Grade Glioma Patients Based on Pyroptosis-Related Genes. Brain Sciences, 2022, 12, 700.	1.1	14
1942	Mutational signatures are markers of drug sensitivity of cancer cells. Nature Communications, 2022, 13, .	5.8	29
1944	Can Drug Repurposing Accelerate Precision Oncology?. Cancer Discovery, 0, , OF1-OF8.	7.7	11
1947	NeuMF: Predicting Anti-cancer Drug Response Through a Neural Matrix Factorization Model. Current Bioinformatics, 2022, 17, 835-847.	0.7	2
1948	In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts. Journal of Mammary Gland Biology and Neoplasia, 2022, 27, 211-230.	1.0	5
1949	Nonparametric variable screening for multivariate additive models. Journal of Multivariate Analysis, 2022, , 105069.	0.5	0
1950	Can artificial intelligence accelerate preclinical drug discovery and precision medicine?. Expert Opinion on Drug Discovery, 0, , 1-5.	2.5	2
1951	Deep reinforcement learning for personalized treatment recommendation. Statistics in Medicine, 2022, 41, 4034-4056.	0.8	13
1952	CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Research, 2022, 82, 3088-3101.	0.4	2
1953	Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. Journal of Thoracic Oncology, 2022, 17, 1014-1031.	0.5	31
1954	The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy. Frontiers in Genetics, 0, 13, .	1.1	10
1955	Interpretable Machine Learning Models to Predict the Resistance of Breast Cancer Patients to Doxorubicin from Their microRNA Profiles. Advanced Science, 2022, 9, .	5.6	9
1957	Multi-omics analysis to screen potential therapeutic biomarkers for anti-cancer compounds. Heliyon, 2022, 8, e09616.	1.4	2
1958	Computational estimation of quality and clinical relevance of cancer cell lines. Molecular Systems Biology, 2022, 18, .	3.2	12
1959	The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma. Molecular Medicine, 2022, 28, .	1.9	3
1960	Identification of pyroptosis-related long non-coding RNAs with prognosis and therapy in lung squamous cell carcinoma. Scientific Reports, 2022, 12, .	1.6	4

#	Article	IF	Citations
1961	Pan-cancer proteomic map of 949 human cell lines. Cancer Cell, 2022, 40, 835-849.e8.	7.7	52
1962	First and further-line multidisciplinary treatment of retroperitoneal sarcomas. Current Opinion in Oncology, 2022, 34, 328-334.	1.1	2
1963	Tissue-specific identification of multi-omics features for pan-cancer drug response prediction. IScience, 2022, , 104767.	1.9	4
1964	Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Molecular Oncology, 2022, 16, 3034-3051.	2.1	8
1965	Establishment of a circular RNA regulatory stemness-related gene pair signature for predicting prognosis and therapeutic response in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	3
1966	Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature, 2022, 607, 799-807.	13.7	93
1967	Anti-cancer Drug Response Prediction System Using Stacked Ensemble Approach. Lecture Notes in Networks and Systems, 2022, , 205-218.	0.5	2
1968	Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma. Scientific Reports, 2022, 12, .	1.6	1
1969	Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system. Journal of Nanobiotechnology, 2022, 20, .	4.2	13
1970	Low-Rank Regression Models for Multiple Binary Responses and their Applications to Cancer Cell-Line Encyclopedia Data. Journal of the American Statistical Association, 2024, 119, 202-216.	1.8	3
1971	High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell Reports, 2022, 40, 111095.	2.9	9
1972	Simultaneous regression and classification for drug sensitivity prediction using an advanced random forest method. Scientific Reports, 2022, 12, .	1.6	2
1973	Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1. Cancer Research Communications, 2022, 2, 1061-1074.	0.7	4
1974	Identifying and characterizing drug sensitivity-related lncRNA-TF-gene regulatory triplets. Briefings in Bioinformatics, 0, , .	3.2	0
1975	Prognostic Signature and Therapeutic Value Based on Membrane Lipid Biosynthesis-Related Genes in Breast Cancer. Journal of Oncology, 2022, 2022, 1-16.	0.6	4
1976	Disruption of cancer cell functions by task-specific drug perturbations. Frontiers in Pharmacology, 0, 13, .	1.6	1
1977	Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets. Nature Communications, 2022, 13, .	5.8	8
1978	The endocytic receptor uPARAP is a regulator of extracellular thrombospondin-1. Matrix Biology, 2022, 111, 307-328.	1.5	3

#	Article	IF	Citations
1979	The application of zebrafish patientâ€derived xenograft tumor models in the development of antitumor agents. Medicinal Research Reviews, 2023, 43, 212-236.	5.0	5
1980	Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids. Laboratory Investigation, 2022, 102, 1355-1366.	1.7	4
1981	Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. Science Translational Medicine, 2022, 14, .	5.8	11
1982	Cancer Study: Cell to the Animal Models. , 2022, , 1-23.		0
1983	Graph Transformer for Drug Response Prediction. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2023, 20, 1065-1072.	1.9	9
1984	Opportunities for pharmacoproteomics in biomarker discovery. Proteomics, 2023, 23, .	1.3	7
1985	A genetic map of the chromatin regulators to drug response in cancer cells. Journal of Translational Medicine, 2022, 20, .	1.8	1
1987	From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer. International Journal of Cancer, 2023, 152, 1304-1313.	2.3	4
1988	An oxidative stress-related prognostic signature for indicating the immune status of oral squamous cell carcinoma and guiding clinical treatment. Frontiers in Genetics, 0, 13, .	1.1	5
1989	Pan-Cancer Analysis and Experimental Validation Identify ACOT7 as a Novel Oncogene and Potential Therapeutic Target in Lung Adenocarcinoma. Cancers, 2022, 14, 4522.	1.7	1
1990	Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 0, 12, .	1.3	3
1991	Evolution of precision oncologyâ€guided treatment paradigms. WIREs Mechanisms of Disease, 2023, 15, .	1.5	5
1992	Harnessing preclinical models for the interrogation of ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	6
1993	Explainable artificial intelligence for precision medicine in acute myeloid leukemia. Frontiers in Immunology, 0, 13, .	2.2	12
1994	Drug Response Prediction Based on 1D Convolutional Neural Network and Attention Mechanism. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-6.	0.7	1
1995	The kinase PLK1 promotes the development of <i>Kras</i> / <i>Tp53</i> -mutant lung adenocarcinoma through transcriptional activation of the receptor RET. Science Signaling, 2022, 15, .	1.6	10
1997	Drug Efficacy Prediction in Tumors Based on LDA Model. , 2022, , .		0
1998	A novel necroptosis-related gene index for predicting prognosis and a cold tumor immune microenvironment in stomach adenocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	17

#	ARTICLE	IF	CITATIONS
1999	Quantitative Framework for Bench-to-Bedside Cancer Research. Cancers, 2022, 14, 5254.	1.7	0
2000	Patient-derived primary breast cancer cells and their potential for predicting sensitivity to chemotherapy. Frontiers in Oncology, 0, 12, .	1.3	1
2002	Morphology and gene expression profiling provide complementary information for mapping cell state. Cell Systems, 2022, 13, 911-923.e9.	2.9	35
2003	Prognostic risk assessment model and drug sensitivity analysis of colon adenocarcinoma (COAD) based on immune-related lncRNA pairs. BMC Bioinformatics, 2022, 23, .	1.2	1
2004	Prediction of Cancer Treatment Using Advancements in Machine Learning. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 364-378.	0.8	3
2006	A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses. Communications Biology, 2022, 5, .	2.0	14
2009	Gene-centric multi-omics integration with convolutional encoders for cancer drug response prediction. Computers in Biology and Medicine, 2022, 151, 106192.	3.9	1
2010	Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
2011	Pharmacological blockade of TEADâ€"YAP reveals its therapeutic limitation in cancer cells. Nature Communications, 2022, 13, .	5.8	33
2013	Opportunities and challenges in interpretable deep learning for drug sensitivity prediction of cancer cells. Frontiers in Bioinformatics, 0, 2, .	1.0	4
2014	Analysis of top-cited articles on melanoma. Acta Dermatovenerologica Alpina, Panonica Et Adriatica, 2022, 31, .	0.1	0
2015	Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression. Touch Reviews in Oncology & Haematology, 2022, 18, 152.	0.1	1
2016	Proteomics reveals that cell density could affect the efficacy of drug treatment. Biochemistry and Biophysics Reports, 2023, 33, 101403.	0.7	1
2017	Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival. International Journal of Molecular Sciences, 2022, 23, 14978.	1.8	7
2018	Harnessing immunomodulation during DNA damage in Ewing sarcoma. Frontiers in Oncology, 0, 12, .	1.3	1
2019	Increased copy number of imprinted genes in the chromosomal region 20q11-q13.32 is associated with resistance to antitumor agents in cancer cell lines. Clinical Epigenetics, 2022, 14, .	1.8	0
2020	Synthetic lethal gene pairs: Experimental approaches and predictive models. Frontiers in Genetics, 0, 13, .	1.1	7
2021	IFITM proteins assist cellular uptake of diverse linked chemotypes. Science, 2022, 378, 1097-1104.	6.0	12

#	ARTICLE	IF	CITATIONS
2023	Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets. Cells, 2023, 12, 101.	1.8	0
2024	Clinical proteomics towards multiomics in cancer. Mass Spectrometry Reviews, 0, , .	2.8	6
2025	Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. Cell Reports, 2022, 41, 111761.	2.9	14
2026	High PPFIA1 expression promotes cancer survival by suppressing CD8+‰T cells in breast cancer: drug discovery and machine learning approach. Breast Cancer, 2023, 30, 259-270.	1.3	2
2027	C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC. International Journal of Molecular Sciences, 2023, 24, 1537.	1.8	1
2028	N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase. Molecular Cancer Therapeutics, 2023, 22, 393-405.	1.9	3
2029	The impact of violating the independence assumption in meta-analysis on biomarker discovery. Frontiers in Genetics, 0, 13, .	1.1	0
2030	Polygenic risk score for prediction of radiotherapy efficacy and radiosensitivity in patients with non-metastatic breast cancer. Radiation Medicine and Protection, 2023, 4, 33-42.	0.4	0
2032	A systematic assessment of deep learning methods for drug response prediction: from in vitro to clinical applications. Briefings in Bioinformatics, 2023, 24, .	3.2	2
2033	A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer. Frontiers in Molecular Biosciences, 0, 10, .	1.6	2
2034	DROEG: a method for cancer drug response prediction based on omics and essential genes integration. Briefings in Bioinformatics, 2023, 24, .	3.2	1
2035	Gene Expression Profiles in Cancers and Their Therapeutic Implications. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	1
2036	scDR: Predicting Drug Response at Single-Cell Resolution. Genes, 2023, 14, 268.	1.0	4
2038	Cancer Study: Cell to the Animal Models. , 2023, , 27-48.		0
2039	Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence. Journal of the American Chemical Society, 2023, 145, 2711-2732.	6.6	8
2040	The potential of PARP as a therapeutic target across pediatric solid malignancies. BMC Cancer, 2023, 23, .	1.1	1
2042	Gamma distribution based predicting model for breast cancer drug response based on multi-layer feature selection. Frontiers in Genetics, 0, 14, .	1.1	0
2043	In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation. Cancer Cell International, 2023, 23, .	1.8	0

#	Article	IF	Citations
2044	GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers. Frontiers in Oncology, 0, 13, .	1.3	4
2045	Preclinical models in head and neck squamous cell carcinoma. British Journal of Cancer, 2023, 128, 1819-1827.	2.9	7
2046	Multilingual translation for zero-shot biomedical classification using BioTranslator. Nature Communications, 2023, 14, .	5.8	4
2047	Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs. Journal of Clinical Medicine, 2023, 12, 1528.	1.0	1
2048	Enzalutamide-induced signatures revealed by epigenetic plasticity using single-cell multi-omics sequencing in prostate cancer. Molecular Therapy - Nucleic Acids, 2023, 31, 648-661.	2.3	2
2049	A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy. Cell Death and Differentiation, 2023, 30, 1166-1183.	5.0	2
2050	Low gammaâ€butyrobetaine dioxygenase (<scp>BBOX1</scp>) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach. Journal of Pathology: Clinical Research, 2023, 9, 236-248.	1.3	1
2052	Immune Gene Therapy of Cancer. , 2023, , 1-45.		0
2054	SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers. Nature Cancer, 2023, 4, 365-381.	5.7	5
2056	Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer. Frontiers in Immunology, 0, 14, .	2.2	0
2057	Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT). SLAS Discovery, 2023, 28, 138-148.	1.4	1
2058	Benchmark of embedding-based methods for accurate and transferable prediction of drug response. Briefings in Bioinformatics, 2023, 24, .	3.2	2
2059	Ï€ â€Extended BTD derivatives: synthesis, photophysical properties, and applications in biological systemsÂimagingÂfor discriminating living and dead cells. Chemistry - an Asian Journal, 0, , .	1.7	0
2061	Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents. Paediatric Drugs, 2023, 25, 389-397.	1.3	1
2062	CTDN (Convolutional Temporal Based Deepâ€Neural Network): An Improvised Stacked Hybrid Computational Approach for Anticancer Drug Response Prediction. Computational Biology and Chemistry, 2023, 105, 107868.	1.1	2
2063	Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235. Scientific Reports, 2023, 13, .	1.6	2
2064	Systems biology tools for the identification of potential drug targets and biological markers effective for cancer therapeutics. , 2023, , 259-292.		0
2065	Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors. , 2023, , 147-200.		1

#	ARTICLE	IF	CITATIONS
2066	Genomeâ€wide screen for anticancer drug resistance in haploid human embryonic stem cells. Cell Proliferation, 2023, 56, .	2.4	0
2077	GÃ©nome tumoral. , 2023, , 3-9.		0
2117	Computational precision therapeutics and drug repositioning. , 2024, , 57-74.		0
2173	Machine Learning Perspective in Cancer Research. , 2023, , 1104-1125.		0